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SUMMARY 
This thesis describes work investigating the response of cultured human 
endothelium to arecoline, which is the main alkaloid found in areca nut.    
 
Chapter 1 summarizes relevant literature on the areca nut, its use by humans as 
a drug and the health effects of areca nut use, including the role of this drug in 
driving oral submucous fibrosis, an important pre-cancerous condition for oral 
squamous cell carcinoma. Also, literature relating to arecoline is discussed, 
because this is the active agent driving addictive psychotropic effects, and also 
the principal endothelial stimulus studied in this thesis.  There is an emphasis on 
the way in which oral submucous fibrosis is accompanied by substantial vascular 
changes, seemingly due to changes in endothelium. Literature describing the cell 
and tissue responses to arecoline is reviewed, and a need to investigate the 
endothelial response to arecoline is identified.  
 
Chapter 2, describes work where, in view of the diminished vasculature seen in 
advanced stages of oral submucous fibrosis, the effect of arecoline upon survival 
of human umbilical vein endothelial cells (HUVEC) was investigated. Arecoline at 
333 µg/ml caused considerable reduction in cell number as determined by 
haemocytometer counts, while reduced mitochondrial function and cytoplasmic 
leakage were further confirmed by MTT and LDH assays. Sub-lethal levels of 
arecoline for human endothelium of 111 µg/ml and below, were comparable to 
those recorded in the literature as present in saliva during areca nut chewing.  
Transmission electron microscopy revealed reversible cell injury, evidence for 
autophagy and cellular stress at these concentrations, while higher levels of 
arecoline resulted in frank necrosis, consistent with cell counts.  Human gingival 
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fibroblasts were relatively resistant to the effect of arecoline, compared with 
HUVEC. 
 
Recognizing endothelial cell products as potentially important for explaining 
progression of oral submucous fibrosis, work was performed as described in 
Chapter 3, investigating the effect of toxic and sub-toxic arecoline levels on the 
production of a range of important inflammatory cytokines and growth factors at 
both protein and mRNA levels. HUVEC were found to have increased levels of 
basic Fibroblast Growth Factor at the protein level only, in response to toxic and 
sub-toxic arecoline exposure, and this may play a role in the pathogenesis of 
OSF in concert with separate fibrogenic factors. The baseline production of pro-
inflammatory cytokines including Granulocyte and Macrophage Granulocyte 
Colony Stimulating Factors, as well as Interleukins 1 and 6 by endothelium was 
down-regulated at both protein and mRNA levels by arecoline, and this seemed 
to reflect down-regulatory signalling as a part of cellular stress response. A 
similar inhibitory effect was observed in TNF-α stimulated HUVEC. Arecoline is a 
cholinergic agonist, so that the role of relevant agonists was investigated, but 
there was no clear support for a receptor mediated effect of arecoline via 
cholinergic receptors in the response seen.  
 
Having seen clear effects on cytokine production in Chapter 3, the possibility that 
separate and unexpected responses might occur was examined in Chapter 4, 
describing Microarray analysis of HUVEC treated with sub-toxic arecoline at 111 
µg/ml. Analysis identified differential expression of genes with a fold change of 
±1.3, and were analyzed using MetaCore software for specific and relevant 
biological functions and pathways. A number of gene groups with important 
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relevant biological functions were seen to be modified, including those involved 
with: the inflammatory response, cell cycle and its regulation, the immune 
response, the oxidative stress response, the DNA damage response, tissue 
remodeling, cell differentiation, apoptosis and mitogenic signalling. Of particular 
relevance was the oxidative stress response, where a number of important genes 
including HMOX1, TXNRD1, HERPUD1 and protein kinase C were up-regulated, 
while a range of separate stress response genes including heat shock proteins 
were also up-regulated. Microarray data were consistent with findings shown in 
chapters 2 and 3, and further validated by quantitative real-time reverse 
transcription polymerase chain reaction. It was concluded that arecoline causes 
oxidative stress in endothelium, that in turn can regulate diverse biological 
pathways involved in the process of oral submucous fibrosis, and potentially 
progression to oral squamous cell carcinoma, as the role of oxidative stress has 
been extensively studied and reported in various fibrotic and cancerous 
conditions. 
 
Chapter 5 outlines the main findings of this thesis in context of the literature, and 
describes further work that would be interesting to pursue in light of the findings 
described.  
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1. CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1. The Areca Palm and Nut 
1.1.1. Botanical Identity of the Areca Palm and Nut  
Areca catechu is a single truncated, slender palm, which can reach to a mature 
height of 10-20 m with 25-40 cm trunk. The areca nut is the hard dried endosperm of 
ripe and unripe seeds of the fruit of the oriental palm Areca catechu Linnaeus. The 
fruit is a fibrous ovoid drupe, yellow to orange or red when ripe, and has a pericarp 
approximately 6 mm thick. There is a single brown, acorn sized seed that has a 
flattened conical or ellipsoid shape. The flowers are unisexual, with both male and 
female parts in the same inflorescence (Staples and Bevacqua 2006).  
 
Areca nut is commonly used as a mild stimulant (Norton 1998, Winstock 2002), but 
because areca nut preparations are often wrapped in the leaf of the betle piper vine, 
the term 'Betel nut' has often been incorrectly used in naming the areca nut proper 
(Humans 2004). To avoid confusion, the botanically correct term 'areca nut' will be 
used in this thesis.  
 
1.1.2. Production and Composition of The Areca Nut 
Areca nut is grown worldwide as an important cash agricultural product. It is 
cultivated from east Africa and the Arabian Peninsula across tropical Asia and 
Indonesia to the Pacific Islands (Staples and Bevacqua 2006). The world's largest 
producers estimated by the Food and Agriculture Organization are shown in Table 
1.1.  
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Table 1.1. Worldwide production of areca nut (metric tons) between 1971      
and 2011 
Country                     1971            1981             1991                2001             2011 
Bangladesh               23369    25051    24120     47000 92589                                 
Bhutan       NA        NA      2395 3200 7352                                         
China 10075 24358   111090 165076 129316                                     
India 141000 195900   238500 330000 478000                                     
Indonesia 15000 18000     65177 130268 183100                                     
Kenya        NA        NA          88 150 110                                           
Malaysia 3000 2500       4000 2500 646                                           
Maldives 1 5 16 37 10                                             
Myanmar 19203 25807 32270 51463 121003                                     
Nepal        NA        NA 2400 3400 7620                                         
Sri Lanka        NA        NA 3000 11000 31600                                       
Thailand        NA        NA 13211 23000 31203                                       
World 211648 291621 496267 767094 1082549                                   
  FAO (2011) 
 
 
 
  
Chapter 1,  Introduction and Literature Review                                                    Page 6 
Production of areca nut is on the rise in most South Asian countries, while it has 
been revealed that the total yield has increased several fold, and countries not 
producing areca nut have started production over the last few decades (FAO, 2011).  
 
1.1.3. The Composition of Areca Nut 
The chemical composition of areca nut varies depending upon the geographical 
location of growth and degree of maturity of the nuts. Comprehensive studies on the 
chemical composition of the areca nut are reported (Raghavan and Baruah 1958, 
Jayalakshmi and Mathew 1982), and describe the main constituents as being 
polysaccharides, protein, fat, polyphenols (Flavonols and Tannins), crude fibre, 
alkaloids and mineral contents (Table 1.2). 
 
Of all constituents identified, alkaloids have been accepted as the most important 
biological components of areca nut from the perspective of human health. The four 
principal alkaloids found are arecoline, arecaidine, guvacoline and guvacine (Lord, 
Lim et al. 2006). Of these, arecoline is considered the principal alkaloid, and as 
shown in Table 1.2 ranges of concentrations within nuts depending on ripeness 
(Humans 2004). Table 1.3 shows the relative percentage of the four relevant 
alkaloids found in fresh areca nut harvested in Darwin, Australia (Huang and McLeish 
1989)  
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Table 1.2. Composition (%) of unprocessed green (unripe) and ripe areca nuts 
Ingredients                            Unripe nut (%)                                     Ripe Nut (%) 
Moisture content                        69.4-74.1                                              38.9-56.7 
Polysaccharides                        17.3–23.0                                             17.8–25.7 
Crude protein                                6.7–9.4                                                 6.2–7.5 
Fat                                               8.1–12.0                                                9.5–15.1 
Crude fibre                                    8.2–9.8                                              11.4–15.4 
Polyphenols                              17.2–29.8                                              11.1–17.8 
Arecoline (Alkaloid)                   0.11–0.14                                              0.12–0.24 
Ash                                               1.2–2.5                                                  1.1–1.5 
 From Jayalakshmi & Mathew (1982) and (IARC Monographs Volume 85) 
 
  
 
Table 1.3. Alkaloids of fresh areca nut obtained from Darwin, Australia 
Alkaloid                                                                                                     Nut (%) 
Arecoline                                                                                                   0.30–0.63 
Arecaidine                                                                                                 0.31–0.66 
Guvacoline                                                                                                0.03–0.06 
Guvacine                                                                                                   0.19–0.72 
From Huang & McLeish (1989) 
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1.2. Areca Nut Use by Humans 
1.2.1. Drug effects of Areca Nut 
Areca nut has been known for its narcotic, psychosomatic and medicinal properties, 
and is chewed owing to its ability to initiate psychotropic effects including induction of 
mild euphoria with resultant heightened alertness and increased performance (Chu 
2001). These drug effects appear to be the main reason for cultivation of the areca 
nut, while the nut has been the subject of trade from early civilization. Arecoline 
appears to be the main explanation for these neurological effects including attendant 
sympathetic stimulation (Chu 2002). 
 
Areca nut also possesses potential analgesic, sedative, anti-inflammatory and anti-
oxidant properties (Bhandare, Kshirsagar et al. 2010). Further medicinal properties 
attributed to areca nut include anthelmintic, anti-mycobacterial, aphrodisiac, 
antidepressant and anti-hypertensive activities (Inokuchi, Okabe et al. 1986, Norton 
1998, Dar and Khatoon 2000, Gautam, Saklani et al. 2007). In addition, areca nut 
has been used as an appetite suppressant in food deficient communities, and in 
order to regulate body weight due to its effect on appetite and energy expenditure 
(Strickland, Veena et al. 2003). Table 1.4 summarizes most of the reported effects of 
areca nut in man, while it seems clear that the wide-ranging use of areca nut across 
thousands of years reflects potent pharmacological effects of the nut. Of concern, is 
that areca nut is now regarded as a human carcinogen (Humans 2004). 
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Table 1.4. Effects and use of areca nut in humans 
Psychosomatic effects 
   A sense of well-being  
   Euphoria  
   Heightened alertness  
   Sweating and warm sensation  
   Increased salivation  
   Prevention of hunger  
   Increased capacity to work  
   Suppression of boredom  
   Addiction 
Medical uses  
   Analgesics 
   Anti-inflammatory 
   Anti-depressant  
   Anthelminthic  
   Mental illness  
   Aphrodisiac  
   Digestive agent  
   Enhance cognitive function 
Social and cultural functions  
   A primary means of initiating and  
   Promoting interpersonal relationships  
   Ceremonial purposes 
Carcinogenic effects 
   Oral squamous cell carcinoma 
Taken from Chu (2001) and Humans (2004) 
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1.2.2. Areca Nut Chewing Habits 
Areca nut chewing habit is strongly interwoven into regional art, religious ceremonies, 
cultural rituals and social costumes across a wide range of communities. The earliest 
records of areca nut use show its application around 600 BC in Benares, India and 
504 BC in Ceylon, while the 3rd century BC Greek philosopher Herodotus also 
reported its use (Rosengarten 1969).  
 
Areca nut is chewed in a variety of ways, and at different stages of the nut's maturity 
according to preference. It has a slightly bitter and characteristic astringent taste, and 
can be consumed as fresh green nuts or after drying and curing with roasting, baking 
and sun drying.  Further, the nut may be combined with various separate ingredients 
in commercially available or home made products as shown in Table 1.5.  
 
Betel quid, which is synonymous with pan or paan, is a popular chewing habit for 
areca nut consumption. The term 'quid' refers to a substance, or mixture of 
substances placed in the mouth or chewed, and remaining in contact with the oral 
mucosa. The quid usually contains areca nut or tobacco, either alone or combined, 
while these may be in raw or processed-manufactured form (Zain, Ikeda et al. 1999). 
Additional ingredients are further added according to taste, so that commonly the 
quid contains areca nut, tobacco, slaked lime, and separate spices such as 
cardamom, saffron, cloves, aniseed, turmeric, mustard and sweeteners, all wrapped 
in the leaf of the betel piper vine. 
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Table 1.5. The composition of differing areca nut preparations 
 Areca nut                            Areca1       Betel2       Catechu    Tobacco    Slaked 
 Chewing                               Nut      Component                                         Lime                                                        
 (Methods)                                                                   
Areca                                        X                                                                        X 
Betel quid without tobacco       X                 X3             X                                    X 
Betel quid with tobacco            X                 X3             X                  X                X 
Gutka                                       X                                  X                  X                X 
Pan masala4                             X                                  X                                    X 
Mawa                                       X                                                       X               X 
Mainpuri tobacco                     X                                                       X               X 
Lao-hwa (Taiwan)                    X                X5                                                     X 
Betel quid (Taiwan)                 X                 X3                                                    X 
Stem quid (Taiwan)                 X                 X6                                                    X 
Modified from IARC 2004 
1 Unripe, raw or processed 
2 Leaf, Inflorescence or stem of betel tree 
3 Leaf of betel 
4 Unripe form 
5 Inflorescence  
6 Stem of inflorescence 
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1.2.3. Prevalence of the Areca Nut Chewing Habit 
Areca nut usage is indigenous to the Indian sub-continent, South East Asia, Pacific 
Islands and in migrant communities arising from these regions. According to one 
estimate, areca nut is consumed by approximately 600 million people worldwide as a 
masticatory substance (Gupta and Warnakulasuriya 2002) so that in the order of 10-
20 % of the world population appears to have consumed areca nut.   
 
Several surveys have been conducted to investigate the prevalence of areca nut 
chewing in selected populations, while one challenge facing accurate documentation 
of areca nut use is the variety of separate added ingredients including tobacco. Data 
from several studies undertaken since 1970 in different countries in population-
based, hospital-based and school-based surveys are listed in Table 1.6 (Gupta and 
Warnakulasuriya 2002).  
 
The percentage incidence of areca nut chewing varies widely in different populations 
and also between men and women within populations. There are many demographic 
and ethnographic differences, but it is interesting to note the great variability in use of 
areca nut by the two sexes across differing communities, while in general, use 
increases with age (Strickland 2002). It is also noteworthy that large groups of people 
originally from South East Asia, but now having migrated to new countries including 
South Africa, The United Kingdom, Australia and The United States, frequently use 
proprietary forms of the areca nut (Humans 2004). 
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Table 1.6. The prevalence of areca nut use among adults in selected 
populations 
                                               Men                    Women                        All 
                                           n           %             n           %                n             % 
India, Bombay                40,071      34        50,527      27           99,598         32 
Pakistan, Karachi             2,661        3          2,093        8             4,754           5  
Sri Lanka                            316       54             817      42             1,133         45 
Thailand                             986       16             880      19             1,816          17  
Taiwan, Kaohsiung             511      28             651         1            1,162          13 
Sarawak                             195       30             263       63               458         49 
Cambodia                          366         7              953       41            1,319         31 
China, Xiangtang city      6,057       39          4,989       30          11,406         35 
Modified from (Gupta and Warnakulasuriya 2002) 
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1.3.  Oral Conditions Associated with Areca Nut Chewing 
1.3.1. Mucosal Surfaces Exposed to Areca Nut 
Although the whole oral mucosal surface is exposed to areca nut during chewing in 
it's various forms, areca nut is often retained in lower buccal sulcus so that this area 
as well as the retro-molar areas seem particularly heavily exposed. A number of 
separate and related oral conditions attributed to areca nut chewing are reported and 
briefly discussed below. 
 
1.3.2. Areca Nut Chewer’s Mucosa 
Areca nut chewer's mucosa refers to yellowish or reddish-brown wrinkled 
encrustations of the oral mucosa in immediate contact with areca nut. These 
encrustations can be scrapped off the mucosa, leaving behind a mucosa that is 
altered in colour to be whitish but non-elevated (Mehta, Pindborg et al. 1971). There 
may also be incorporation of quid particles within the oral mucosa.  
 
This condition is thought to be caused by either the direct effect of the quid on the 
mucosa, or alternatively the traumatic action of chewing, or both combined to cause 
epithelial desquamation. This condition is not thought to be pre-malignant.  
 
1.3.3. Licheniod Oral Mucosal Lesions 
Oral mucosal lesions with some characteristics similar to the auto-immune condition 
'lichen planus' have been reported in areca nut chewers, particularly in the buccal 
vestibule where the quid is placed (Daftary, Bhonsle et al. 1980). These lichenoid 
lesions present as fine, wavy, non-elevated and unilateral white parallel lines, with no 
crossing striations, and occasionally radiating from central erythematous areas. The 
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similarity in appearance to lichen planus has led to the suggestion that the lichenoid 
reaction to areca nut is a form of hypersensitivity reaction (Trivedy, Craig et al. 2002).  
 
Betel quid associated licheniod oral lesions regress and resolve spontaneously 
following cessation of areca nut use, and have a completely different natural history 
in intervention studies compared with lichen planus, so that it seems reasonable to 
conclude that lichenoid reactions are distinctly separate entities to lichen planus 
proper (Zain, Ikeda et al. 1999). Lichenoid reactions are not thought to have any 
malignant potential.  
 
1.3.4. Oral Leukoplakia and Erythroplakia 
Oral Leukoplakia is defined as a white patch or plaque that cannot be scraped off, 
and also cannot be characterized clinically or pathologically as any other disease, 
and is not attributable to any known cause except tobacco (Axell, Holmstrup et al. 
1984). Oral erythrplakia is similarly defined as a red oral mucosal lesion that cannot 
be attributed to any known cause (Fischman, Ulmansky et al. 1982).  
 
The white appearance of the oral mucosa in leukoplakia is the result of hyper-
keratinization of the oral epithelium, while the red appearance is attributed to atrophy 
of the oral epithelium combined with vascular changes and inflammation in the sub 
epithelium. 
 
Leukoplakia has potential for malignant transformation, with a rates reported as 
varying from 0.1 to 17.5 % (Van der Waal, Schepman et al. 1997).  Erythroplakia has 
a greater potential for malignant transformation, with up to 25% of cases presenting 
with invasive oral squamous cell carcinoma (Gupta, Bhonsle et al. 1989).  A strong 
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and direct relation has been reported between the chewing of areca nut and oral 
leukoplakia in extensive research studies from different countries (Trivedy, Craig et 
al. 2002). 
 
1.3.5. Oral Sub Mucous Fibrosis 
Oral sub mucous fibrosis (OSF) is a chronic fibrotic pre-malignant condition of the 
oral cavity characterised by deposition of fibrous bands in the sub epithelial layers of 
the pharynx, palate, fauces, cheek and lips, to produce varying levels of physical 
restriction. A similar condition was mentioned as early as 600 BC, however in recent 
times it was first reported in 1952 in five Kenyan women of Indian origin (Schwartz 
1952).  
 
OSF is now considered to be a condition with progressive fibrosis of the oral mucosa, 
which is uniquely associated with areca nut chewing. Areca nut use has a strong 
association with the development of OSF reported by numerous studies over the last 
5 to 6 decades, and this condition will be discussed in more detail in section 1.6 of 
this thesis. 
 
1.3.6. Oral Squamous Cell Carcinoma  
Areca nut chewing is a high risk factor for the development of oral squamous cell 
carcinoma in areas where a high portion of the population practices this habit. Oral 
cancer has a traditionally high incidence in Asia, with a higher proportion of victims 
(3-5%) has reported in Asia compared to western countries (Parkin, Whelan et al. 
2003).  
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Numerous risk factors for oral cancer are reported including: genetic factors, alcohol 
consumption, dietary deficiencies, tobacco, and infections such as by Human 
Papilloma Virus (Smith, Hoffman et al. 1998, Warnakulasuriya 2009).  Of relevance 
for the current thesis, are numerous epidemiological studies over the last six decades 
confirming that areca nut chewing increases the risk of developing oral squamous 
cell carcinoma (Humans 2004).  
 
In one follow-up study, 9 out of 410 patients with leukoplakia who were chewing 
areca nut with tobacco developed oral cancer within 10 years (Gupta, Mehta et al. 
1980). This study further revealed that 1 in 44 cases of oral sub mucous fibrosis 
developed in to oral cancer.  In a separate 5 to15 year follow-up study of 66 patients 
presenting with OSF, malignant transformation was seen in in 3 cases at 3, 4, 7 
years after diagnosis, with an overall rate of 4.5 % malignant change (Pindborg, Murti 
et al. 1984). In a further population sampling of 27,600 subjects conducted in Kerala 
India, 66 patients diagnosed with OSF were followed for 17 years, while 5 of these 
patients developed oral squamous cell carcinoma, thus making a malignant 
transformation rate of 7.6 % (Murti, Bhonsle et al. 1985).  In an aged and sex 
matched control study conducted in Karachi, Pakistan, it was found that areca nut 
chewers were 9.9 times more likely to develop oral cancer than non-chewers, while 
the same study revealed that subjects diagnosed with OSF developed oral cancer 
19.1 times more frequently than those without it (Merchant, Husain et al. 2000).  
 
In addition, an association exists between areca nut use and cancer of separate 
organs such as the lungs, liver, and stomach in both human and animal studies 
(Humans 2004, Sharan 2010). 
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1.4. Systemic Conditions Associated with Areca Nut use 
Areca nut chewing has been reported to affect a number of physiological systems 
including the cardiovascular system to cause hypertension, tachycardia and 
ventricular fibrillation (Tseng 2008).  In addition, areca nut is associated with 
cerebrovascular conditions including epilepsy, coma and dizziness (Deng, Ger et al. 
2001, Huang, Xiao et al. 2003).  Areca nut use is also associated with a high risk for 
obesity, hyperglycemia and type 2 diabetes (Yen, Chiu et al. 2006, Lin, Pi‐Sunyer et 
al. 2009). Further conditions associated with areca nut use are: hepatic disorders 
(Tsai, Jeng et al. 2004, Wu, Boucher et al. 2009);  esophageal inflammation and 
fibrosis; aggravation of asthma, bronchospasm and respiratory discomfort (Misra, 
Misra et al. 1998, Deng, Ger et al. 2001); urolithiasis and chronic kidney disease 
(Chou, Cheng et al. 2009); and  low birth weight (Yang, Chung et al. 2001, Yang, Lee 
et al. 2008).  
 
1.5. Arecoline 
1.5.1. The Chemical Structure of Arecoline 
Arecoline (methyl-1, 2, 5, 6-tetrahydro-1-methylnicotinate) has a molecular mass of 
155.194 Da and is the main alkaloid found in areca nut in addition to arecaidine, 
guvacine and guvacoline as shown in Tables 1.2 and 1.3.  Although areca nut is 
reported to contain 6 alkaloids, only 4 have been precisely identified with the 
chemical structure as shown in Figure1.1 (Mujumdar, Kapadi et al. 1982). The effects 
of areca nut chewing on sympathetic and parasympathetic nervous systems are 
mainly due to pharmacological actions of arecoline on these systems as shown in 
Table 1.4 (Taylor 1980).  
 
 
Chapter 1,  Introduction and Literature Review                                                    Page 19 
 
 
 
 
 
 
 
 
 
Figure 1.1. The chemical structure of four areca nut alkaloids.  
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1.5.2. The Pharmacology of Arecoline 
Arecoline joins pilocarpine and muscarine as the 3rd naturally occurring 
cholinomimetic alkaloid (Taylor 1980). Arecoline is a known muscarinic agonist 
affecting both central and autonomic nervous systems, and predominantly the 
parasympathetic nervous system (Soncrant, Raffaele et al. 1993). Nonetheless, it 
has been suggested that together with other components in areca nut, arecoline has 
a stimulatory effect on the sympathetic nervous system (Richards 1990, Chu 2001). 
 
Arecoline has been detected in blood plasma by quantitative analysis using gas 
chromatography-mass spectrometry (GC-MS) after dermal and oral mucosal 
application. Strickland et al. (2003) studied the absorption and plasma level of 
arecoline in eight subjects. He assayed freshly dried areca nut for arecoline content 
(0.17%), which was applied to buccal mucosa so as to deliver 0, 5, 10 and 20 mg 
arecoline. Arecoline was detected in blood plasma, and increased in concentration in 
a dose and time dependent manner. 
 
The metabolism of arecoline is complex and has been reported in few studies, mainly 
involving the use of animal experiments (Humans 2004). Arecoline metabolism is 
predominantly in the liver and kidney, and the principal metabolic pathway appears to 
be hydrolysis to arecaidine, before N-oxidation, together with double bond reduction 
to produce arecoline N-oxide, and N-methylnipecotic acid.  A very little quantity of 
arecoline comprising as little as 0.3 to 0.4% of a single dose, is excreted unchanged 
in urine (Humans 2004, Giri, Idle et al. 2006). 
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1.5.3. Arecoline in the Management of Psychiatric Disorders and Alzheimer’s 
Disease 
Arecoline has been investigated in clinical trials in psychiatric and neurological 
disorders because of arecoline's cholinergic activities and cholinergic mechanisms 
have been implicated in these conditions. 
 
Little improvement is reported following arecoline treatment of severe depression and 
schizophrenia.  A limiting factor, has been the associated side effects which include 
tremors, stiffness, and idiosyncratic responses such as bradycardia or tachycardia, 
as well as possible toxicity at higher doses (Abramson, Brown et al. 1985, Sullivan, 
Allen et al. 2000, Tammenmaa, McGrath et al. 2002). 
 
Alzheimer’s disease associated dementia has been treated with arecoline with 
significant and replicable improvement in memory in some subjects, but limited 
success in others (Soncrant, Raffaele et al. 1993, Cummings 2000). Variability in 
effectiveness amongst patients, together with emergence of many side effects 
through non-selective binding of muscarinic receptors, undermines use of arecoline 
for this patient group (Francis, Palmer et al. 1999). 
 
1.5.4. The Carcinogenic Potential of Arecoline 
Areca nut is regarded as group 1 carcinogen by the international agency of research 
on cancer (IARC) (Humans 2004), while arecoline has tumorigenic potential in some 
systems (Humans 2004).  For example, arecoline cause tumors in liver, lungs and 
stomach of Swiss strain mice after oral administration (Bhide, Gothoskar et al. 1984). 
Mutagenicity in cell culture system has been reported for arecoline causing mutation 
in Chinese hamster V79 cells (Shirname, Menon et al. 1984); chromosomal 
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aberration and sister-chromatid exchange in hamster ovary (CHO) cells (Dave, 
Trivedi et al. 1992); and inhibition of p53 gene and suppression of DNA repair in 
human epithelial cells (Tsai, Lee et al. 2008).  
 
One recent animal study concluded that arecoline might be involved in the induction 
of gene mutation in vulnerable individuals (Wu, Xing et al. 2012). In summary, 
arecoline seems to be a risk factor in the causation of cancer but the exact 
mechanisms are yet to be further explored. 
 
1.5.5.  The Cytotoxic Potential of Arecoline 
Arecoline induced cyto-toxicity has been extensively studied and various 
mechanisms have been suggested, with most studies focusing on either cell culture 
systems (Humans 2004), or animal-based experiments (Humans 2004, Dasgupta, 
Saha et al. 2006) .  
 
Arecoline is toxic for numerous cell lines, although the response differs depending 
upon the cell type, concentration of arecoline, and time of incubation (Chang, Liao et 
al. 2004, Humans 2004). Both cytostatic and cytotoxic effects are reported for oral 
mucosal fibroblasts in cell culture, and these effects are modulated by changes in cell 
density, serum concentrations and duration of exposure (Tsai, Kuo et al. 1997). A 
reduction in human buccal fibroblast culture density occurs in response to 0.2mM 
arecoline, which is further reduced with glutathione depletion suggestive of a role for 
oxidation mechanisms (Chang, Tai et al. 1998, Jeng, Tsai et al. 1999). Inhibition of 
mitochondrial activity and depletion of intracellular thiol has been reported as one of 
the toxic responses to arecoline in human gingival fibroblasts at concentrations 
above 50 µg/ml (Chang, Hu et al. 2001). Prolonged exposure of KB cancer and SAS 
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epithelial cells to arecoline at 0.4mM induces cell cycle deregulation and death  (Lee, 
Chang et al. 2006, Chang, Chan et al. 2012).  
 
At the time work described in this thesis commenced, there were no reports of 
arecoline toxicity in endothelium so that work described in Chapter 2 was 
unprecedented for endothelium upon commencement.  Of particular relevance and 
consistent with the findings described in Chapter 2 of this thesis, however, is the very 
recent report of arecoline induced cytotoxicity in human endothelial cells (Tseng, 
Chang et al. 2012). 
 
Intra cellular production of reactive oxygen species (ROS) in response to arecoline 
has been shown to cause chromosomal aberration, DNA damage and apoptosis 
(Yen, Lin et al. 2011). In addition, there are numerous in vitro research studies, which 
further explain the cytotoxic potential of arecoline, but the underlying mechanisms 
are not fully identified and well characterized (Chang, Hu et al. 2001, Lee, Chang et 
al. 2006).  
 
Arecoline has been reported to cause toxic and genotoxic effects in a number of 
animal studies affecting cells of different origins such as hepatocytes, lymphocytes 
and bone marrow cells (Dasgupta, Saha et al. 2006, Chou, Guh et al. 2008).  
Embryos of zebrafish exhibit developmental growth retardation in response to toxic 
effects of arecoline (Chang, Liao et al. 2004). Furthermore, administration of 
arecoline in mice at peri-implantation stages of pregnancy results in a decreased 
number of implanted embryos, and also trophoblastic outgrowth of blastocysta is 
inhibited due to toxicity (Liu, Young et al. 2011). 
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 1.5.6. The Immune-Modulatory Effects of Arecoline 
Arecoline has immune-modulatory and immune-suppressive effects by mechanisms 
not fully understood. When injected subcutaneously in mice, arecoline suppresses 
both humoral and cell-mediated immunity (Rao, Shahabuddin et al. 1980). Arecoline 
administration to mice for few weeks causes considerable reduction in mass and 
cellularity of the thymus, spleen and mesenteric lymph nodes, while white and red 
blood cell counts decrease in a dose dependent manner (Selvan, Venkateswaran et 
al. 1989). The immune suppression has been attributed to cholinergic arecoline 
targeting of the muscarinic acetylcholine receptors of the non-neuronal cholinergic 
system (Wen, Zhang et al. 2006).  
 
Recently published studies describe an inhibitory effect of arecoline on Interleukin 6 
(IL-6) production by Keratinocytes, KB epithelial (epithelial cell line) and basal cell 
carcinoma cells, along with apoptosis and cell cycle arrest (Huang, Hsieh et al. 
2012).  The cellular response to arecoline with down regulation of inflammatory 
cytokines may contribute to immune modulation, but there is little literature describing 
this aspect of the cellular response to arecoline.  
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1.6. Detailed Description of Oral Submucous Fibrosis  
1.6.1. The Clinical Features of Oral Submucous Fibrosis Include Reduced 
Tissue Vascularity 
As very briefly outlined in 1.3.5 above, OSF is an insidious chronic, fibrotic disease of 
the oral cavity with considerable functional morbidity and malignant potential. The 
hallmark of the disease is sub mucosal fibrosis affecting the oral cavity, pharynx and 
upper esophagus. In its early stages, fibrosis is limited to the lamina propria, but with 
time may extend further into deeper tissues including underlying muscles, and the 
effect of this is progressive and significant loss in mucosal fibro-elasticity. As a 
consequence, patients experience rigidity of the lips, tongue and palate, with difficulty 
in mouth opening. In addition, a burning sensation and intolerance to spicy foods has 
been reported (Tilakaratne, Klinikowski et al. 2006). 
 
OSF affects both genders but several researchers report a female predominance 
(Klieb and Karen Burgess , Shah, Lewis et al. 2001). Most patients present in 
different stages of progression between 20 and 40 years of age, although there is 
great regional variability (Gupta, Mehta et al. 1980). The retromolar area and buccal 
mucosa are the two predominantly affected sites followed by the soft palate, fauces, 
uvula, tongue and labial mucosa. Many observers conclude that OSF originates in 
the posterior part of the oral cavity, with gradual involvement of anterior structures 
(Canniff, Harvey et al. 1986). The commonest presenting complaint is limited mouth 
opening, with a burning sensation on eating. Other symptoms include difficulty in 
eating, altered taste, fluctuation in saliva production, and a nasalized voice. 
 
The earliest visible sign is a characteristic blanching of the oral mucosa, which may 
be localized, generalized or diffused to impart a marble-like appearance, while 
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blanching appears to be the result of increased fibrosis together with a reduced 
vasculature. As the disease progresses, fibrous bands are observed in the buccal 
mucosa, posterior part of the mouth and labial mucosa, and these stiffen the mucosa 
to limit mouth opening. In addition, mobility of the soft palate is affected, the uvula 
shrinks to appear bud-like, and the tongue becomes stiff with papillary atrophy as 
well as limited mobility and protrusion. The floor of the mouth becomes blanched and 
leathery and the gingiva appears fibrotic and depigmented with loss of stippling (Cox 
and Walker 1996). 
 
1.6.2. The Histological Features of Oral Submucous Fibrosis Include 
Progressive Vascular Obliteration 
Histologically, the epithelium appears atrophic and exhibits para-keratosis and or 
ortho-keratosis. There may also be dysplastic changes in epithelium affecting up to 
25% of cases, predominantly consisting of irregular stratification, enhanced mitotic 
activity, nuclear pleomorphism and hyperchromatism (Cox and Walker 1996). OSF 
specimen has shown predominance of collagen type I, loss of procollagen type III 
and almost complete loss of collagen type VI (Reichart, Wyk et al. 1994). 
 
Pindborg and Sirsat defined connective tissue changes as belonging to four 
categories. In the very early stage, the connective tissue accumulate fine fibrillar 
collagen, with pronounced edema, large fibroblasts, dilated and congested blood 
vessels and inflammatory infiltrates consisting mainly of neutrophils and occasional 
eosinophils (Pindborg and Sirsat 1966). 
 
The early stage is marked by initial hyalinization, thick collagen bundle and a 
reduction in fibroblast density, with congested and dilated blood vessels and 
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inflammatory cells consisting of mononuclear lymphocytes, eosinophils and 
occasional plasma cells (Pindborg and Sirsat 1966).  
Progression to the moderately advanced stage is associated with moderate 
hyalinization of the connective tissues, with thickened collagen bundle, residual 
edema, adult fibroblasts with elongated spindle shaped nuclei and scanty cytoplasm, 
constricted blood vessels and an inflammatory infiltrate mainly comprising 
lymphocytes and plasma cells with occasional eosinophils (Pindborg and Sirsat 
1966). 
 
The advanced stage is characterized by advanced hyalinization to form of a smooth 
sheet of collagenous material with few fibroblasts, although occasional thin elongated 
cells or vestigial nuclei are occasionally seen, as well as the complete absence of 
edema and the presence of lymphocytes and plasma cells. Notably, this late stage of 
the disease is accompanied by great rarefaction of the vasculature.  
 
Of particular importance for this thesis, is that development of the disease from early 
through to the advanced stage is associated with progressive narrowing and 
obliteration of blood vessels (Pindborg and Sirsat 1966).  In light of the important role 
of arecoline in OSF, as well as the progressive reduction in vasculature with 
advancing disease, this thesis investigated the potentially toxic effect of arecoline on 
human endothelium.  
 
 1.6.3. The Aetiology and Pathogenesis of OSF 
OSF was first reported in 1952 as an idiopathic disorder (Schwartz 1952), although 
the researchers tried to implicate various environmental agents as the possible 
etiological factors. It is now concluded that areca nut use is the major cause of OSF, 
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since the disease is ubiquitous in South Asia and neighboring countries where this 
habit has been prevalent since prehistoric times. In addition, numerous 
epidemiological and cross-sectional surveys, case control studies, case-series 
reports, intervention, and cohort studies provide strong evidence that areca nut is the 
main aetiological factor (Tilakaratne, Klinikowski et al. 2006). There seems only a 
single paper available in the literature demonstrating the presence of OSF in few 
individuals  who were not areca nut chewers (Seedat and Van Wyk 1988). 
 
Of particular importance is the role of extracellular matrix (ECM) in OSF (Tilakaratne, 
Klinikowski et al. 2006), and it seems evident that enhanced collagen production and 
or reduced collagen degradation plays an important role, so that altered expression 
of biological pathways relevant to production and degradation of the ECM must play 
a role (Rajalalitha and Vali 2005).  
 
1.6.4.  Role of Areca Nut Alkaloid in Fibroblast Proliferation and Increased 
Collagen Production 
Arecoline and its metabolite arecaidine have been shown to cause proliferation of 
fibroblasts and increased synthesis of collagen in cell culture as well as in histological 
sections of oral mucosa in OSF patients (Harvey, Scutt et al. 1986). In addition, in 
vitro studies on human fibroblasts demonstrate increased collagen production by 
OSF fibroblasts compared to normal fibroblasts in response to arecoline, and this 
may reflect clonal selection of fibroblast populations in the altered tissue environment 
of OSF under the influence of local factors such as inflammatory cytokines (Meghji, 
Scutt et al. 1987).  
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Several mechanisms have been reported that support a primary role for arecoline in 
the causation of OSF (Rajalalitha and Vali 2005, Tilakaratne, Klinikowski et al. 2006). 
Transforming growth factor beta (TGF- β) is a pro-fibrotic cytokine that is significantly 
overexpressed in tissues affected with OSF. In vitro studies demonstrate that 
arecoline regulates TGF- β  expression in epithelial cells by calcium and protein 
kinase C dependent pathways via activation of M-3 muscarinic receptors (Thangjam, 
Agarwal et al. 2009). 
 
Connective tissue growth factor (CTGF) is associated with the onset and progression 
of fibrosis in many human tissues, and immunohistochemical staining reveals 
expression of CTGF in fibroblasts, epithelial and endothelial cells. In vitro studies 
demonstrate that arecoline stimulates the production of CTGF in buccal mucosal 
fibroblasts, while this appears mediated by ROS, NF-kB, JNK and P38 MAPK 
pathways (Deng, Chen et al. 2009). 
 
Transglutaminase-2 (TGM-2), a calcium binding protein that stabilizes ECM and 
S100 calcium binding protein A4 (S100A4) has been over expressed in various 
fibrotic disorders including OSF. Arecoline up-regulates the expression of TGM-2 in 
human gingival fibroblasts, and this appears to be mediated via M-2 muscarinic 
receptor activity (Thangjam, Agarwal et al. 2009). Similarly S100A4 expression is 
elevated in fibroblasts by arecoline, and this is inhibited by mTOR inhibitor rapamycin 
(Yu, Tsai et al. 2013). 
 
In conclusion, there are many studies consistent with a fibrotic response to arecoline, 
while some of these include roles for plasminogen activator inhibitor-1, cyclo-
oxygenase-2, tissue inhibitor of matrix metalloproteinase (TIMP), and collagen 
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phagocytosis as will be further discussed in the following sections (Rajalalitha and 
Vali 2005, Tilakaratne, Klinikowski et al. 2006). 
 
1.6.5. Fibrogenic Cytokines in Oral Submucous Fibrosis 
Increased levels of fibrogenic cytokines including Transforming Growth Factor-β 
(TGF-β), Platelet Derived Growth Factor (PDGF), and Basic Fibroblast Growth Factor 
(bFGF) have been demonstrated in tissues affected with OSF compared with 
unaffected tissues (Haque, Harris et al. 1998). Furthermore, pro-inflammatory and 
anti-fibrotic cytokines including Interferon-g (IFN-g) have been demonstrated in OSF 
(Haque, Meghji et al. 2000). Cytokines are accepted as important in many conditions, 
including systemic sclerosis and other fibrotic disorders that OSF is similar to (Scala, 
Pallotta et al. 2004). In view of the role of cytokines in driving many aspects of fibrotic 
conditions (Koch, Kronfeld-Harrington et al. 1993, Coker and Laurent 1998), one 
aspect investigated in this thesis is the cytokine synthetic response of endothelium to 
arecoline.  
 
1.6.6. The Role of Areca Nut Constituents Other Than Arecoline in Oral 
Submucous Fibrosis 
Although the emphasis in this thesis is upon the role of arecoline in OSF, it is 
accepted that other components of the nut also may play an important role in the 
disease.  For example, tannins from the areca nut inhibit collagenase and thus 
increase the resistance of collagen fibrils to degradation by collagenase.  This activity 
could combine with that of arecoline which stimulates collagen production, to greatly 
increase fibrosis (Meghji, Canniff et al. 1982, Scutt, Meghji et al. 1987). 
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In a separate example, copper levels are elevated in the mucosa of areca nut 
chewers, and since lysyl oxidase is a copper dependent enzyme important for 
maturation of collagen fibres, copper from areca nut may help drive tissue fibrosis 
(Trivedy, Warnakulasuriya et al. 1999).  
 
Notwithstanding the likelihood that there will be many agents in areca nuts that may 
influence OSF, arecoline remains an important and prevalent constituent with known 
biological effects across a range of cells, while there is a paucity of information on the 
endothelial response to arecoline. For this reason, it seems reasonable to focus 
initially on the response of endothelium to arecoline as opposed to other potentially 
important areca nut constituents, as described in this thesis.  
 
1.6.7. Up Regulation of Cyclooxygenase2 in Oral Submucous Fibrosis 
Cyclooxygenase-2 (Cox-2) is an enzyme responsible for synthesis of a range of 
important arachidonic acid derived inflammatory mediators including prostaglandins, 
which might be involved in the pathogenesis of OSF.  Biopsies of buccal mucosa 
from OSF patients with moderate fibrosis demonstrate increased expression of Cox-
2, consistent with an inflammatory response at this stage of the disease (Tilakaratne, 
Klinikowski et al. 2006). This observation is supported by increased Cox-2 
expression by cultured buccal mucosal fibroblasts in response to arecoline (Tsai, 
Chou et al. 2003). 
 
1.6.8. Decreased Collagen Phagocytosis and Collagen Matrix Stabilization in 
Oral Submucous Fibrosis 
Collagen phagocytosis by fibroblasts is an important event during remodeling of 
connective tissues, so that an imbalance in ECM remodeling by reduced collagen 
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phagocytosis may contribute to OSF. Interestingly, fibroblasts from OSF patients 
show a frank reduction in phagocytic activity compared with fibroblasts from control 
subjects (Tsai, Ma et al. 1999). 
 
A balance between Matrix Metalloproteinase (MMPs) and TIMP is required for 
normal deposition of ECM, because disruption could result in excessive retention of 
collagen and ECM. OSF fibroblasts have been shown to produce more TIMP protein 
than normal fibroblasts when incubated with arecoline and arecaidine in cell culture 
(Shieh, Chiang et al. 2003). 
 
1.6.9. The Malignant Potential of Oral Submucous Fibrosis 
The pre-malignant nature of OSF was first reported in 1956 when OSCC was 
observed in one third of the OSF patients (Paymaster 1956). A high prevalence of 
epithelial dysplasia and leukoplakia have been reported in OSF, and according to 
one estimate from 7% to 26% of patients are affected, with some demographic 
variations (Pindborg, Poulsen et al. 1967, Murti, Bhonsle et al. 1985). The malignant 
transformation rate of OSF into OSCC has been reported to vary from 7 to 13% 
(Gupta, Mhaske et al. 2008).  One long term follow up study demonstrated a 
malignant transformation rate of 7.6% over a period of 17 years (Murti, Bhonsle et al. 
1985).  Further supporting a premalignant role for OSF is recognition of areca nut as 
a group one carcinogen by IARC (Humans 2004), and the association of areca nut 
with OSF (Murti, Bhonsle et al. 1995). 
 
It has been hypothesized that dense fibrosis with extremely reduced vascularity of 
the sub mucosal layer along with altered cytokine activity provide a favorable 
environment in which the less protected oral epithelium continuously exposed to 
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carcinogens from areca nut undergoes malignant transformation (Tilakaratne, 
Klinikowski et al. 2006). A role for endothelium in this process, has, however, not as 
yet been described.  
 
1.7. Human Vascular Endothelium 
1.7.1. The Origin and Location of Endothelial Cells 
Vascular endothelial cells form a monolayer on the inner luminal surface of the entire 
vascular system. These cells are quantitatively significant, in that endothelial cells 
comprise approximately 1kg of a 70kg human, with approximately 1013 cells in total, 
and covering an area of about 700m2. Endothelial cells and hematopoietic cells 
derive from a common precursor, the hemangioblast, which is a blast-like bi-potential 
cell (Choi, Kennedy et al. 1998) thought to originate from the ventral floor of the 
dorsal aorta within the aorto-gonad-mesonephros region (Marshall, Moore et al. 
1999). Splanchno-pleuric mesoderm gives rise to mesenchymal cells, which then 
transform into hemangioblasts prior to differentiation to intermediate pre-endothelial 
cells. The pre-endothelial cells then develop into either a hematopoietic or endothelial 
cell line. Endothelial cells have the ability to trans-differentiate into mesechymal and 
intimal smooth muscle cells (Arciniegas, Ponce et al. 2000). 
 
1.7.2. Functional Properties of Human Endothelium 
Endothelial cells are very dynamic and perform numerous metabolic and synthetic 
functions (Sumpio, Timothy Riley et al. 2002). Via both paracrine and endocrine 
activities, endothelial products are capable of influencing cells and tissues throughout 
the body (Michiels 2003).   
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Endothelial cells have tight junctions and act as a semipermeable membrane 
regulating the movement of molecules and cells between the circulation and 
extravascular tissue compartment. Essential macromolecules from the blood are 
carried to the surrounding tissue and cells via specific endothelial transport 
mechanisms to satisfy tissue metabolic demands (Mann, Yudilevich et al. 2003). 
The endothelium regulates vascular tone and blood flow by producing a number of 
vasoconstrictor and vasodilator substances including: nitric oxide, prostacyclin and 
endothelin. In addition these mediators control recruitment and activity of 
inflammatory cells, platelet aggregation and thrombosis, and cell proliferation 
(Epstein, Vane et al. 1990). 
 
Residing at the boundary between blood and tissues, endothelial cells are in strategic 
position to orchestrate immune and inflammatory responses (Danese, Dejana et al. 
2007). Inflammatory cytokines are proteins with a wide range of often overlapping 
activities central to the inflammatory and immune response.  Some of these have 
already been mentioned above in context of OSF (section 1.6.5.), while it is important 
for this thesis to note that endothelial cells are capable of producing many cytokines 
that can be secreted either into the blood or alternatively into the surrounding 
extracellular matrix (An, Schedle et al. 2010).  
 
Endothelial cytokines include Granulocyte Macrophage Colony Stimulating Factor 
(GM-CSF), Granulocyte Colony Stimulating Factor (G-CSF), Interleukin-1 (IL-1), IL-6, 
and bFGF, while expression of these cytokines is modified by stimulation with still 
further cytokines from other sources, drugs, chemical agents, toxins, bacterial 
products, hypoxia, antigens and other mediators (Mantovani, Bussolino et al. 1997). 
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Vascular endothelial growth factor (VEGF) and fibroblast growth factors are 
angiogenic proteins produced by endothelium and other cells. Fibroblast growth 
factors are presented to FGF receptors by binding with high affinity to the heparin 
sulfate proteoglycans (HSPGs) on the surface of many cells and within the ECM, 
forming a reservoir which can be released in a regulated manner (Sanderson, Yang 
et al. 2005). VEGF, via its specific receptors on endothelium, promotes angiogenesis 
from the pre-existing endothelial cells (Hoeben, Landuyt et al. 2004). 
 
Furthermore, endothelial cells have key roles in the maintenance and regulation of a 
non-thrombogenic blood-tissue interface, and so play an important role in 
coagulation, thrombosis, thrombolysis, and platelet adhesion, while endothelial cells 
are further central to wound healing, host defense, leukocyte recruitment (Michiels 
2003).  Figure 1.2 provides a brief summary of endothelial mediators and their 
functions (Galley and Webster 2004). 
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Figure 1.2.  Products of endothelial cells known to contribute to inflammation, 
immunity, haemostasis, anti-coagulation and extracellular matrix production.  
Endothelial cells produce a wide range of products that regulate many important 
biological processes.  
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1.7.3. Human Endothelium in Pathological Conditions 
Because endothelium acts as a receptor-effector structure that counters injurious 
agents to help maintain homeostasis, discordant stimulation and or uncontrolled 
endothelial responses may contribute to pathological conditions including: 
atherosclerosis, vasculopathies, hypertension, heart failure, thrombosis, metastasis, 
sepsis and inflammatory syndromes (Sumpio, Riley et al. 2002).  
 
Vascular insult results in inflammatory and fibro-proliferative responses stimulated in 
partly by endothelial cells, and this has particular bearing on atherosclerosis in which 
endothelial cells contribute to formation of the fatty streak and monocyte adhesion 
(Galley and Webster 2004). 
 
In context of the microvasculature, endothelial cells are activated by numerous 
mechanisms, often related to infection, with a variety of signals involved including 
pathogen recognition pathways such as toll like receptor and lipopolysaccharide, and 
inflammatory mediators including kinins, complement, cytokines, and reactive oxygen 
intermediates (Hunt and Jurd 1998). In addition, contact with adjacent cells and 
matrix stimulates endothelium including inter-endothelial binding, binding to the ECM, 
and binding of platelet, neutrophils, lymphocytes, mast cells, eosinophils and 
mononuclear cells (Pate, Damarla et al. 2010). 
 
1.7.4. Endothelial Cells in Fibrotic Disorders 
Tissue damage from various acute and chronic stimuli such as infection, chemical 
injury, autoimmune reactions or mechanical injury leads to a tissue response which 
may be regenerative in which the damaged cells are replaced by cells of the same 
type, or alternatively may be characterized by the formation of reparative granulation 
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tissue with maturation by fibrosis (Wynn 2007, Kumar, Abbas et al. 2012).  As such, 
fibrosis often results from prolonged tissue injury combined with attempts at repair in 
context of chronic inflammation. 
 
Fibrotic disorders encompass a wide spectrum of disease entities including systemic 
sclerosis, multifocal fibrosclerosis, nephrogenic fibrosis and organ specific conditions 
such as pulmonary, kidney, oral mucosal and hepatic fibrosis (Piera-Velazquez, Li et 
al. 2011). Although fibrosis has diverse causes and variable pathogenesis, the 
disordered and exaggerated deposition of ECM with a large number of activated 
fibroblasts or myofibroblasts appears to be a common feature.  Mechanisms 
contributing to chronic inflammatory fibrosis include: injury to endothelium, activation 
of fibroblasts, release of fibrogenic cytokines such as TGF-β and FGF, inflammatory 
cell recruitment, induction of ROS, matrix induced activation of myofibroblasts, and 
endothelial-mesechyme and epithelial mesenchyme transitions (Kisseleva and 
Brenner 2008, Piera-Velazquez, Li et al. 2011). 
 
Injured endothelium often acquires a pro-thrombotic synthetic profile contributing to 
haemostasis and formation of a provisional ECM. Additionally, platelets activated by 
exposure to the sub endothelium may through their degranulation products drive 
increased vascular permeability (Cloutier, Paré et al. 2012). Endothelial cells, 
epithelial cells and myofibroblasts responsible for contraction during wound 
maturation, produce MMPs that disrupt the vascular basement membrane 
(Stamenkovic 2003). In addition, these cells produce growth factors, cytokines and 
chemokines to recruit inflammatory cells to the site of injury. As part of the attendant 
progressive healing response, inflammatory mediators with fibrogenic and angiogenic 
potential drive repeated cycles of wound healing and fibrosis during persistent 
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chronic injury, and this seems to account for excessive deposition of ECM with 
permanent fibrosis (Wynn 2007, Kisseleva and Brenner 2008).  It seems reasonable 
to see the progressive fibrosis in OSF as an example of this class of chronic 
inflammatory process. 
 
Systemic sclerosis (SSC) is a multi-organ fibrotic disease with significant reduction in 
vasculature and the emergence of avascular areas. Vascular injury plays a key role 
in the pathogenesis of SSC, and was reported as early as 1925 (Brown and O'Leary 
1925). Progressive vascular injury in SSC involves endothelial activation and 
damage, intimal thickening and vascular obliteration, with subsequent tissue 
ischemia, fibrosis and organ dysfunction. Impaired vascular permeability and tone, 
imbalance in vasoconstrictor and vasodilator substances, platelet activation and 
increased procoagulant activity with reduced fibrinolysis are features of vascular 
dysfunction in SSC (Kahaleh 2008).  
 
Vascular injury and dysfunction has been reported in many other fibrotic conditions 
as well. A series of patients with pulmonary fibrosis demonstrated serological and 
pathological changes supporting a role for endothelial injury in propagation of 
parenchymal fibroplasia. In this study, electron microscopy revealed degenerative 
changes in endothelium, signs of endothelial activation such as endothelial swelling 
and pinocytotic vesicles, endothelial cell necrosis and detachment and intravascular 
fibrin formation (Magro, Waldman et al. 2006).  
 
It can be argued that the central role of endothelium in fibrotic processes raises the 
possibility of improved disease control by therapies targeted to endothelium mediated 
mechanisms.    
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1.8. The Cellular Response to Injury 
1.8.1. Cellular Injury, Necrosis, Apoptosis and Autophagy 
Cells constantly adapt to internal and external stimuli to maintain a steady 
homeostatic state. Injury drives cells away from their normal homeostatic state, and 
while adaptation to cellular injuries may restore a new homeostatic state, 
overwhelming injury may drive cells beyond their homeostatic capacity and there is 
consequent cell death (Kumar, Abbas et al. 2012).  
 
With mild injury or in early stages of more significant injury, changes may be 
reversible so that cells are able to survive, despite the presence of reversible 
morphological changes including hydropic degeneration with organellar and cellular 
swelling, or fatty change with the accumulation of lipid droplets in the cytoplasm. 
Reversible injury is often characterized by adenosine triphosphate (ATP) depletion, 
reduced oxidative phosphorylation, while cellular swelling occurs through changed 
ion exchange and water influx (Kumar, Abbas et al. 2012).  
 
When irreversible injury occurs through loss of homeostasis, cells are recognized as 
having become necrotic. Escape of denatured proteins and cell cytoplasm associated 
cytokines into the surrounding tissues drives a significant inflammatory response 
adjacent to necrotic tissues (Kanduc, Mittelman et al. 2002).  
 
Apoptosis is by comparison a much more controlled process, whereby cells also die 
but without loss of plasma membrane integrity, cellular leakage or inflammation.  
Apoptosis removes cells excess to the body in processes such as embryogenesis 
and development, maintenance of certain cell populations, immunological cell death 
caused by cytotoxic T cells. Many pathological conditions have been identified where 
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cell death occurs via apoptosis such as various injurious stimuli including chemicals 
and drugs, radiation, heat and hypoxia, which cause damage to DNA and cellular 
components beyond capacity to repair. Furthermore, apoptosis has been reported in 
viral conditions such as viral hepatitis, pathologic atrophy as seen in the pancreas, 
parotid gland and kidney, and cell death observed in tumors (Elmore 2007). Of 
relevance to the work presented in this thesis, is that endothelial apoptosis accounts 
for reduced vascularity with wound maturation and chronic inflammation (Bolitho, 
Xaymardan et al. 2010). In apoptosis, cells fragment into multiple small apoptotic 
bodies despite maintenance of the integrity of both organellar and plasma 
membranes (Elmore 2007).  
 
Autophagy involves reduction in the size of cells in which there is lysosomal digestion 
of cellular components sequestered within autophagolysosomes. (Kumar, Abbas et 
al. 2012). 
 
1.8.2. Molecular Mechanisms of Cellular Injury  
It is convenient to group types of cellular injury as being either: chemical agents or 
drugs; oxygen deprivation; physical agents; immunological reactions; genetic defects; 
or nutritional imbalances (Kumar, Abbas et al. 2012). In light of the great diversity of 
stimuli involved, it is unsurprising that mechanisms contributing to cell injury are 
diverse and may operate independently or collectively depending upon the kind of 
injurious stimulus.  
 
ATP depletion and decreased ATP synthesis occur in hypoxic injury and some forms 
of chemical toxicity, resulting in disturbances in a wide range of physiological cellular 
processes including: loss of membrane transport systems; lipogenesis; altered 
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metabolic activity and inactivation of many enzymes; failed nucleic acid and protein 
production; detachment of ribosomes and ultimately cell death (Jurkowitz‐Alexander, 
Altschuld et al. 1992, Sheridan and Bonventre 2000). 
 
Mitochondrial damage occurs following exposure to many injurious agents including 
toxins exerting their effect directly and or indirectly. The mechanisms involved seem 
to be oxidative stress, raised cytosolic calcium level and the breakdown of 
phospholipids and other cellular constituents. Mitochondrial damage is expressed by 
altered permeability defect of the inner membrane, called the mitochondrial 
permeability transition. Persistence of inciting stimuli causes permanent disruption in 
mitochondrial membrane potential and oxidative phosphorylation, with subsequently 
irreversible damage and release of cytochrome C into the cytoplasm (Newmeyer and 
Ferguson-Miller 2003, Rasola and Bernardi 2007). The release of cytochrome C has 
the interesting consequence of activating the caspase proteinase cascade 
responsible for mediating apoptosis (Jiang and Wang 2004), but separately failed 
mitochondrial function with reduced ATP can lead to necrosis as well (Susin, Lorenzo 
et al. 1999).  
 
One common pathway towards the morphology of necrosis is greatly elevated 
cytoplasmic calcium. Failed membrane integrity of the endoplasmic reticulum, 
mitochondria and or plasma membrane results in an influx of calcium ions into the 
cytoplasm. This results in greatly enhanced activity of a range of important lytic 
enzymes including ATPases, phosphatases, proteinases, lipases and 
endonucleases, and these enzymes combine to: deplete cells of ATP; deprive cells 
of normal ion pump, protein synthesis and nucleic acid synthesis; degrade RNA, 
DNA and proteins; and further damage membranes.  Notably, there is great 
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interconnectedness of these disparate biochemical events, such that for example, 
reduced ATP further reduces protein and nucleic acid synthesis, or separately 
nucleic acid degradation precludes protein production and hence replacement of 
membrane ion pumps with osmotic swelling and further membrane compromise. 
Ultimately, these multiple interconnected biochemical failures overwhelm the 
homeostatic capacity of cells, so that the cell becomes necrotic.(Trump and 
Berezesky 1998, Orrenius, Zhivotovsky et al. 2003). 
 
In many pathological conditions, cell injury is caused by oxidative stress, a condition 
created due to imbalance between the generation and scavenging of free radicals in 
cells. Constant and prolonged oxidative stress ultimately results in irreversible cell 
injury. Free radicles are chemical species with unpaired electrons in the outer shell 
and are generated as byproducts during mitochondrial respiration as well as by 
peroxisome and other biochemical mechanisms.  ROS are oxygen derived radicals 
used by leukocytes to kill phagocytosed microorganisms (Dupré-Crochet, Erard et al. 
2013), and include superoxide ion (O-), hydroxyl ion (OH), and hydrogen peroxide 
(H2O2), while nitric oxide (NO) is produced through the enzymatic degradation of 
arginine (Bayr 2005, Ott, Gogvadze et al. 2007). Physiologic level of free radicles has 
important roles in transcription, cell signaling and defense against pathogens, but 
excessive production unopposed by normal radical scavenging mechanisms can 
cause cell damage. ROS react with many cellular components including: proteins to 
cause fragmentation, cross-linking and oxidative modification; lipids to result in 
peroxidation of membranes; carbohydrates to cause fragmentation; and nucleic acids 
to cause both fragmentation and mutation (Circu and Aw 2010). Many agents 
increase ROS production including: toxins, drugs, ionizing radiation, ischemia, 
reduction-oxidation reactions and transition elements either donating or accepting 
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free electrons (Hensley, Robinson et al. 2000). Cells respond to the toxic effects of 
ROS by different mechanisms such as generation and activation of antioxidants 
including glutathione, vitamin A and E and enzymatic free radical scavenging 
systems comprising catalases, superoxide dismutase and glutathione peroxidases 
(GSH). The intracellular ratio of oxidized to reduced GSH is used as a marker of 
oxidative state of the cells and is considered an important aspect of the capacity for 
cells to inactivate ROS (Dröge 2002, Li and Jackson 2002, Kumar, Abbas et al. 
2012).  
 
Loss of membrane integrity is common to many forms of cell injury. Defects in 
membrane permeability eventually results in permanent damage, and influence all 
cellular membranes including plasma and organellar membranes. Membrane 
damage may be the result of direct injury by chemical or physical agents, some 
bacterial toxins and viruses, and activated complement, or indirectly via a series of 
events involving loss of calcium homeostasis, ATP depletion and calcium-induced 
activation of phospholipases as briefly mentioned above. Some of the mechanisms 
involved involve mitochondrial dysfunction, resulting in decreased synthesis of 
phospholipids and activation of phospholipases, loss of membrane phospholipids, 
activation of proteases and cytoskeletal breakdown, ROS and lipid breakdown 
products which have a detergent-like effect on membranes. Defects in membrane 
permeability lead to influx of ions and fluid, as well as loss of protein, enzymes, RNA 
and important metabolites. In addition, with the loss of membrane integrity, lysosomal 
enzymes including proteinases, RNases, DNases and phosphatases leak into the 
cytoplasm, with consequent degradation of the respective cellular components 
(Newmeyer and Ferguson-Miller 2003, Kumar, Abbas et al. 2012). 
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1.8.3. Morphological Features of Necrosis 
As outlined above in Section 1.8.1, necrosis refers to 'passive' or 'accidental' cell 
death, where homeostasis fails and displays a spectrum of morphological changes 
consequent to progressive degradative enzyme activity. Necrosis has been regarded 
as an uncontrolled and pathological cell death, however, recent studies appear to 
demonstrate that necrotic cell death can be regulated, in some instances, and that 
this may help to maintain organismal homeostasis and contribute to development 
(Henriquez, Armisen et al. 2008, Kung, Konstantinidis et al. 2011).  
 
During necrosis, cells lose membrane integrity as a consequence of irreversible 
exogenous injury and their contents are released to the external environment, which 
may trigger inflammation.  The enzymatic digestion of cellular components gives rise 
to characteristic morphological changes of increased eosinophylia due to 
precipitation of denatured proteins, while nuclear changes through DNase activity 
include nuclear shrinkage with increased basophilia termed pyknosis, fragmentation 
of pyknotic or patially pyknotic nuclei termed karyorrhexis, and complete dissolution 
of nuclei termed karyolysis. Consistent with the wide range of insults leading to 
necrosis, is significant diversity in the morphological features seen, such that in 
addition to degradation and loss of nuclei, there may be 'coagulative necrosis' in 
which overall cell outline remains visible in histological sections, or 'liquefactive' 
necrosis with complete dissolution of cellular and tissue integrity, while 'caseous 
necrosis' seems to represent a condition half way between the coagulative and 
liquefactive extremes and is seen almost exclusively in tuberculosis (Kumar, Abbas 
et al. 2012).  
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At the level of the transmission electron microscope, necrosis is characterized by 
electron-lucent cytoplasm, which becomes vacuolated due to enzymatic digestion 
and accumulation of water. In addition, phospholipids precipitate as whorled masses 
called myelin figures, and discontinuities in plasma membranes as well as in 
organellar membranes are seen. There is mitochondrial swelling, dissociation of 
ribosomes from the endoplasmic reticulum, dilatation of cellular organelles and 
aggregates of 'fluffy material' which appears to be denatured protein (Ziegler and 
Groscurth 2004, Zong and Thompson 2006, Kumar, Abbas et al. 2012). 
 
1.8.4. The Mechanisms and Morphology of Apoptosis 
As briefly outlined above in Section 1.8.1, apoptosis is a pathway of programmed cell 
death with distinct morphological characteristics induced by tightly regulated energy 
dependent intracellular biochemical pathways, which activate enzymes that degrade 
the cell's DNA, nuclear and cytoplasmic proteins and important biochemical 
molecules.  As a consequence, the cells die with intact plasma membranes with no 
cytoplasmic leakage into the ECM so that there is also no inflammatory response 
(Kerr, Wyllie et al. 1972, Kumar, Abbas et al. 2012). 
 
The term necrosis was used for all types of cell death until 1971, when Kerr 
demonstrated a form of non-pathologic cell death in some tissues, and coined the 
term 'apoptosis', after the Greek designation for 'falling off' (Kerr 1971, Kerr, Wyllie et 
al. 1972). Recent studies suggest a continuum of apoptosis and necrosis, and 
various injurious agents have been demonstrated to induce apoptosis at low doses 
and necrosis at higher doses (Zong and Thompson 2006). In addition, features of 
both apoptosis and necrosis may coexist in the same cell (Kamiński, Karbowski et al. 
2002).   
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In tissues, apoptotic particles are phagocytosed by neighboring cells before there is 
failed homeostasis of the progressively degrading apoptotic bodies, however, in cell 
culture there may be insufficient phagocytosis to remove apoptotic cells so that 
necrotic features are often seen in very late apoptotic bodies, representing 
exhaustion of cellular energy and failed homeostasis with plasma membrane 
leakage, a presentation which is termed “apoptotic necrosis” or “secondary necrosis” 
(Majno and Joris 1995, Zong and Thompson 2006). 
 
The apoptotic cells demonstrate specific morphological features as revealed by light 
and electron microscopy.  Cell shrinkage is the earliest light microscopic feature of 
apoptosis, and hence apototic cells are smaller in size with dense cytoplasm and 
tightly packed organelles. Condensation and fragmentation of nuclei into multiple 
rounded masses of nuclear material is also characteristic of apoptosis, as is further 
blebbing and fragmentation of cells into multiple rounded apoptotic particles. By 
transmission electron microscopy, apoptotic particles are seen to derive from 
cytoplasmic blebbing and fragmentation, and contain cytoplasm, and tightly packed 
cellular organelles with or without nuclear fragments. Apoptotic bodies are readily 
phagocytosed by macrophages or surrounding cells, and become rapidly degraded 
within phago-lysosomes. This classical description is seen during physiological 
apoptosis such as during embryogenesis and deletion of immune cells. Features of 
both necrosis and apoptosis may simultaneously co-exist and the fate of the cell 
death is determined by the severity of the injurious insult. A distinguishing feature of 
necrotic cell death includes early plasma membrane damage and cellular swelling, 
while cellular shrinkage is seen in apoptosis (Wyllie 1997, Elmore 2007, Kumar, 
Abbas et al. 2012).  
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Apoptosis begins as a cascade of molecular events that may be initiated by 
activation of caspases, which are member of the cysteine proteases group of 
proteins. Activated caspases not only cleave important cellular proteins but also 
activate DNases leading to degradation of nuclear DNA (Enari, Sakahira et al. 1998). 
Notably, apoptotic fragmentation of DNA is primarily at internucleosomal sites, and 
this produces a laddered effect upon DNA gel electrophoresis that contrasts with the 
non-specific smear of DNA purified from necrotic cells (Zhivotosky and Orrenius 
2001). Apoptosis can be divided into two phases, the initiation phase characterized 
by activation of caspases and the execution phases in which these enzymes cause 
cell death by various mechanisms. The initiation of apoptosis is elicited by signals 
from two distinct but convergent pathways, the extrinsic pathway that is initiated by 
engagement of cell surface death receptor by agents including TNF-a, and the 
intrinsic or mitochondrial pathway which is activated by increased mitochondrial 
permeability and releases pro-apoptotic molecules into cytoplasm (Strasser, 
O'Connor et al. 2000, Grossmann 2002). 
 
1.9. Cytokines 
1.9.1. General Features of Cytokines 
Cytokines are a broad group of small signaling proteins and glycoproteins, mostly 
between 8 and 30kDa in molecular mass, and produced in all tissues by most cells 
after activation. Cytokines regulate diverse biological processes during 
developmental, physiological and pathological processes, so that study of these 
signaling molecules has potential to inform understanding across many biological 
processes (Tartakovsky and Goldstein 1990). The word cytokine originates from the 
Greek kytos meaning ‘hollow’ or ‘vessel’ and kinein meaning ‘to move’, and was 
initially used to identify as separate proteins affecting immune cells compared with 
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growth factors regulating proliferation and activation of non-immune cells. Cytokines 
are able to act as autocrine, paracrine and or endocrine mediators, and bind specific 
receptors on the cell’s surface to elicit cellular responses. Cytokines are produced by 
almost all cells, and close observation of physiological and pathological effects of up-
regulated and down-regulated expression of various cytokines suggests that 
members of this class of proteins participate in all biological processes to control 
cellular proliferation, differentiation, regulation of the immune system, inflammation, 
wound healing, angiogenesis and oncogenesis. Almost all cells are capable of 
producing some cytokines, and while different cell types can produce same kind of 
cytokine, there is also diversity amongst cells with regard to their specific cytokine 
synthetic potential. In addition, cytokines have been shown to exhibit pleiotropy and 
redundancy. The major classes of cytokines with their respective functions have 
been shown in Table 1.7 (Hopkins 2003, Tisoncik, Korth et al. 2012). 
 
1.9.2. Basic Fibroblast Growth Factor (bFGF) 
bFGF or 'FGF-2'  has broad mitogenic and angiogenic activity and is a member of 
fibroblast growth factor family comprising 23 structurally related family members, 
while this cytokine was initially purified from bovine pituitary extract (Gospodarowicz 
1975).  bFGF is known for its diverse biological activities such as proliferation, 
angiogenesis and differentiation of a broad spectrum of mesodermal cells and neuro-
ectodermal cells.  
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Table 1.7. Major classifications of cytokines and their functions 
Cytokine family                               Actions 
Interleukins                                    Regulation of immunity and inflammation 
Interferons                                      Anti-viral and immune-regulatory 
Chemokines                                   Control of chemo-taxis, leukocyte recruitment  
                                                       and Inflammation             
Colony stimulating factors              Stimulation, proliferation and differentiation of  
                                                       Hematopoietic progenitor cells 
Tumor necrosis factor                    Pro-inflammatory and activates cytotoxic T-  
                                                       Lymphocytes   
Growth factors                               Regulation of growth of various cells 
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Five isoforms of bFGF have been identified which are derived from a single type 
messenger RNA. The molecular weight of these isoforms ranges from 18 to 34 kDa, 
with four high molecular weight isoforms arising from an upstream CUG codon and 
one 18-kDa extracellular matrix isoform that arises from downstream AUG codon 
(Prats, Kaghad et al. 1989, Arnaud, Touriol et al. 1999). The high molecular weight 
isoforms are predominantly found in the nucleus while the 18-kDa form is primarily a 
cytosolic protein, but generally sequestered to the ECM by binding heparin sulfate 
proteoglycans (HSPGs) (Bikfalvi, Klein et al. 1997).  
 
Interaction between bFGF and HSPGs is essential for extracellular export, which 
involves unconventional secretion. bFGF is recruited to the inner surface of the 
plasma membrane prior to membrane translocation in a HSPGs-dependent manner. 
Approximately 10% of bFGF molecules are exported to the cell surface while the 
remaining 90% resides in the cytosol under steady state conditions (Zehe, Engling et 
al. 2006, Nickel 2007). 
 
It has been suggested that bFGF is released from cells such as endothelial and 
fibroblasts as a consequence of cell injury, cell death and damage to the cell 
membrane. bFGF leaking out of damaged cells could thus act a signal for cell injury, 
while bFGF subsequently binds to HSPGs and a high affinity trans-membrane 
receptor (FGFR1-FGFR4) to act as a paracrine and or autocrine growth factor. The 
ligand and receptor interaction causes receptor dimerization and trans-
phosphorylation, which leads to initiation of signalling cascades (Johnson and 
Williams 1992, Conrad 1997). 
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bFGF is a multifunctional growth factor which has a key role in development, ECM 
remodeling and numerous pathological conditions in almost every organ system 
(Bikfalvi, Klein et al. 1997). Many such reported functions have been associated with 
the 18-kDa isoform, which is ubiquitously found in most tissues.  bFGF was initially 
described as a mitogenic growth factor for fibroblasts, which have a significant role in 
tissue remodeling and regeneration, bFGF also drives growth of endothelial and 
smooth muscle cells and is considered a potent angiogenic factor potentially involved 
in tumor progression and metastasis (Basilico and Moscatelli 1992). The HMW 
isoforms have been shown to trigger mitogenic responses in cells deprived of serum 
(Arese, Chen et al. 1999). 
 
bFGF plays a key role in various fibrotic conditions and regulates expression of type 
1 collagen during endothelial mesenchymal transformation (EMT), which may 
contribute to corneal fibrosis (Ko and Kay 2005). Increased expression of bFGF is 
seen in skin biopsies of patients afflicted with SSC (Lawrence, Khanna et al. 2006). 
 
1.9.3. Interleukin 1 alpha and interleukin 1 beta (IL-1 α and IL-1β) 
IL-1 was first described in 1940 as a fever inducing substance secreted by 
leukocytes, and was called “pyrexin” or “endogenous pyrogen”.  However, the 
cytokine was cloned in 1980s, and is now recognized as a family of cytokines 
comprising 11 members with notable roles in inflammation and various cellular 
activities such as proliferation, differentiation and apoptosis (Atkins 1960, Auron, 
Webb et al. 1984).  Interestingly, IL-1 has been described as an important 
therapeutic target for various pathological conditions.  
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IL-1α and IL-1β are encoded by two separate genes located side by side on the 
same chromosome. Both these cytokines bind to the same receptor and elicit 
identical intracellular signals (March, Mosley et al. 1985).  Further, both IL-1α and IL-
1β are produced as 31-kDa precursors, which can be cleaved to yield 17-kDa mature 
forms. A number of cells including stimulated monocytes and macrophage, 
endothelial cells, epithelial cells, smooth muscle cells and fibroblasts can produced 
these cytokines in response to various stimuli. Similar to bFGF, IL-1 cytokines lack 
leader peptides, and are hence secreted by an unconventional pathway independent 
of ER and the Golgi apparatus, however, both have unique cellular localization and 
mechanisms of maturation and secretion. These cytokines mediate activity by 
binding to a specific IL-1 receptor type1, which is expressed at the surface of a 
variety of cells (Sims, March et al. 1988). 
 
Both IL-1 α and IL-1β are prototypical pro-inflammatory cytokines involved in diverse 
local and systemic inflammatory responses to injury. Occasionally, such effects may 
be detrimental as seen in the case of chronic inflammatory disease and septic shock, 
but the response may also be essential in the control and resolution of infections 
(Miller, O'Connell et al. 2006). IL-1 induces expression of adhesion molecules by 
endothelial cells to promote the recruitment of inflammatory cells sites of 
inflammation. IL-1 also promotes production of various enzymes including cyclo-
oxygenase 2, phospholipase A2 and nitric oxide synthase, which leads to the release 
of separate inflammatory mediators contributing to local and systemic responses. In 
addition, IL-1 stimulates several metalloproteinases, which cause connective tissue 
breakdown. Furthermore, IL-1 inhibits the synthesis of proteoglycan and type-II 
collagen and thereby affects articular cartilage. Some of the important systemic 
effects include hypotension, fever, thrombocytosis, neutrophilia, the generation of 
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acute phase proteins and regulation of adaptive immune responses. These effects 
may be indirect via the induction of downstream cytokines and or by stimulation of 
inflammatory mediators (Dinarello 1996, Gabay, Lamacchia et al. 2010). 
 
1.9.4. Interleukin 6 (IL-6) 
IL-6 is a pro-inflammatory cytokine with a key role in the immune response, and was 
discovered in 1986 as a B cell stimulatory protein mediating immunoglobulin 
production (Hirano, Yasukawa et al. 1986, Kishimoto 2005). IL-6 is a member of the 
4-helical cytokine family, and is produced by a wide range of cells including 
lymphocytes, endothelial cells, epithelial cells, fibroblasts, and several tumor cell 
types in response to many signals including trauma, tissue damage, inflammation, IL-
1 and TNF-α.  IL-6 acts by binding to its specific receptor (IL-6R, gp80), which is 
expressed on hepatocytes, monocytes, B cells, and neutrophils. Fibroblasts and 
endothelial cells don’t possess these receptors and are thought to respond via trans 
signaling. In trans-signaling, IL-6 encounters soluble IL-6R prior to binding to the gp-
130 molecule carried by broad spectrum of cells (Romano, Sironi et al. 1997). 
 
IL-6 is a potent pleiotropic and NF-kB activating cytokine, which regulates a plethora 
of physiological events during normal and pathological conditions. Key roles 
mediated by IL-6 include regulation of inflammation and acute phase responses, 
bone resorption, development and differentiation of lymphocytes, cell proliferation, 
cell survival and induction of apoptotic signals (Hirano, Akira et al. 1990, Kishimoto, 
Akira et al. 1995). In addition studies in recent years have provided substantial 
evidence that IL-6 plays an important role in the pathogenesis of many inflammatory 
and autoimmune diseases including: sepsis, rheumatoid arthritis, multiple sclerosis, 
diabetes and asthma. It has also been found to play a predominant role in the 
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association of tumor growth and inflammatory conditions as seen in the development 
of colonic cancer in inflammatory bowel disease (Neurath and Finotto 2011, Mihara, 
Hashizume et al. 2012). 
 
1.9.5. Colony Stimulating Factors (CSFs) 
Colony stimulating factors (CSF) are 18kDa to 70kDa glycoproteins produced by 
most tissues and cell types in the body, and regulate the generation and functions of 
leukocytes (Metcalf and Nicola 1995). Four CSFs have been identified which were 
first cloned between 1984-1986. Over time, these factors have emerged as key 
regulars of hematopoietic linages, and two of these namely granulocyte-monocyte 
colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-
CSF), have been in clinical use for the last two decades (Metcalf 2010). 
 
GM-CSF was originally discovered as a factor capable of generating granulocyte and 
macrophage colonies from precursor cells, however, it has been shown to be a 
multifunctional cytokine. Its actions are mediated by binding to high affinity receptor 
comprising a major binding subunit (GM-CSFα) and a major signaling subunit (βc), 
which is also shared with IL-3 and IL-5, and is expressed by cells of the 
myelomonocytic lineage and certain nonhemopoietic cell types (Gearing, King et al. 
1989, Hayashida, Kitamura et al. 1990). GM-CSF regulates the production and 
functional activation of hempoietic cells such as monocyte/macrophages, eosinophils 
colony, and at higher concentration, megakaryocytes, with a substantial role in innate 
and acquired immunity. GM-CSF and its receptors were assumed to be involved in 
the regulation of steady-state functions because of the widespread expression of 
these receptors in hematopoietic cells (Hercus, Broughton et al. 2012). Additionally, a 
growing body of evidence suggests that GM-CSF has key roles in signaling 
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emergency hemopoiesis in response to infection, such as generation of granulocytes 
and macrophages in the bone marrow and subsequent maintenance, survival, and 
functional activation at the site of injury and infections (Metcalf 2008). GM-CSF is 
also viewed as a pro-inflammatory cytokine, which has been shown to play a pivotal 
role in inflammatory/autoimmune pathologies such as rheumatoid arthritis, 
inflammatory renal and lung disorders and other autoimmune conditions. GM-CSF 
has also been implicated in various pathological conditions such as activating 
mutations in downstream components of its receptor signaling pathway in 
myeloproliferative disorders. GM-CSF is also used as a chemotherapeutic agent in 
various conditions such as chemotherapy-associated neutropenia (Hamilton and 
Anderson 2004, Metcalf 2010). 
 
G-CSF is a 25-kDa extracellular glycoprotein regulating haemopoiesis and the innate 
immune system, which is secreted by endothelium, macrophages, leukocytes and 
related mesenchymal cells during physiological events, and in response to 
pathological insults and inflammatory stimuli such as LPS, IL-1, and TNF-α (Metcalf 
1989).  The G-CSF responses are mediated via the G-CSF receptor (G-CSFR), 
which is expressed by both hematopoietic and non-hematopoietic cell types such as 
hematopoietic stem cells and progenitor cells, endothelial cells, cardiomyocytes and 
adult neural stem cells (Larsen, Davis et al. 1990). G-CSF is the major cytokine 
regulator for neutrophils, which has been shown to influence the survival, 
proliferation, and differentiation of various cells in the neutrophil lineage from 
hematopoietic progenitor cells through to mature neutrophils (Roberts 2005). 
Additionally, it controls the functions of mature neutrophils (Håkansson, Höglund et 
al. 1997). G-CSF is a potent mobilizer of hematopoietic stem cells from the bone 
marrow to blood and regulator of the immune response. It reduces the transit time of 
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developing neutrophils in the bone marrow, and accelerates the release of cells 
which have undergone recent cell division (Zsebo, Cohen et al. 1986). Furthermore, 
G-CSF mediates T cell tolerance by regulating its development and function, 
improving cardiomyocyte survival and cardiac repair, and protecting neuronal survival 
and recovery from cortical ischemia. Like GM-CSF, G-CSF has been integrated into 
clinical medicine as a therapeutic agent for the treatment of neutropenia associated 
with the use of chemotherapeutic agent for cancer and other bone marrow disorders 
(Roberts 2005, Panopoulos and Watowich 2008).  
 
1.10. Questions Arising From the Literature 
While the cytotoxic response of fibroblasts and keratinocytes to arecoline is well 
described (Jeng, Tsai et al. 1999, Chang, Ho et al. 2001), at the time that work in this 
thesis commenced there was no information on the potentially cytotoxic effect of 
arecoline on endothelium, this despite the reduction in vasculature seen in 
developing OSF (Sirsat and Pindborg 1967, Sirsat and Pindborg 1967).  To that end, 
an important initial aim of work in this thesis was to determine if arecoline was toxic 
to endothelium, and to also characterize any possible toxicity in terms of either 
necrotic or apoptotic responses.  
 
It was interesting that during this thesis, a paper was published demonstrating toxicity 
of arecoline for endothelium, but the further need to consider the possible effect of 
arecoline on cytokine synthesis was not described (Tseng, Chang et al. 2012).   
 
In light of the capacity of endothelium to produce inflammatory cytokines secreted 
both into the blood to mediate systemic effects, such as CSFs, and locally to regulate 
local effects, it becomes interesting to characterize the effect of arecoline on 
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endothelial cytokine synthesis, particularly with reference to the concomitant toxicity 
observed in early work of this thesis and published by others (Tseng, Chang et al. 
2012). This question was also addressed in this thesis, with a view to better 
understanding mechanisms in OSF.  
 
In view of both the rarefaction of endothelium in OSF, as well as the paucity of 
knowledge on the effect of arecoline on endothelium, this thesis aimed to determine 
firstly if arecoline has toxic activity for endothelium, and further what changes in 
synthetic activity potentially relevant to OSF might occur. 
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2.  CHAPTER 2:  ARECOLINE CYTOTOXICITY FOR HUMAN 
UMBILICAL VEIN ENDOTHELIUM 
2.1. Introduction 
2.1.1. Vascularity in Oral Submucous Fibrosis 
Reduced vascular density is an important histological feature of OSF, and is 
responsible for the characteristic blanched clinical appearance of affected mucosa.  
Biopsies of sites affected by OSF show extremely narrowed or obliterated blood 
vessels in the advanced stage of the disease (Sirsat and Pindborg 1967).  This 
contrasts with events in the early stage of the disease, where the vasculature is 
dilated associated with profound inflammation. Obliteration of the vasculature has 
been hypothesized to be secondary to sub-epithelial fibrosis, which has been thought 
to cause epithelial aberration as a result of a compromised blood supply (Sirsat and 
Pindborg 1967). More recently, ultrasonography has revealed decreased blood flow 
velocity in the vicinity of fibrous bands in OSF (Manjunath, Rajaram et al. 2011).  
 
In the light of above, it seems reasonable to suggest that there is a toxic effect of 
areca nut ingredients upon oral mucosal tissues, and that this results in inflammation, 
vascular dilatation and increased permeability in the early phases of OSF, but that 
with further progression, there is a reduced inflammatory response with diminished 
vasculature due to toxic effects on the vasculature. 
 
2.1.2. Areca Nut and Human Endothelium   
Human endothelium plays a pivotal role in various fibrotic conditions, which have 
been described in section 1.5.3. However there is limited information on the effect of 
areca nut and its ingredients on endothelial cells and the possible role of endothelium 
in the pathogenesis of OSF. A mouse model has been used to evaluate the effect of 
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areca nut on the buccal mucosa in female BALB/c strain mice, and changes seen 
support the suggestion that areca nut plays a key role in the causation of OSF. 
Substantial reduction in the number of blood vessels and fibrosis is seen, consistent 
with the classical features of OSF (Sumeth Perera, Gunasinghe et al. 2007).  
 
Arecoline, the main alkaloid of areca nut, has been studied extensively in various 
systems to elucidate its role in the pathogenesis of OSF, as well as the subsequent 
transformation to oral cancer as discussed in sections 1.3 and 1.5. The salivary 
concentration of arecoline has been shown to reach 142.43 µg/ml during chewing of 
areca nut (Nair, Ohshima et al. 1985). An updated study on the level of arecoline 
achieved during areca nut chewing reports the peak level as 97.39 µg/ml using high-
pressure liquid chromatography-mass spectrometry (HPLC-MS) (Cox, Vickers et al. 
2010). 
 
Arecoline-induced toxicity has been studied in a variety of cell lines as outlined in 
section 1.3.4, however, only two publications have shown cytotoxic effect of arecoline 
on endothelial cells. Arecoline at high concentrations in dose response studies 
ranging from 10-1000µM, inhibited growth of endothelial cells over 24 hr or 48 hr time 
periods (Kuo, Wu et al. 2005). More recently, arecoline was shown to be cytotoxic for 
EAHY endothelial cell line, causing a 31 % reduction in the number of viable cells at 
a concentration of 0.8mM, equating to approximately 188.88 µg/ml (Tseng, Chang et 
al. 2012).   
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2.1.3. Cell Injury, Patterns of Cell Death and Associated Ultra-Structural 
Changes 
Cells exhibit diverse morphological changes and variations in response to injury, 
which depend on the type and severity of cell injury.  Cell injury may result in 
apoptosis or necrosis with distinct morphological changes as discussed in section 
1.6.2 and 1.6.3. Occasionally features of both types of cell death coexist and 
intermediate forms of cell death have been observed leading some to suggest the 
term “aponecrosis” (Formigli, Papucci et al. 2000). In addition, some morphological 
alterations are seen in response to sub-lethal injury, which is proposed as a third type 
of cell death and termed as autophagy-associated cell death, with the term  
'autophagy' derived from the Greek and meaning 'self-eating' (Klionsky 2007). There 
are numerous biochemical and molecular attributes used to determine the pattern of 
cell death, however, morphological features as defined by light and or transmission 
electron microscopy (TEM) remain the least ambiguous criteria for differentiating one 
form of cell death from another.  
 
Necrotic cell death is associated with early loss of membrane integrity, allowing influx 
of extracellular contents and subsequent swelling and disruption of the cell and its 
organelles.  In apoptosis, however, the cell membrane remains intact although there 
is cleavage of cytoskeletal elements, chromatin condensation, nuclear fragmentation, 
formation of plasma membrane blebs and finally, fragmentation of the cell into 
apoptotic bodies (Kumar, Abbas et al. 2012). Autophagy-induced cell death is 
characterized by the presence of autophagosomes, comprising a double membrane 
enclosed vesicle in the cytoplasm that engulfs components of cytosol such as 
mitochondria, cytoskelal elements, endoplasmic reticulum and protein aggregates, 
and occurs in response to stress induced by a variety of injurious agents and 
Chapter 2,  Arecoline Cytotoxicity for HUVEC                                                         Page 62 
environmental factors. Subsequently, these vesicles fuse with lysosomes resulting in 
degradation of the cargo by lysosomal enzymes of the same cell (Gozuacik and 
Kimchi 2007, Klionsky 2007). 
 
2.1.4. Investigation of Cytotoxicity 
In vitro cytotoxicity can be evaluated by various separate methods involving either or 
both cell quantification or biochemical techniques.  
 
Because necrotic cells become rapidly degenerated, direct cell counts remain a 
simple, rapid and an inherently valid approach to evaluating base line cytotoxicity, 
and are readily performed by haemocytometer. However, early toxic insults or mild or 
chronic sub-lethal cell injury cannot be detected by cell counts, so that ultrastructural 
changes including hydropic and fatty degeneration become important for detection of 
sub-lethal injury (Bhuyan, Loughman et al. 1976, Mitchell and Acosta 1981).  A range 
of cytotoxicity assays provide validated techniques to analyze the biological effect of 
toxic agents on cell systems and quantify ranges of toxic doses of chemical agents 
under investigation.  
 
MTT (Methyl Thiazol Tetrazolium, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) is a water-soluble tetrazolium salt that is reduced by living cells to blue 
formazan crystals, which can be solubilized by solvents such as isopropanol for 
colorimetric evaluation of mitochondrial activity and hence cell viability (Mosmann 
1983). From this, changes in formazan level have been widely used to study the 
response of cells to toxic substances (Mosmann 1983, Edmondson, Armstrong et al. 
1988, Hart, Lee et al. 1999, Tully, Collins et al. 2000). The reduction of MTT is 
believed to mainly occur in mitochondria by the action of succinate dehydrogenase 
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(Slater, Sawyer et al. 1963), however, there are reports indicating that formation of 
formazan may also takes place in the cytosol mediated by NADH or NADPH (Liu, 
Peterson et al. 1997).  
 
Another commonly used colorimetric assay involves measurement of lactate 
dehydrogenase (LDH) released from the cytoplasm following damage to the cell 
membrane (Korzeniewski and Callewaert 1983). LDH is a stable cytoplasmic 
oxidoreductase enzyme present in all cells, and is responsible for inter-conversion of 
pyruvate and lactate (Sasaki, Kawai et al. 1992). In this assay LDH reduces INT (2-
[4-iodophenyl]-3-[4-nitrophenyl]-5-phenyltetrazolium chloride), a tetrazolium salt, to 
formazan coupled to the oxidation of lactate to pyruvate, which can be detected 
spectrophotometrically (Nachlas, Margulies et al. 1960). The amount of formazan 
formed is directly correlated to LDH level, which is proportional to the number of dead 
cells. LDH is a quick, reliable and simple assay, widely accepted as precise for 
determining cell viability (Decker and Lohmann-Matthes 1988). 
 
Nonetheless, electron microscopy remains a powerful and unambiguous tool for 
investigation of the toxic response of cells to agents. The ultra-structural features of 
apoptosis and necrosis and the associated mechanisms, have been described in 
sections 1.6.2 and 1.6.3.  The distinctive morphological features of endothelial cells 
in different patterns of cell death following injury can be identified by using scanning 
and transmission electron microscope (Cotran and Majno 1964, Ham and Hurley 
1968, Koster and Klumperman 2003). 
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2.1.5. Human Umbilical Vein Endothelium as a Convenient Endothelial Culture 
Model 
From the perspective of understanding human disease, it seems sensible to study 
specifically human endothelium, so that although porcine and bovine aortic 
endothelial cells are convenient and inexpensive for cell culture (Booyse, Quarfoot et 
al. 1977, Schwartz 1978), there seems advantage in using endothelial cells of human 
origin.  Human endothelium can be readily cultured from foreskin (Davison, Bensch 
et al. 1980), or dermal biopsy (Detmar, Imcke et al. 1990), but the small number of 
cells obtainable by these methods limits experimental capacity. Human umbilical vein 
endothelial cells (HUVEC), are readily cultured from umbilical cords and have 
become widely accepted as a reasonable model system for the study of the response 
of human endothelium to a wide variety of stimuli (Jaffe, Nachman et al. 1973).   
 
This chapter describes experiments in which the toxic effect of arecoline on HUVEC 
is studied by cell counts, TEM, LDH and MTT assays.  
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2.2. Materials 
2.2.1. Materials for cell culture 
Cell culture medium 199 (M199), Hanks Balanced Salt Solution (HBSS), Polymyxin B 
solution, Haematoxylin and Gelatine were purchased from Sigma Aldrich (St. Louis, 
Mo, USA). The antibiotics Penicillin and Streptomycin were obtained from CSL 
Biosciences (Melbourne, VIC, Australia). Endothelial Cell Growth Supplement 
(ECGS) was obtained from Upstate (New York, USA). Heparin was bought from 
Pharmacia and Upjohn (Perth, WA, Australia). Phosphate Buffered Saline (PBS) 
tablets were purchased from Oxoid (Hampshire, England). Iron fortified bovine calf 
serum (BCS) was obtained from Bovogen (Melbourne, VIC, Australia). Trypsin 
(0.25%) / EDTA (1mM) was from JRH Biosciences (Lenexa, USA) while Bovine 
Serum Albumin (BSA) fraction V and Amphotericin B were bought from ICN 
Biomaterials Inc. (Ohio, USA). Dimethyl Sulfoxide (DMSO) was obtained from Ajax 
Chemicals (Sydney, NSW, Australia). Plasticware including cell culture flasks 
(25cm2, 75cm2, and 225cm2, cell culture plates (6 wells, 12 wells, 24 wells, 96 wells) 
and centrifuge tubes were supplied by Costar (Cambridge, USA). Disposable 
membrane filters were purchased from Santorius, Ministart (Gottingen, Germany). 
Arecoline Hydrobromide was from Sigma-Aldrich. 
 
2.2.2. Materials for Investigation of Cytotoxicity in HUVEC 
A Haemocytometer from HIRSCHMANN EM TECHCOLOR, Neubauer Improved 
(Eberstadt, Germany) was used, while MTT and LDH Assay Kits were purchased 
from Roche Applied Science (Penzberg, Germany). 
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2.2.3. Materials for Scanning Electron Microscopy and Transmission Electron 
Microscopy 
Fluka (Buchs, Switzerland) supplied Cocodylate Buffer, as well as Uranyl Acetate 
and Lead Nitrate used in the preparation of Reynold’s Lead Citrate by stoichiometric 
reaction. Spurr’s low viscosity resin was obtained from Taab Laboratories Equipment 
Inc. (Aldermaston, Berkshire, UK). Ajax chemicals (Auburn, NSW, Australia) supplied 
Trisodium Citrate.  Glutaraldehyade and Osmium Tetraoxide were purchased from 
ProSciTech (Thuringowa, Qld. Australia).  Absolute Ethanol and Acetone were 
supplied by BDH Laboratory Supplies (Poole, England), while Methylene Blue was 
purchased from Medos Co. Pty. Ltd. (Lidcombe, NSW Australia).  
 
2.3. Methods 
2.3.1. Isolation of Human Umbilical Vein Endothelial Cells  
Umbilical cords were obtained from the Westmead Hospital Maternity Unit with 
informed consent as approved by the Sydney West Area Health service Human 
Research Ethics Committee. Umbilical cords were transported in HBSS in sterile jars 
with the antibiotics Penicillin (100 U/ml), Streptomycin (100µg/ml) and Amphotericin 
B (0.25µg/ml). HUVEC were isolated by the collagenase perfusion method (Jaffe, 
Nachman et al. 1973). In brief, cords were first inspected for clamp marks and likely 
leakage points by wiping down with sterile gauze. Damaged segments of cords were 
removed and discarded, and any blood clots if present milked out of the remaining 
cord material. Veins were cannulated with one way cannulae and washed four times 
with 20 ml volumes of HBSS using 20 ml disposable syringes.  Veins were perfused 
with 20 ml volumes of warmed collagenase (1mg/ml) in HBSS via cannulae before 
immediate clamping of the free cord ends to slightly distend the perfused veins. The 
cords were then covered with gauze soaked in HBSS for 20 to 30 minutes to allow 
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collagenase digestion. The detached HUVEC were harvested into 5 ml volumes of 
BCS by flushing with 80 ml of HBSS. The resulting cell suspensions were centrifuged 
at 1500 rmp at 4ºC for 10 minutes. Resulting cell pellets were resuspended in 5 ml 
volumes of Complete Culture Medium (CM) consisting of Medium 199 (80%), BCS 
(20%), Heparin (30 U/ml) and ECGS (40µ/ml) with the antibiotics Penicillin (100 
U/ml), Streptomycin (100µg/ml) and Amphotericin B (2.5 µg/ml). Freshly isolated 
HUVEC were cultured in 25 cm2 tissue culture flasks pre-coated with gelatine (0.1%) 
in HBSS and incubated at 37ºC under 5% CO2, and medium changed each day.  
 
2.3.2. Culture and Confirmation of the Identity of HUVEC 
Confluent HUVEC were released using Trypsin/EDTA and collected into 5ml volumes 
of BCS before pelleting by centrifugation at 1500 rpm and 4ºC for 8 minutes, and 
passage at a split ratio of 1:3 in CM using 10 ml CM for 75 cm2 flasks and 30 ml CM 
for 225 cm2 Flasks. CM was changed every 3 to 4 days while all experiments were 
with cells in passages 4 or 5. HUVEC were used for experiments in fourth or fifth 
passage.  
 
2.3.3. Isolation of Human Gingival Fibroblasts  
Human gingival biopsies were obtained from the Oral Surgery unit, Westmead 
Centre for Oral Health, Westmead Hospital, with informed written consent as 
approved by the Sydney West Area Health service Human Research Ethics 
Committee. Specimens were collected in sterile jars containing HBSS supplemented 
with the Antibiotics penicillin (100U/ml), Streptomycin (100µg/ml) and Amphotericin B 
(0.25µg/ml). 
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Specimens were washed five times with M199 containing antibiotics and then cut into 
1-2 mm fragments and placed into 6 well tissue culture plates. Attachment of 
fragments was aided by scoring tissue culture plates in up to five separate places 
with a scalpel to produce 3 to 4 curve converging near parallel lines. Explant tissues 
were then covered with a culture medium of M199, BCS (20%), antibiotics penicillin 
(100U/ml), streptomycin (100µg/ml) and amphotericin B (0.25µg/ml). The tissue 
remained covered in media sufficient to form a meniscus. Plates were then incubated 
at 37ºC under 5% CO2.  Media were replaced daily for a week, after which BCS was 
used at a lower concentration (10%) and changed every three days. 
 
By the end of first week, some Human Gingival Fibroblasts (HGF) were usually found 
spreading out from the edges of the tissue fragments. When these had reached a 
number sufficient for retention, tissue fragments were carefully removed by 
aspiration, and the adherent fibroblasts were incubated with 1 ml of complete 
Fibroblast Complete Medium (FCM) comprised of M199 with BCS (10%) and the 
antibiotics penicillin (100U/ml), streptomycin (100µg/ml) and amphotericin B 
(0.25µg/ml).  Once confluent, media was aspirated, and cells washed with HBSS for 
detachment with trypsin/EDTA and transfer to 15ml centrifuge tubes with 3 to 5ml of 
BCS to quench proteinase activity. Cells were subjected to centrifugation at 1500 
rpm at 4ºC for 8 minutes and pellets resuspended in 5 ml of FCM in gelatine coated 
25cm2 tissue culture flasks at 37ºC and 5 % CO2.   
 
2.3.4. Culture of Human Gingival Fibroblasts 
HGF were passaged at a split ratio of 1:3 and cultured in FCM on gelatine-coated 
flasks. Experiments were performed with HGF in Passage 6.  
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2.3.5. Storage of HUVEC and HGF in Liquid Nitrogen 
Confluent HUVEC in passage 4 or 5 and confluent HGF in passage 6 in 75 cm2 or 
225 cm2 flasks, were washed with HBSS, released with trypsin/EDTA and transferred 
to 50 ml centrifuge tubes along with 5 ml BCS per tube and centrifuged at 15000 rmp 
and 4ºC for 8 minutes. Cell pellets were then resuspended in appropriate volumes of 
CM comprising of M199 with BCS, being 20% for HUVEC and 10 % for HGF, as well 
as antibiotics and 10% DMSO as a cryoprotectant, such that 1 ml represented one 
confluent 75 cm2 flask. One ml volumes of these cell suspensions were transferred to 
single cryovials and placed in foam containers with Isopropyl Alcohol for slow 
freezing overnight to -80ºC before transfer to liquid nitrogen (N2) for long term 
storage.  
 
When needed, cryovials were thawed in a 37ºC water bath with gentle agitation. 
Melted cell suspensions were quickly transferred to 50ml centrifuge tubes containing 
5ml of BCS to dilute DMSO and centrifuged at 1500 rmp and 4 ºC for 8 minutes. Cell 
pellets were then resuspended in 10ml of CM for HUVECs or FCM for HGF and 
seeded in gelatin coated 75cm2 flasks for further culture and experiments. 
 
2.3.6. Cell Culture Conditions for Investigation of Arecoline Induced 
Cytotoxicity  
Confluent HUVEC in passages 4 or 5, or HGF in passages 6 or 7, were harvested 
using Trypsin/EDTA and seeded at confluence into gelatinized 24 well tissue culture 
plates with each well receiving 500 µl cell suspension. After overnight attachment at 
37ºC under 5 % CO2, cells were washed twice with M199 and treated in triplicate 
wells for 24 hr with 500µl volumes of arecoline at concentrations ranging from 0 
µg/ml to 1000 µg/ml, in M199 with 4% bovine serum albumin (BSA). In some 
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experiments, the response of cells was followed at 4 hr intervals using concentrations 
of arecoline of 0 µg/ml, 37 µg/ml and 1000 µg/ml.  Also, some experiments were 
performed with cells seeded at confluence into 96 well tissue culture plates in 100µl 
volumes.  
 
2.3.7. Quantitative Methods Evaluating Cell Injury and Survival  
Surviving cell number was determined by three separate methods in separate 
experiments. In most experiments, cells were washed twice with 500µl HBSS prior 
detachment with 500µl trypsin/EDTA, and direct haemocytometer counts. The 
number of cells per well was expressed as average values with standard deviations 
across triplicate wells.  
 
Cytoplasmic leakage was evaluated using the LDH assay, in which culture 
supernatants were harvested from wells and transferred to 1.5ml eppendorf tubes for 
centrifugation at 2000 rmp for 2 minutes to remove floating debris. Supernatants 
were then carefully transferred to separate eppendorf tubes for evaluation of LDH 
activity using the LDH Cytotoxicity detection Kit available from Roche.  In this assay, 
100µl volumes of supernatants were transferred to wells of an optically clear 96 well 
tissue culture microplate, and 100µl volumes of freshly prepared reaction mixture 
added and incubated for up to 30 minutes at RT protecting from light as per the 
manufacturer's instructions. Absorbance was measured at 492nm using 600nm as a 
reference wavelength in the Bio-Rad Model 3550 ELISA microplate reader. 
 
Cell viability was further evaluated in some experiments by the MTT assay, using 
cells seeded into 96 well tissue culture plates.  Following 24 hr stimulation, 10µl of 
MTT labelling reagent as supplied by Roche was added to each well to achieve a 
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final concentration of 0.5 mg/ml. Microplates were then incubated for 4 hr in a 
humidified atmosphere at 37ºC under 5% CO2 during which time viable cells 
converted MTT to a water insoluble formazan dye.  Deposited dye was solublilized 
overnight at at 37ºC and 5% CO2 by addition of 100µl of Solubilization solution 
supplied by the manufacturer. Absorbance was measured at 570nm with a reference 
wavelength of 650nm using a microplate reader (Bio-Rad Model 3550 plate reader). 
 
2.3.8. Transmission Electron Microscopy 
Confluent cultures of HUVEC in passage 5 were incubated in 75cm2 tissue culture 
flasks with concentrations of Arecoline of 0 µg/ml, 37 µg/ml, 111 µg/ml, 333 µg/ml or 
1000 µg/ml, in M199 and 4% BSA for 4 hr or 24 hr, before harvesting with 
Trypsin/EDTA. Cells were then washed briefly in MOPS before fixation for 1 hr in 
Karnovsky’s fixative compriing glutaraldehyede (5% v/v) and formaldehyde (4.8% 
v/v) in MOPS. Cells were then rinsed with MOPS and post-fixed with osmium tetra-
oxide (2%) for 2 hr and transfer to 2% uranyl acetate and incubation for 1 hr before 
dehydration with graded ethanols (50%, 70%, 95%, 100%). The dehydrated cells 
were washed with acetone (100%) for 10 minutes prior to immersion in acetone/resin 
at a ratio of 1:1 for 1 hr. The specimens were infiltrated with neat resin 3 times at 
70ºC for 10 minutes and finally embedded in fresh resin and allowed to polymerize 
overnight at 70ºC. Semi-thin sections were cut using a Reichert Ultracut E microtome 
(Vienna, Austria) and stained with methylene blue (1%) for 2 minutes, and were 
observed under the light microscope to select appropriate regions. Ultra-thin sections 
were cut using a diamond knife and collected on copper grids, and then stained with 
uranyl acetate (2%) in ethanol (100%) at a ratio of 1:1 for 15 minutes before washing 
with double distilled water for 15 seconds. Grids were stained with Reynold’s lead 
citrate for 4 minutes and again washed with ultrapure water. Grids were examined 
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with a Philips CM-120 BioTWIN, transmission electron microscope (Eindhoven, The 
Netherlands) at 100 kV and digital images of various magnifications recoded. 
 
2.3.9. Statistical Analysis 
Six or more independent experiments were performed for arecoline dose responses 
and Wilcoxon matched pairs test used to evaluate possible statistically significant 
changes between groups. Two independent experiments were conducted for LDH 
and MTT assays and for comparison between HGF and HUVEC, and student t-test 
was used for statistical evaluation in these instances and data were expressed as 
Mean ± SEM. A p value <0.05 was considered to indicate a statistically significant 
difference.  
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2.4. Results 
2.4.1.  HUVEC and Gingival Fibroblasts Displayed Expected Culture 
Characteristics 
Cells harvested from umbilical veins formed clusters within 2 to 3 days and took 
roughly one week to become confluent. Confluent cells exhibited the characteristic 
cobblestone morphology typical of HUVEC. Cells cultured in this way were positive 
for the endothelial marker Ulex europaeus lectin-1 (UEA-1).  
 
Gingival explants displayed visible outgrowths within 3-4 days after isolation. 
Confluent monolayers of cells were observed around tissue explants fragments in 10-
14 days in culture. These HGF cells had a homogeneous appearance and displayed 
morphological features characteristic of gingival fibroblasts including oval nuclei, 
elongated cell bodies and linear arrangements of cells.  
 
2.4.2. High Levels of Arecoline Reduced Endothelial Cell Number But Had Less 
Effect on Fibroblasts 
Haemocytometer counts of HUVEC revealed considerable reduction in cell number 
at and above 333 µg/ml of arecoline (p <0.05) in 7 experiments with cells from 7 
separate donors, although there was no clear effect at lower concentrations of 
arecoline (Figure 2.1). At these high arecoline concentrations, a significant reduction 
in cell culture density was noticeable as early as 4 hr. HUVEC subjected to these 
levels also displayed successive morphological features over time under light 
microscope, which included shrinkage of cells, cytoplasmic vacuolization and finally 
detachment (Figures 2.2 and 2.3). HGF by comparison appeared relatively resistant 
to the effects of arecoline, such that a clear reduction in HGF number was only seen 
at 1000 µg/ml of arecoline (Figure 2.4). 
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2.4.3. High Levels of Arecoline Caused Release of Lactate Dehydrogenase by 
Endothelium  
Leakage of cytoplasmic contents from HUVEC exposed to high levels of arecoline 
was confirmed by the LDH release assay. Significant LDH release was found at 333 
µg/ml and 1000 µg/ml arecoline (p < 0.05), but not at lower concentrations of this 
agent (Figure 2.5), consistent with the results of haemocytometer counts (Figure 2.1).  
 
2.4.4. Loss of HUVEC Viability at High Concentrations of Arecoline was 
Confirmed by the MTT Assay  
Concentrations of arecoline that reduced cell number and increased LDH release 
were also associated with loss of cell viability as determined by the MTT assay (p < 
0.05) (Figure 2.6).   
 
2.4.5. Transmission Electron Microscopy Revealed Progressive Cytotoxic 
Changes with Increasing Arecoline Exposure 
Figures 2.7 and 2.8 reveal occasional lipid droplets and autophagocytic vacuoles in 
HUVEC not exposed to arecoline, consistent with mild stress of cells in culture. 
Increasing exposure to arecoline with regard to both concentration and time, was 
associated with progressive ultrastructural evidence for cell injury. While 
autophagocytic vacuoles became more prevalent, there was also reduced ribosomal 
studding of RER indicative of reduced protein synthetic capacity, and increasing 
vacuolation consistent with hydropic degeneration through reduced effectiveness of 
membrane pumps. An apparent reduction in the number of mitochondrial cristae was 
seen together with slight swelling, while at the highest levels of arecoline tested (333 
µg/ml and 1000 µg/ml), mitochondrial matrix was condensed and electron dense and 
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cristae were swollen at 4 hr, while frank necrosis of almost all cells was seen by 24 hr 
at these high arecoline levels (Figures 2.7 and 2.8).  
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Figure 2.1. Histograms showing the effect of increasing concentrations of 
arecoline on HUVEC survival over 24 hr (A), and the time course of the effect of 
arecoline at increasing concentrations (B). (A) Arecoline reduced HUVEC number 
at and above 333 µg/ml by 24 hr incubation (p<0.05), but no significant effect of 
arecoline was observed on HUVEC at or below 111 µg/ml. (B) The highest 
concentration of arecoline (1000 µg/ml) caused a significant reduction in HUVEC as 
early as 4 hr, with and complete loss of HUVEC by 12 hr incubation (p<0.05).  
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Figure 2.2. Phase contrast photomicrographs of HUVEC incubated with 
increasing concentrations of arecoline for 4 hr. Arecoline at 1000 µg/ml caused 
death and detachment of HUVEC, with acquisition of a rounded morphology in 
detached cells.  HUVEC exposed to arecoline at 333 µg/ml also started to detach, 
leaving empty spaces in cell culture plates, while there was also loss of the normal 
cobblestone appearance and a greatly increased elongation in the shape of cells.  
There was no clear effect, however, on the morphology of HUVEC incubated with 
lower concentrations of arecoline. (Bars = 200µm) 
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Figure 2.3. Phase contrast photomicrographs of HUVEC incubated with 
increasing concentrations of arecoline for 24 hr. Arecoline at and above 333 
µg/ml caused death and detachment of HUVEC, with acquisition of a rounded 
morphology in detached cells.  Lower concentrations of arecoline had little effect on 
HUVEC morphology, although some spaces did appear between cells at 111 µg/ml 
(arrows) together with elongation of cells. (Bars = 200µm) 
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Figure 2.4. Histogram showing the effect of increasing concentrations of 
arecoline over 24 hr on the number of Human Umbilical Vein Endothelial Cells 
and Human Gingival Fibroblasts.  While there was a clear reduction in HUVEC 
number by 333 µg/ml of arecoline, consistent with the findings of haemocytometer 
counts (Figure 2.1), there was no clear effect on HGF till levels of arecoline reached 
1000 µg/ml. 
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Figure 2.5. Graphs showing the effect of increasing concentrations of 
arecoline over 24 hr on LDH release by Human Umbilical Vein 
Endothelial Cells.  LDH release from cells into culture supernatant was 
seen at 333 µg/ml of arecoline (p < 0.05), consistent with the findings of 
haemocytometer counts (Figure 2.1) and indicating little if any effect on cell 
leakage at lower concentrations.  	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Figure 2.6. Phase contrast photomicrographs demonstrating formation of 
formazan crystals in the MTT assay in cultures of HUVEC at increasing 
concentrations of arecoline (A), as well as a graph quantitating formazan by 
measurement of optical density at 570 nm.  (A) Formazan crystals were evident in 
metabolically active cells up to a concentration of 111µg/ml arecoline where there 
appeared to be a reduction in crystal crystals density, while no formazan was evident 
at higher levels of arecoline. (B) Quantitation of formazan, however, did not confirm 
the visual impression of reduced formazan at 111µg/ml arecoline, although there was 
clear loss of formazan at higher levels of arecoline (p < 0.05).  (Bars = 500µm)
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Figure 2.7.  Transmission electron micrographs of HUVEC treated for 4 hr with 
arecoline at concentrations of 0 µg/ml (A, B), 333 µg/ml (C, D, E), and 1000 
µg/ml (F, G, H), with the location of higher magnification images marked in 
rectangles. Organellar structures were readily identified at all concentrations of 
arecoline used, and included: nuclei (N), mitochondria (small arrows), RER (arrow 
heads), and autophagocytic vacuoles (large arrows), while occasional Golgi 
apparatus (Golgi), lipid droplets (L) and large vacuoles (V) were also seen. The 
cultured cells were mildly stressed even without exposure to arecoline, as evidenced 
by occasional lipid droplets expected where there is lipid acccumulation as a 
manifestation of reversible cell injury. Mitochondrial cristae were tubular in shape and 
well defined in the absence of arecoline as well as up to 333 µg/ml of the agent (A to 
E). At 1000 µg/ml, however, mitochondria often contained electron dense material in 
the intermembrane space, and appeared to have fewer and slightly distended cristae 
(F to H). Ribosomes heavily studded RER at lower concentrations of arecoline, but 
appeared to be less frequent on RER at 1000 µg/ml (F to H). Also at 1000 µg/ml, 
large vacuoles were seen in the cytoplasm of cells, while there appeared to be subtle 
dilation and disruption of Golgi saccules (F to H). Bars: A, C, F = 5 µm; B, D, E, G, H 
= 1 µm 
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Figure 2.8.  Transmission electron micrographs of HUVEC treated for 24 hr with 
arecoline at concentrations of 0 µg/ml (A, B), 37 µg/ml (C, D, E), 111 µg/ml (F, 
G), and 333 µg/ml (H), with the location of higher magnification images marked 
in rectangles. Organellar structures were readily identified and included: nuclei (N), 
mitochondria (small arrows), RER (arrow heads), and autophagocytic vacuoles (large 
arrows), while lipid droplets (L) and vacuoles (V) were also seen. The cultured cells 
were mildly stressed even without exposure to arecoline, as evidenced by occasional 
lipid droplets expected where there is lipid acccumulation as a manifestation of 
reversible cell injury. At 111µg/ml arecoline or less, mitochondrial cristae were tubular 
in shape (A to G), while autophagocytic vacuoles often appeared more prominent in 
arecoline treated cells.  RER also appeared less intensely studded with ribosomes at 
111 µg/ml (G) compared with control cells cultured without arecoline (B). At 333 
µg/ml arecoline, there was frank necrosis of HUVEC such that degenerate cell rests 
(DC) predominated with disrupted cell membranes, reduced cytoplasmic electron 
density and loss of organellar structure (H). Amongst these necrotic cells, however, 
were occasional essentially intact cells (White Star) (H). Bars: A, C, F = 2 µm; B, D, 
E, G = 1 µm; H = 10 µm 
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2.5. Discussion 
The approach used to evaluate the potentially toxic effect of arecoline on 
endothelium applied the widely accepted HUVEC culture model system, which 
provides both sufficient cell numbers for large experiments to be performed, and 
while it is accepted that microvascular endothelium may respond differently to 
HUVEC (Jaffe, Nachman et al. 1973, Tan, Chan et al. 2004), significant differences 
in toxic response seem unlikely between these two cell types. Also, specifically oral 
mucosal endothelial cells would be very difficult to obtain in adequate number to 
perform the experiments described, and while these may be optimal for study of 
OSF, HUVEC are nonetheless widely accepted as a reasonable model for study of 
endothelial responses relevant to disease (Bouïs, Hospers et al. 2001, Laplante, 
Raymond et al. 2005).  The response of endothelium to a wide range of arecoline 
levels consistent with in-vivo observations was studied (Nair, Ohshima et al. 1985, 
Cox, Vickers et al. 2010), and this too seems appropriate in view of the widely variant 
levels of arecoline expected during chewing of areca nut.  
 
Cell survival was quantitated by direct cell counts of adherent surviving cells, and it is 
argued that this provides an unambiguous and strongly defensible measure for cell 
survival. Results of cell counting experiments were essentially paralleled by those of 
the MTT assay, which was performed as further confirmation for data, while cell 
counts are suggested as superior to the MTT assay on grounds that there is no 
possible confounder by potential modification of mitochondrial function by arecoline.  
The modest changes seen by electron microscopy in mitochondria do support a 
possible indirect effect on the MTT assay by arecoline, and despite the absence of 
any clear difference in the MTT results relative to direct cell counts, do support the 
idea that haemocytometer counts provide a suitably conservative measure for cell 
Chapter 2,  Arecoline Cytotoxicity for HUVEC                                                         Page 87 
survival.  LDH assays were performed to further probe possible cytoplasmic leakage 
at sub-lethal doses of arecoline, while the absence of a difference in LDH results 
relative to haemocytometer counts does not support any such effect.  Transmission 
electron microscopy permits detection of subtle cytotoxic changes in both reversibly 
and irreversibly damaged cells, while the current study revealed changes consistent 
with a dose and time dependent effect of arecoline. From the above, it is argued that 
the experimental approach used in this study was reasonable and appropriate to 
evaluate the toxic effect of arecoline on endothelium.  
 
Progressive cell injury was associated with increasing concentrations and time of 
exposure to arecoline, and changes consistent with hydropic degeneration support a 
cytotoxic effect. Reduced ribosomal studding suggests failing ATP production 
(Kumar, Abbas et al. 2012), consistent with the mitochondrial changes, and it is of 
note that the most extreme mitochondrial changes were seen at 4 hr at the two 
concentrations of arecoline associated with frank necrosis of cells by 24 hr. 
Increased autophagosome levels also suggests increased turnover of cytoplasmic 
components related to cell injury (Murrow and Debnath 2013). Ultrastructural 
changes seen were consistent with the vacuolation observed at the light microscope 
level.  
 
The changes seen in the current study are consistent with reduced vasculature in 
OSF, and do support the idea that arecoline could contribute to the disease by 
damaging the vasculature (Sirsat and Pindborg 1967). Endothelial injury and 
dysfunction is seen in response to a variety of insults and is associated with the 
pathogenesis of systemic and organ specific fibrotic disorders (Adamson and 
Bowden 1983, Friedman 2000, Magro, Waldman et al. 2006, Trojanowska 2010). It is 
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possible that injury to endothelium in response to toxic effects of arecoline could 
contribute to initiation and progression of fibrosis in the oral mucosa of areca nut 
chewers. 
 
Arecoline may reach levels of 97.39-142.93 µg/ml in the mouth during areca nut 
chewing (Nair, Ohshima et al. 1985, Cox, Vickers et al. 2010), and although this is 
modestly lower than the levels causing HUVEC death, ultrastructural changes were 
seen at 111 µg/ml by 24 hr exposure, while it also seems possible that local 
concentrations of arecoline could reach the toxic level for endothelium in some parts 
of the mouth. Our results are very similar to the recently published data, which 
demonstrate insignificant cytotoxic potential of arecoline at 0.4 mM (94.44 µg/ml), 
however 31% reduction in EAHY endothelial cell density is reported in response to 
0.8 mM (188.87 µg/m) for 24 hr (Tseng, Chang et al. 2012). Notably, the EAHY cells 
are a transformed cell line (Edgell, McDonald et al. 1983), which is refractory to 
senescence and thus possibly less appropriate for study of cell survival as described 
in this Chapter using HUVEC.  
 
Arecoline causes cytotoxicity in oral epithelial cells, oral mucosal fibroblasts and 
many other cell types at variable concentrations (Tsai, Kuo et al. 1997, Chang, Ho et 
al. 2001, Lee, Chang et al. 2006). Differences amongst cells with regard to sensitivity 
to arecoline might reflect an inherent ability of some cell lines to resist toxic arecoline 
injury, or alternatively this may be the consequence of variations in different cell 
culture systems. To address this issue, the current study compared HUVEC with 
HGF survival with arecoline, and the increased sensitivity of HUVEC relative to HGF 
in similar culture conditions suggests increased sensitivity of endothelium compared 
with fibroblasts. This may also be reflected in OSF where extremely diminished 
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vasculature is seen along with active fibroblast production of collagen (Kuo, Chen et 
al. 1995, Waal, Olivier et al. 1997). 
 
Cell death in response to chemical insult may be necrotic or apoptotic, depending 
upon various factors such as sensitivity of cells, type of injury, and magnitude and 
duration of the insult (Zong and Thompson 2006). Apoptotic cells may undergo 
secondary necrosis at the end stage of apoptosis, when the cells are no longer able 
to maintain homeostasis as a result of autolysis and disintegration of cellular 
components (Silva 2010). Some agents with cytotoxic potential may cause either 
apoptosis or necrosis, with apoptosis at a lower concentrations and necrosis at 
higher concentrations (Bonfoco, Krainc et al. 1995), while the current study suggests 
that arecoline does not behave in this way for endothelium, with only a frankly 
necrotic effect seen at high concentrations.  
 
The frequency of areca nut chewing per day varies as much as from 1 to 76 times, 
while the range of salivary arecoline concentrations is from 5.66 to 97.39 µg/ml within 
25 minutes of chewing, and background levels are often above 0.1µg/ml (Cox, 
Vickers et al. 2010).  It is important to note that these levels of arecoline are 
consistent with the levels examined in the current Chapter, while there is clearly a 
relationship between dose and time of exposure of endothelium. The toxicity 
observed in this study, together with ultrastructural changes at lower levels of 
arecoline, raise the possibility that separate to endothelial cell death, there may be 
other important endothelial responses to arecoline, and Chapter 3 explores this 
possibility through examination of the cytokine synthetic response of endothelium.  
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3. CHAPTER 3: EFFECT OF ARECOLINE ON CYTOKINE 
PRODUCTION BY HUVEC 
3.1. Introduction 
3.1.1. Studies on the Role of Cytokines in OSF 
Overproduction of ECM components by fibroblasts is the hallmark of widespread 
fibrotic disorders such as systemic sclerosis, localized scleroderma, and keloid 
formation (Denton and Abraham 2001), while as noted in Chapter 2 these conditions 
are also accompanied by loss of vasculature. Although the pathogenesis of these 
conditions is obscure, numerous growth factors and cytokines secreted by 
inflammatory leukocytes, fibroblasts, and endothelial cells likely contribute 
significantly to initiation and progression of connective tissue fibrosis (Jimenez, 
Hitraya et al. 1996). As discussed in Section 1.9, cytokines are secreted proteins that 
mediate and regulate a range of cellular responses in development, inflammation, 
and immunity, so that these proteins contribute to a wide variety of pathological 
processes. Cytokines have been extensively studied in a variety of fibrotic disorders, 
but there is limited information on the importance of these mediators in the 
pathogenesis of OSF.  
 
The earliest report on the cytokine profile in OSF appears to be from 1998, where 
increased expression of fibrogenic and inflammatory cytokines such as IL-1α and IL-
1β, IL-6, TGF-β, bFGF and PDFG was seen by immunohistochemistry in tissues 
affected with OSF (Haque, Harris et al. 1998). In addition, peripheral blood 
mononuclear cells (PBMC) isolated from OSF patients have overexpression of pro-
inflammatory cytokines such as IL-1β, IL-6, TNF-α, and have down regulation of anti-
fibrotic IFN-γ in in-vitro (Haque, Meghji et al. 2000, Haque, Meghji et al. 2001). 
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Similarity between various ECM molecules of OSF and those found in reparative 
granulation tissue suggest OSF has a significant component of the wound healing 
response (Utsunomiya, Tilakaratne et al. 2005, Gupta, Mhaske et al. 2008), and this 
is consistent with the traditional view of diffuse chronic inflammation as a condition 
where there is simultaneous injury and repair with the formation of reparative 
granulation tissue due to a persistent injury (Kumar, Abbas et al. 2012).  
 
3.1.2. Expression of bFGF in OSF and Other Fibrotic Disorders  
Basic FGF is a member of a large family of proteins that bind heparin and heparan 
sulphate, and is a potent regulator of many cellular functions including proliferation, 
differentiation, survival, migration, adhesion and apoptosis, so that this cytokine 
growth factor contributes to numerous patho-biological processes including wound 
healing, angiogenesis, deposition of ECM and cancer development, as discussed in 
Section 1.9.2. bFGF is chemotactic for fibroblasts and endothelial cells, and acts 
mainly though paracrine and autocrine mechanisms, while there is often synergy with 
other growth factors to promote the deposition of ECM (Powers, McLeskey et al. 
2000). Despite the fact that the best known function of bFGF is the regulation of 
vasculature (Montesano, Vassalli et al. 1986, Cross and Claesson-Welsh 2001), its 
receptors have been demonstrated in fibroblasts, suggesting a role in the synthesis 
of collagen (Gonzalez, Buscaglia et al. 1992). Stimulation of fibroblasts and 
deposition of connective tissue matrix, a feature common to fibrotic disorders, is 
secondary to overexpression of several stimulatory factors including bFGF, TGF-β, 
and PDF (Chaudhary, Roth et al. 2007, Wynn 2008). 
 
bFGF is present in the basement membrane and sub-endothelial ECM of the 
vasculature, and from this location may induce the proliferation of fibroblasts and 
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endothelial cells in fibrosis and angiogenesis (Dinbergs, Brown et al. 1996, Makino, 
Jinnin et al. 2010). As outlined below, increased expression of bFGF has been 
reported in association with a variety of fibrotic disorders.  Endothelial derived bFGF 
and other growth factors have a potential stimulatory effect on fibroblasts in 
scleroderma (Denton, Shi-wen et al. 1997). In addition, mast cells overexpress bFGF 
in idiopathic pulmonary fibrosis, which might exert fibrogenic and proliferative effects 
on smooth muscle cells or myofibroblast-like cells (Inoue, King et al. 2002). Further, 
bFGF acts synergistically with other growth factors in the induction of collagen 
production by stimulating skin fibroblasts, a mechanism implicated in skin fibrosis 
(Chujo, Shirasaki et al. 2009). Many tumors exhibit fibrosis resulting from 
exaggerated production of ECM in response to autocrine and or paracrine stimulation 
of tumor or tissue stromal cells through synthesis and secretion of growth factors 
(Eckes, Kessler et al. 2000).  
 
Of particular relevance to work in this Chapter, is that increased bFGF expression in 
response to arecoline occurs in fibroblasts and endothelial cells in OSF as detected 
by immunohistochemistry (Bishen, Radhakrishnan et al. 2008). Prolonged exposure 
to areca nut causes progression of OSF to oral squamous cell carcinoma, while the 
increased bFGF expression in OSF is consistent with this carcinogenic progression 
(Raimondi, Molinolo et al. 2006).  
 
Fibrosis is a complex process, which involves sequential activation of fibroblasts and 
deposition of ECM components. Interaction of activated fibroblasts with the 
neighboring ECM and subsequent fibrosis involves many cytokines and growth 
factors (Eckes, Kessler et al. 2000). Understanding the growth factors regulating 
various stages of fibrosis may lead to insight into the pathogenesis of fibrosis, so that 
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work in the current Chapter reflects an attempt to better understand the progressive 
fibrotic response of OSF by arecoline stimulated endothelium.  
 
3.1.3. Release of bFGF Following Injury to Endothelium and its Role in Fibrosis 
Endothelial injury and dysfunction is a wclell characterised feature of many 
pathological processes as discussed in section 1.7.2. In scleroderma, for example, 
vascular injury in response to agents such as autoantibodies, chemicals and 
environmental factors, and infectious agents has been proposed as triggering events 
leading to widespread fibrosis (Kahaleh 2008).  Injury to endothelium plays a 
possible role in the initiation and progression of fibrosis through complex 
mechanisms, which involve the interaction of endothelial derived growth factors and 
cytokines with potential fibrogenic properties.  
 
The biological activities of bFGF are mediated via paracrine (Dow and deVere White 
2000), autocrine (Seghezzi, Patel et al. 1998) and intracrine mechanisms (Chu-
Huang, Poucher et al. 2004). Since bFGF lacks a leader sequence, this factor must 
be released by a non-classical pathway (Backhaus, Zehe et al. 2004), while 
association with heparin and heparan sulphate binds bFGF to the extracellular matrix 
where it may control angiogenesis and fibrosis by acting as an autocrine and 
paracrine mediator respectively (Dinbergs, Brown et al. 1996). 
 
Cell death or damage following irreversible and sub-lethal cell injury is the main 
cause of bFGF release from endothelial cells, and has been regarded an evolved 
wound hormone response driving tissue repair (Klagsbrun and Vlodavsky 1988, 
D'Amore 1990, Hartnett, Garcia et al. 1999). Endothelial cells release bFGF when 
exposed to endotoxin-induced injury (Gajdusek and Carbon 1989) and in response to 
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sub-lethal injury as a result of transient tears in the plasma membrane (McNeil, 
Muthukrishnan et al. 1989). In addition, the synthesis and release of bFGF by 
endothelial cells in response to toxic and sub-toxic injury suggests a role in recovery 
from cell injury (Ku and D'Amore 1995). 
 
Fibroblasts clearly contribute to fibrotic conditions, while these cells are recognized 
as sensitive to agents released by immune cells, endothelial cells, or separate 
activated fibroblasts (LeRoy 1994). In this way, endothelial cell release of bFGF 
subsequent to chronic injury has potential to drive excess ECM production by 
fibroblasts, leading to fibrosis and scaring, an established feature of fibrotic 
conditions.  
 
3.1.4. The Role of Endothelial Injury and Pro-inflammatory Cytokines in the 
Pathogenesis of Tissue Fibrosis 
Fibrosis is a common response to widespread physical, chemical and biological 
injuries such as surgery, drugs, infectious agents and autoimmune reactions often 
associated with inflammation. Vascular injury is an important event occurring in 
fibrogenesis and is one of the key mechanisms in systemic sclerosis as discussed in 
section 1.7.3. Injury to endothelium contributes to the vascular thickening, production 
of pro-inflammatory cytokines and growth factors, tissue hypoxia, oxidative stress, 
aggregation of platelets, reduced NO synthesis; all likely early events in the 
development of fibrosis (Jain and Varga 2006, Steen 2006). Endothelial cells are 
located in close proximity to ECM, fibroblasts and epithelial cells so that injury to 
endothelial cells may have substantial effect on the ECM and epithelium as a result 
of cross talk among these differing cell populations. In response to injury, the 
endothelial cells generate and secrete cytokines, growth factors and chemo-attractive 
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agents for inflammatory cells, and may undergo apoptosis, or may even trans-
differentiate into fibroblasts a phenomena known as endothelial-mesenchymal 
transition (Wynn 2007).  
 
The orderly replacement of damaged tissue following tissues injury is a fundamental 
biological mechanism, a process critically important for and survival. However, 
deregulation of this process can lead to the development of permanent fibrotic scar 
tissue (Wynn 2007). The process of wound healing comprise of four distinct phases; 
the clotting and coagulation phase; an inflammatory phase; a fibroblast migration and 
proliferation phase; and a remodeling phase. These differing phases are under the 
strict control of numerous mediators, growth factors and cytokines released by the 
injured cells.  A chronic and sustained injury leads to a continued repair response, 
resulting in persistent fibroblast activation and ultimately tissue fibrosis (Wei, 
Bhattacharyya et al. 2011). 
 
The inflammatory phase of the tissue response to injury is mediated by the release of 
pro-inflammatory cytokines such as Tumor Necrosis Factor- a (TNF-a). interleukins 
and CFSs (Newton and Dixit 2012). Various pro-inflammatory cytokines with distinct 
biological functions have been discussed in detail in section 1.9. Study of the 
individual cytokines has revealed diverse roles in the regulation of fibrotic processes 
such as chemotactic and mitogenic mediators for fibroblasts, alteration of contractile 
phenotype of fibroblasts, regulation of inflammatory cells and stimulation of ECM 
production (Kisseleva and Brenner 2008, Biswas, Bunderson-Schelvan et al. 2011). 
The release of pro-inflammatory cytokines by endothelial cells represents a normal 
physiological response to vascular injury, and likely plays a key role in defense and 
repair, however, any aberration such as suppression or exaggerated production of 
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these cytokines may have deleterious effects on immunity and tissue repair 
processes. Work described in this Chapter addresses the possibility that arecoline 
may have a direct effect on the production of endothelial cytokines, in consideration 
of the possible role of such cytokines in OSF.  
 
3.1.5. Detection of Cytokine Expression Using Enzyme-Linked Immunosorbent 
Assay 
Enzyme-linked Immunosorbent Assay (ELISA) is a widely accepted plate-based 
assay technique designed for detection and quantification of substances such as 
proteins, peptides, antigen, antibodies, cytokines and hormones, based upon 
antibodies specific for the respective agent of interest. In this technique, an antigen is 
immobilized to a solid surface prior to binding with an antibody that is linked to an 
enzyme and detection is accomplished by assessing the conjugated enzyme activity 
by incubating with a substrate to yield a measurable product. ELISA can be 
performed with several modifications to the basic technique, and the commonest 
formats of ELISA include direct assay, indirect assay and capture assay which is also 
sometimes referred to as 'sandwich', where one specific antibody is used to initially 
capture the antigen, and a second antibody preparation is then used to detect the 
bound antigen (DeForge and Remick 1991, Chiswick, Duffy et al. 2012). 
 
ELISA is widely used by medical diagnostics laboratories, manufacturers of in vitro 
diagnostic products, regulatory bodies, and quality assessment and proficiency 
testing organizations. The immunoassay technique was invented in 1960 for 
measurement of endogenous plasma insulin (Yalow and Berson 1960), however 
ELISA was first reported in 1971 demonstrating quantitative measurement of IgG in 
rabbit serum with alkaline phosphatase as the reporter label, and quantification of 
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human chorionic gonadotropin concentration in urine (Engvall and Perlmann 1971, 
Van Weemen and Schuurs 1971). 
 
3.1.6. Cytokine mRNA Expression Using Real-time Reverse Transcription 
Polymerase Chain Reaction  
Real Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) has become 
an increasingly popular technique for quantification of cytokine mRNA, and provides 
the best tool for easy detection of cytokine mRNA transcripts in a limited number of 
cells, even when protein levels are very low (Stordeur, Poulin et al. 2002, Overbergh, 
Giulietti et al. 2003). Various modifications have been made to the original PCR 
technique since its discovery (Mullis, Faloona et al. 1986).  Highuchi et al pioneered 
the RT-PCR system that detects PCR products as they accumulate (Higuchi, 
Dollinger et al. 1992, Higuchi, Fockler et al. 1993). 
 
While ELISA permits detection of protein levels for specific cytokines, RT-PCR 
permits quantitation of relevant mRNA levels (Yin, Shackel et al. 2001), and this 
approach has been further used for clinical diagnostics (Stordeur, Poulin et al. 2002), 
cancer diagnostics (Bernard and Wittwer 2002), detection of pathogens (Norton 
2002), quantification of viral load (Niesters 2001), and measurement of DNA or 
transgene copy number and allelic discrimination (Sevall 2001).  
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3.2. Materials 
3.2.1. Materials for Cell Culture 
Materials for cell culture were the same as those described in section 2.2.1. 
Additional materials included cell scrapers (from Iwaki® Scitech Division (Chiba, 
Japan), and Triton X1000 (Merk, Darmstadt Germany). 
 
3.2.2. Chemicals for Cell Culture  
Arecoline Hydrobromide, Nicotine, Acetylcholine Chloride and Muscarine Chloride 
were purchased from Sigma-Aldrich® (USA), while TNF-α was bought from 
Chemicon (Billerica, USA). 
 
3.2.3. Materials for ELISA 
ELISA kits for bFGF, IL-1α, IL-1β, IL-6, GM-CSF, G-CSF detection were in the 
Duoset® ELISA Development System, which included primary antibodies, secondary 
antibodies, Streptavidin-HRP, and substrate reagents, and were purchased from R & 
D Systems (Minneapolis, USA). Sulphuric acid (H2SO4) was aquired from APS 
Chemicals (NSW, Australia). Phosphate Buffer Saline (PBS) tablets were obtained 
from Oxiod (Hampshire, England). Bovine Serum Albumin and Tween-20 were 
purchased from Sigma-Aldrich (St. Louis, USA) while ELISA plates were purchased 
from Becton Dickinson Labware (NJ, USA).  
 
3.2.4. Materials for RNA Isolation 
RNeasy® Mini Kits for extraction of RNA from HUVEC and Nuclease Free Water were 
purchased from QIAGEN (GmbH Hilden, Germany).  β mercaptoethanol (β-ME) and 
AR Ethanol from Sigma Aldrich (St. Louis, USA), DPBS from BioWhittaker (Lonza, 
USA).  Ambion® RNaseZap® was purchased from Invitrogen (Carslsbad, CA, USA). 
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3.2.5. Materials for Reverse Transcription 
Superscript III Reverse Transcriptase (200U/µl), Oligo(dT)20, primers. 10mM dNTP 
mix, 10X RT buffer, 25mM MgCl, 0.1M DTT, RNaseOUTTM (40U/µl) and RNase H 
were purchased from Invitrogen (Carslsbad, CA, USA).  Nuclease Free Water was 
purchased from QIAGEN (GmbH Hilden, Germany). Eppendorf tubes (0.2ml, 0.5ml, 
1.5ml and 2ml) were bought from Eppednorf. 
 
3.2.6. Materials for Polymerase Chain Reaction 
Platinum® SYBR® Green qPCR SeperMix-UDG was obtained from Invitrogen by life 
technologies (Carisbad, California, USA). Gene specific primers (bFGF, IL-1α, IL-1β, 
IL-6, GM-CSF, G-CSF) and primers for housekeeping genes (GAPDH, β-Actin) were 
ordered from GeneWorks Pty Ltd (Hindmarch, SA, Australia). PCR Strip Tubes 
(0.1ml) and Caps were purchased from QIAGEN (Hilden, Germany). 
 
3.3. Methods 
3.3.1. Isolation, Culture and Storage of HUVEC 
Isolation, culture and storage of HUVEC was as described in Sections 2.3.1, 2.3.2 
and 2.3.5 respectively. 
 
3.3.2. Evaluation of the Effect of Arecoline on Cytokine Production by HUVEC 
at the Protein Level 
3.3.2.a. Incubation of HUVEC with Arecoline in Cell Culture for ELISA 
Confluent cultures of HUVEC in passage 4 or 5 were collected from 75cm2 tissue 
culture flasks using Trypsin/EDTA treatment and pelleted with BCS as outlined in 
Section 2.3.2. Cell pellets were resuspended in appropriate volumes of complete 
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media and seeded into gelatinize 24 well tissue culture plates at confluence with 
each well receiving 500 µl of cell suspension. HUVEC were allowed to attach and 
incubated for 2 to 3 days at 37ºC, under 5 % CO2 and 95% relative humidity before 
incubation with arecoline. HUVEC were washed twice with M199 and treated for 24 
hr in triplicate with 500 µl volumes of 1/3 dilutions of arecoline at concentrations of 
1000 µg/ml, 333 µg/ml, 111 µg/ml, 37 µg/ml, 12.34 µg/ml, 4.11 µg/ml, 1.37 µg/ml, 
0.46 µg/ml, 0.15 µg/ml, 0.05 µg/ml and 0 µg/ml in M199 supplemented with 4% 
bovine serum albumin (BSA). To evaluate the time course of the HUVEC responses 
to arecoline, cells were stimulated with 0 µg/ml, 37 µg/ml, or 1000 µg/ml arecoline for 
increasing times of: 0 hr, 4 hr, 8 hr, 12 hr, 16 hr, and 24 hr.   
 
3.3.2.b. Collection of Culture Supernatants and Lysates for ELISA 
Cell culture supernatants were collected from HUVEC into 2ml eppendorf tubes and 
centrifuged at 2000 rpm for 2 minutes to pellet cellular debris, before transfer of the 
remaining supernatant to fresh eppendorf tubes. Cell lysates were obtained from the 
remaining monolayers, which were washed twice with M199 prior to lysis and 
scraping into 500 µl volumes of Triton X 100 in PBS (0.5%) and collection into 
separate fresh eppendorf tubes. Samples were stored at -20ºC for later ELISA assay. 
 
3.3.2.c. Enzyme Linked Immunosorbent Assays  
Assays were performed following the manufacturer's instructions, quantifying 
cytokines with standard curves established by material provided by the manufacturer. 
In brief, 96-well ELISA plates were coated with cytokine specific capture antibodies 
(100µl/ml per well) after prior dilution to the prescribed working dilution in PBS (Table 
3.1), and allowed to incubate overnight at room temperature after sealing plates. 
Next day, wells were washed three times with wash buffer consisting of Tween 20 
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(0.05% in PBS), before blotting against clean paper towels. The plates were then 
blocked for non-specific binding using 300 µl per well of reagent diluents (1% BSA in 
PBS), and incubated at room temperature for 1 hour. Wells were then washed with 
wash buffer before application of 100µl per well of cell supernatants or lysates, while 
a series of 7 separate 1 in 2 serial dilutions of standards was also applied in reagent 
diluent to establish standard curves. Plates were then sealed and allowed to incubate 
for 2 hours at room temperature (Table 3.1). ELISA plates were subsequently 
washed three times in wash buffer prior to addition of 100 µl/well volumes of 
biotinylated detection antibodies in reagent diluent at the working dilution, and 
incubation for 2 hr at room temperature (Table 3.1). Plates were then washed three 
times with wash buffer, and 100 µl/well Streptavidin-Horse Radish Peroxidase (HRP) 
conjugate diluted to 1:200 in reagent diluent added. Plates were then allowed to 
further incubate for 20 min at room temperature, sealing and covering the plates to 
avoid direct light. The plates were then washed three times with wash buffer before 
incubation with substrate solution (100µl/well) comprising a 1:1 mixture of H202 and 
tetramethylbenzidine for 20 minutes at room temperature, after first sealing and 
covering to protect from direct light.  This reaction resulted in generation of a yellow 
colour, which was stopped by addition of stop solution (50µl per well) consisting of 
H2SO4 (1M) followed by thorough mixing by gentle taping. Immediately, optical 
density (OD) of each well was determined using a microplate reader (Bio-Rad Model 
3550 plate reader) at 450 nm and a corrective measurement at 570 nm. 
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Table 3.1 Working concentrations of capture antibody, detection antibodies 
and highest concentration of standards for quantification of cytokines by 
ELISA in this study 
Cytokine 
Capture Antibody 
(µg/ml) 
Standard-highest 
concentration (pg/ml) 
  Detection      
Antibody 
bFGF 2 1000      0.25µg/ml 
IL-1α 2 200     12.5ng/ml 
IL-1β 4 250     200ng/ml 
IL-6 2 500     200ng/ml 
G-CSF 2 500     200ng/ml 
GM-CSF 2 250-500    0.5µg/ml 
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3.3.3. Evaluation of the Effect of Arecoline on Cytokine Production by HUVEC 
at mRNA Level 
3.3.3.a. Incubation of HUVEC with Arecoline in Cell Culture for RT-PCR 
Confluent cultures of HUVEC in passage 5 were harvested as outlined in Section 
2.3.2, and seeded at confluence in gelatinized 6 well tissue culture plates, with each 
well receiving 2 ml cell suspension. HUVEC were allowed to attach and incubate for 
2 to 3 days at 37ºC, 5 % CO2 and 95% relative humidity, before treatment with 
arecoline at 111 µg/ml in M199 supplemented with 4% BSA for 24 hr prior to mRNA 
isolation. Experiments were performed three times with cells from three separate 
donors.  
 
3.3.3.b. Isolation of mRNA from HUVEC 
mRNA was isolated according to the manufacturer’s instructions. In brief, each well 
with HUVEC was washed twice with 2ml of sterile PBS after collection of 
supernatants for verification of cytokine production by ELISA, followed by addition of 
350 µl Buffer RLT with β-ME at a ratio of 1:100 per well to disrupt the monolayer and 
lyse cells. Cell lysates were homogenized by vortexing after transferring to RNase 
free 2 µl tubes prior to mixing with 350 µl of 70% AR ethanol at a ratio of 1:1 by 
gentle pipetting. The 700µl samples were then transferred to RNeasy spin columns 
placed in 2ml collection tubes and centrifuged at 10,000rmp for 15 sec. The flow 
though was discarded before adding 700µl Buffer RW1 to RNeasy spin columns and 
then centrifuted at 10,000rmp for 15 sec. After discarding the flow through again, 500 
µl Buffer RPE was added and centrifuged at 10,000 rmp for 15 seconds, and this was 
repeated with a further 2 minutes spin time. RNeasy spin columns were then placed 
into fresh 2 ml RNase free tubes before the addition of 50µl RNase free water and 
spun at 10,000rmp for 1 minute to elute the RNA. The mRNA thus obtained was 
Chapter 3,  Effect of Arecoline on Cytokine Production by HUVEC                           Page 102 
stored at -20o C and used for RT-PCR before measurement by spectrophotometer. 
RNA integrity Number (RIN) was evaluated using an Agilent 2100 Bioanalyzer 
following the manufacturer’s instructions, and Table 3.2 shows both mRNA yields 
and RIN results for all samples prepared.  
 
3.3.3.c. Reverse Transcription 
Following isolation of mRNA, reverse transcription was performed on samples using 
the SuperScriptTM III First-Strand Synthesis System for RT-PCR according to the 
manufacturer’s instructions. A minimum of 32 ng mRNA containing 8µl of RNase free 
water was combined with 1 µl 50 µM oligo(dT)20 primer and 1 µl 10mM dNTP mix in 
0.2ml RNase free tube before incubation at 65ºC for 5 min followed by immediate 
transfer on ice for at least 1 minute. The cDNA synthesis Mix was prepared by mixing 
2µl 10X RT buffer, 4µl 25mM MgCl2, 2µl 0.1M DTT, 1µl RNaseOUTTM(40U/µl) and 
1µl SuperScriptTM III RT(200U/µl) and added to each RNA/primer mixture followed by 
gentle mixing and collected by brief centrifugation prior to incubation at 50ºC for 50 
min. Reactions were terminated by incubation at 85ºC for 5 minute and chilled on ice 
and collected by brief centrifugation before the addition of 1µl of RNase H to each 
tube to degrade mRNA templates from the cDNA:RNA hybrid molecule and 
incubation for 20 min at 37ºC. cDNA synthesis reaction products were stored at -
20ºC to be used for RT-PCR. 
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Table 3.2. mRNA yields and RNA Integrity Number results for HUVEC treated 
with  111 µg/ml arecoline for 24 hr compared with untreated controls from three 
separate donors 
 
 
  
Samples Donors Treatment mRNA (ng/ml) RIN 
1 D1 Control 17.2 8.1 
2 D1 Arecoline 17.6 7.4 
3 D2 Control 20.4 8.1 
4 D2 Arecoline 19.2 7.9 
5 D3 Control 16 4.4 
6 D3 Arecoline 18.8 7.2 
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3.3.3.d. Real Time Reverse Transcription Polymerase Chain Reaction 
RT-PCR was performed on the cDNA synthesized as described above in section 
4.3.3.c. for bFGF, IL-1α, IL-1β, IL-6, GM-CSF and G-CSF, and for the housekeeping 
genes of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Beta Actin. 
Gene specific primers were designed using the Universal Probe Library (Roche 
Applied Science) website, and primer 3 Software (Table 4.3). Standard curves were 
generated for each RT-PCR reaction by mixing the original cDNA from all the 
samples and 6 further 1:5 dilutions of the pool while cDNA template of all samples 
were diluted in 1:50 to be subjected to RT-PCR for differential expression of genes 
under investigation. RT-PCR reactions were prepared by mixing Platinum® SYBR 
Green (5 µl), forward primer (0.3 µl), reverse primer (0.3 µl), and RNase free water 
(1.4 µl), and transferring to RT-PCR strip tubes prior to addition of diluted cDNA 
templates (5 µl) for a total final volume of 12 µl. All the reaction tubes were 
transferred to a Rotor Gene 6000 PCR machine and run with the RT-PCR 
temperature conditions set as follows: 1st hold:  50ºC for 2 minutes; 2nd hold:  95ºC 
for 2 minutes; Cycling:  95ºC for 15 seconds; 60ºC for 45 seconds.             
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Table 3.3. Sequence of primers for real time reverse transcription polymerase 
chain reaction analysis  
Gene Name Primer from 5' to 3' Sequence of Primer 
bFGF Reverse TTCTTCCTGCGCATCCAC 
bFGF Reverse TGCTTGAAGTTGTAGCTTGATGT 
IL-1α Forward 
AATGACGCCCTCAATCAAAG 
IL-1α Reverse 
TGGGTATCTCAGGCATCTCC 
IL-1β Forward 
TACCTGTCCTGCGTGTTGAA 
IL-1β Reverse 
TCTTTGGGTAATTTTTGGGATCT 
IL-6 Forward 
GATGAGTACAAAAGTCCTGATCCA 
IL-6 Reverse 
CTGCAGCCACTGGTTCTGT 
GM-CSF Forward 
TCTCAGAAATGTTTGACCTCCA 
GM-CSF Reverse 
GCCCTTGAGCTTGGTGAG 
G-CSF Forward 
GAGCAAGTGAGGAAGATCCAG 
G-CSF Reverse 
CAGCTTGTAGGTGGCACACTC 
GAPDH Forward 
GAGTCAACGGATTTGGTCGT 
GAPDH Reverse 
TTGATTTTGGAGGGATCTCG 
Beta Actin Forward 
CCAACCGCGAGAAGATGA 
Beta Actin Reverse CCAGAGGCGTACAGGGATAG 
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3.3.4. Cells Culture Conditions for Comparison of the HUVEC Response to 
Arecoline with That to Acetylcholine, Muscarine and Nicotine 
HUVEC were seeded into 12 well tissue culture plates as described in Sections 
3.3.2.a, and stimulated in triplicate for 24 hr in M199 and BSA (4%) with arecoline, 
acetylcholine, muscarine or nicotine at equimolar concentrations being 0 M, 10-5 M, 
10-4 M, 10-3 M, and 10-2 M. Culture supernatants and lysates were harvested at 24 hr 
as outlined in Section 3.3.2.b, and subsequently tested for cytokine expression by 
ELISA as in Section 3.3.2.c.  
 
3.3.5. Cell culture Conditions to Evaluate the Effect of Arecoline on HUVEC 
Stimulated with TNF-α  
For reasons that will become clear in the Results Section, it became interesting to 
evaluate the effect of arecoline on cytokine synthesis in endothelium also stimulated 
with the potent inflammatory signal TNF-α .   In these experiments, HUVEC in 
triplicate 12 well culture plates were stimulated with arecoline as outlined in Section 
3.3.3.a, but with the distinction of inclusion or otherwise of TNF-α at 3nM, shown in 
separate preliminary experiments to be maximally stimulatory for HUVEC cytokine 
production.  
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3.3.6.   Data Analysis 
3.3.6.a.    Analysis of ELISA Data 
The optical densities of duplicate standards with known concentrations of cytokine 
were used to produce standard curves for each set of samples assayed, and these 
data used to generate a formula for each standard curve describing a straight line in 
the Cartesian plane, and relevant formulae were then used to calculate the 
concentration of cytokine in individual samples. Most experiments were performed at 
least six times, with cells from six separate biological donors. Data were analysed by 
Wilcoxon-singed Rank test was used to evaluate statistical significance between 
different treatment groups across multiple experiments, while the Mann Whitney U 
Test was used in considering results within groups across experiments, and 
Student's T Test was applied within individual experiments or where data across 
separate experiments was clearly normally distributed. A p value <0.05 was 
considered statistically significant. Where appropriate, data were expressed as Mean 
± SEM. 
 
3.3.6.b.    Analysis of RT-PCR Data 
RT-PCR data was analysed using Corbett Rotor-6000 Application Software, version 
1.7 to obtain the Ct values for each sample. Duplicate values were obtained for each 
sample for three separate biological donors. Each experiment was repeated multiple 
times for optimization until reproducible results were obtained. Further analysis for 
differential gene expression was performed following the 2ΔΔCT method (Livak and 
Schmittgen 2001). Due to the limited sample size, and non-parametric distribution of 
RT-PCR data across different donors, statistical analysis across donors could not be 
reliably performed and results are shown as average values of gene expression for 
each donor. 
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3.4. Results 
3.4.1. HUVEC Produced bFGF in Response to Arecoline in Cell Culture  
bFGF antigen was mostly in cell lysates, with only low levels found in culture 
supernatants (Figure 3.1). Levels of bFGF increased upon stimulation with arecoline 
in a dose dependent manner, with synthesis increasing at 4.11 µg/ml and reaching a 
maximum by 111 µg/ml (p < 0.01) (Figure 3.1 A, B). Consistent with the results in 
Chapter 2, arecoline at 333 µg/ml or above resulted in HUVEC death and this was 
associated with release of bFGF from cells into supernatants (Figure 3.1 A, B).  
Similar results were found in 7 experiments with cells obtained from 6 separate 
donors.  
 
Considering the time course of bFGF synthesis, when cells were treated with 
arecoline at 37 µg/ml there was a significant increase in bFGF levels in lysates by 4-8 
hr of stimulation (p < 0.05), with little change in antigen level over the remaining 24 hr 
incubation. Stimulation with 1000 µg/ml, however, did not increase total bFGF levels, 
but instead resulted in release of bFGF from cells into supernatants starting at 8 hr 
and increasing till 24 hr  (p < 0.05) (Figure 3.1 C, D). Similar results were obtained in 
3 experiments with cells from 3 separate donors.  
 
3.4.2. Arecoline Reduced Production of IL-6, G-CSF and GM-CSF at the Protein 
Level 
IL-6, G-CSF and GM-CSF were found mainly in the culture supernatants, with 
comparatively low levels found in cell lysates, and arecoline significantly reduced 
production of these cytokines (p < 0.05) (Figures 3.2, 3,3, 3.4).  Reduction in cytokine 
production was seen by 37 µg/ml arecoline (p < 0.05), while by 333 µg/ml and 1000 
µg/ml arecoline levels were minimal (p < 0.05), reflecting cell death. Time course 
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experiments revealed reduction in cytokine production induced by arecoline by 8 hrs 
in most experiments performed (p < 0.05). Similar results were obtained in 6 dose 
response experiments with cells from 6 separate donors, and in 3 time course 
experiments with cells from 3 separate donors.  
 
3.4.3. Arecoline reduced IL-1α and IL-1β in HUVEC  
Levels of IL-1a were similar in cell lysates as in culture supernatants (Figure 3.5 A, 
B), and reduced with increasing concentration of arecoline, with cytokine levels 
detectably reduced in both culture supernatants and lysates by 1.37 µg/ml of 
arecoline (p < 0.05), and maximal reduction seen by 333 µg/ml arecoline (p < 0.05).  
IL-1b was primarily in cell lysates, and displayed a dose response more similar to 
that of IL-6, G-CSF and GM-CSF, with appreciable reduction in lysate levels of IL-1b 
by 37 µg/ml of arecoline (p < 0.05), and maximal reduction seen by 333 µg/ml 
arecoline (p < 0.05).  Similar results were obtained in 4 experiments with cells 
obtained from 4 separate donors. Time course experiments showed minimal 
production of both these cytokines and detectable amount was observed only after 
24 hr. 
 
3.4.4. Arecoline Suppressed TNF-a Production of IL-6 and GM-CSF 
Figures 3.3 to 3.5 demonstrate reduced background levels of inflammatory cytokines 
in endothelium treated with arecoline, and to test the possibility that similar reduction 
occurs for stimulated cytokine production, the effect of arecoline on TNF-a stimulated 
cytokine synthesis was studied. Figure 3.6 demonstrates increased culture 
supernatant levels of IL-6 and GM-CSF upon treatment of HUVEC with TNF-a (p < 
0.05) and suppression of this by arecoline to a similar extent to that seen in the 
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absence of TNF-a (p < 0.05) . Similar results were obtained in two experiments with 
HUVEC from separate donors.  
 
3.4.5. Arecoline Down-regulated IL-6, G-CSF, GM-CSF, IL-1α and IL-1β mRNA 
Expression by HUVEC but did not affect mRNA levels for bFGF  
Figure 3.7 shows the results of three separate experiments with cells from three 
separate donors, comparing the relative amounts of mRNA detected by RT-PCR for 
all endothelial cytokines measured. Although arecoline did not significantly increase 
mRNA levels for b-FGF, levels for IL-1a, IL-1b, IL-6, G-CSF and GM-CSF were all 
lower compared with control cells. The extent to which arecoline reduced mRNA 
levels differed amongst the cytokines, however, such that only very slight reduction 
was seen for IL-1a and the greatest reduction occurred in mRNA levels for GM-CSF.  
 
3.4.6. Nicotine Induced b-FGF Antigen Expression in HUVEC Similar to 
Arecoline, but Acetylcholine Agonists Had No Other Similar Effects on 
Endothelial Cytokine Production Compared with Arecoline  
To evaluate the possible action of arecoline via acetylcholine receptors in 
endothelium, HUVEC were treated with equimolar concentrations of arecoline, 
acetylcholine, nicotine and muscarine.  Figure 3.8 demonstrates a similar effect of 
nicotine to arecoline in increasing bFGF levels (p < 0.05), with arecoline being the 
more potent of the two agents with regard to increasing bFGF levels (p < 0.01). 
Neither acetylcholine nor muscarine had similar effect. However, Figure 3.9 
demonstrates little if any effect of acetylcholine, nicotine or muscarine on antigen 
levels for IL-6, G-CSF, and GM-CSF.  Similar results were obtained in three separate 
experiments with cells from three separate donors.  
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Figure 3.1. Graphs showing the 24 hr HUVEC arecoline dose response (A, B) 
and time course (C, D) for bFGF antigen levels in culture supernatants (B, D) 
and cell lysates (A, C).  (A) Arecoline increased HUVEC lysate levels of bFGF in a 
dose dependent manner, and this was maximal by 111 µg/ml (p < 0.01).  (B) 
Although bFGF was primarily in cell lysates, lysate levels were greatly reduced by 
333 µg/ml and 1000 µg/ml with transfer of antigen to the supernatants due to cell 
death and lysis (p < 0.01). (C) Stimulation with 37 µg/ml arecoline increased lysate 
bFGF levels by 4 hr (p < 0.05), with little change on further incubation. (D) Significant 
reduction in cell associated bFGF occurred by 8 hr of treatment with 1000 µg/ml 
arecoline (p < 0.05), with collection of the released bFGF in culture supernatants (D).   
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Figure 3.2. Graphs showing the 24 hr HUVEC arecoline dose response (A, B) 
and time course (C, D) for IL6 antigen levels in culture supernatants (B, D) and 
cell lysates (A, C).   (A) Arecoline decreased HUVEC lysate levels of IL-6 in a dose 
dependent manner, and this was maximal by 111 µg/ml (p < 0.01).  (B) IL-6 was 
primarily in culture supernatants, and levels were greatly reduced by 37 µg/ml 
arecoline (p < 0.05). (C) Stimulation with 37 µg/ml arecoline reduced lysate IL-6 
levels by 4 hr (p < 0.05), and in supernatants by 12 hr (p < 0.05) (D), while arecoline 
at 1000 µg/ml achieved maximal reduction in IL-6 supernatant levels by 4 hr 
incubation (p < 0.05).  
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Figure 3.3. Graphs showing the 24 hr HUVEC arecoline dose response (A, B) 
and time course (C, D) for G-CSF antigen levels in culture supernatants (B, D) 
and cell lysates (A, C).   (A) Arecoline decreased HUVEC lysate levels of G-CSF in 
a dose dependent manner, and this was maximal by 111 µg/ml (p < 0.05).  (B) G-
CSF was primarily in culture supernatants, and levels were greatly reduced by 37 
µg/ml arecoline (p < 0.05). (C) Stimulation with 37 µg/ml arecoline reduced lysate G-
CSF levels by 4 hr (p < 0.05), and in supernatants by 12 hr (p < 0.05) (D), while 
arecoline at 1000 µg/ml achieved maximal reduction in G-CSF supernatant levels by 
4 hr incubation (p < 0.05).   
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Figure 3.4. Graphs showing the 24 hr HUVEC arecoline dose response (A, B) 
and time course (C, D) for GM-CSF antigen levels in culture supernatants (B, D) 
and cell lysates (A, C).   (A) Arecoline decreased HUVEC lysate levels of GM-CSF 
in a dose dependent manner, and this was maximal by 111 µg/ml (p < 0.05).  (B) 
GM-CSF was primarily in culture supernatants, and levels were reduced by 37 µg/ml 
arecoline (p < 0.05). (C) Stimulation with 37 µg/ml arecoline reduced lysate GM-CSF 
levels by 4 hr (p < 0.05), and in supernatants by 8 hr (p < 0.05) (D), while arecoline at 
1000 µg/ml achieved maximal reduction in GM-CSF supernatant levels by 4 hr 
incubation (p < 0.05).   
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Figure 3.5. Graphs showing the 24 hr HUVEC arecoline dose response for IL-1a 
(A,B) and IL-1b (C,D) in culture supernatants (B, D) and cell lysates (A, C).  IL-
1a was present in similar quantity in both cell lysates and supernatants (A, B), while 
IL-1b was primarily in cell lysates (C, D).  Similar to the effect of arecoline on IL-6, G-
CSF and GM-CSF (Figures 3.2, 3.3 and 3.4), arecoline reduced levels of both IL-
1a and IL-1b (p < 0.05).  However, in the case of IL-1a, reduction in cytokine levels 
were achieved at lower concentrations of arecoline than seen for other cytokines 
tested (p < 0.05).  
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Figure 3.6. Graphs of IL-6 and GM-CSF antigen in 24 hr culture supernatants of 
HUVEC treated with or without TNF-a with increasing concentrations of 
arecoline.  TNF-a increased both IL-6 and GM-CSF (p < 0.05), while arecoline 
reduced both TNF-a stimulated and background IL-6 and GM-CSF in a 
proportionately similar way (p < 0.05). 
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Figure 3.7.  Scattergram demonstrating the effect of arecoline on levels of 
mRNA for bFGF, IL-6, G-CSF, GM-CSF, IL-1α and IL-1β in HUVEC treated with 
arecoline at 111 µg/ml for 24 hr, relative to control cells in three separate 
experiments.  mRNA levels for control cells was assigned a value of 1, so that all 
data shown are relative to this unit value within each experiment. Contrary to 
observations with bFGF protein, there was no increase in mRNA level for this growth 
factor. However, there was reduction in levels of all other cytokines tested, with only 
a slight reduction seen for IL-1a, and greater reductions for other cytokines and GM-
CSF mRNA levels being most intensely reduced by arecoline treatment.  
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Figure 3.8. Graphs showing the effect of 24 hr arecoline, acetylcholine, nicotine 
and muscarine treatment on bFGF antigen levels in cell lysates (A) and culture 
supernatants (B) of HUVEC.  (A) bFGF was primarily in cell lysates and was 
increased by both arecoline (p < 0.01) and to a very modest extent by nicotine (p < 
0.05). (B) Culture supernatants only contained appreciable bFGF when there was 
significant cell death, as occurred with the highest levels of arecoline and nicotine 
tested.  
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3.9. Graphs showing the 
effect of 24 hr arecoline, 
acetylcholine, nicotine and 
muscarine treatment on IL-
6 (A), G-CSF (B) and GM-
CSF (C) antigen levels in 
culture supernatants of 
HUVEC.  Arecoline 
significantly attenuated the 
baseline levels of IL-6 (A), G-
CSF (B) and GM-CSF (C) at 
1000µM (p < 0.05), but other 
cholinergic agents such as 
acetylcholine, nicotine and 
muscarine has no clear 
effect, with the exception of 
modest reduction in GM-CSF 
levels at the highest 
concentration tested (C).  
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3.5. Discussion 
ELISA is extensively used or quantitation of cytokines in sera, and cell culture 
supernatants and lysates (Favre, Bordmann et al. 1997, Nemzek, Siddiqui et al. 
2001, Leng, McElhaney et al. 2008). ELISA has significant advantage in that it 
permits quantification of a single cytokine at a time in a given sample, although 
difficulty may arise in comparing cytokine levels measured by two different ELISA 
assays under some variable conditions (Leng, McElhaney et al. 2008). A further 
difficulty is that the dynamic range over which a linear relationship exists between 
cytokine concentration and absorbance readings is narrow in relation to the range for 
other techniques such as multiplex assays and, hence the samples with cytokine 
concentration above the dynamic range have to be diluted which not only reduces 
the concentration but may also diminish the level of circulating inhibitors or binding 
protein (Leng, McElhaney et al. 2008). Nonetheless, despite these difficulties, the 
decision to use an ELISA approach seems reasonable in the current study to 
evaluate cytokine antigen levels due to its simplicity, reliability, and ability to make 
meaningful quantitative comparisons between experiments. 
 
The current study used RT-PCR to quantitate mRNA levels, but alternative methods 
include Northern blotting, in situ hybridization, RNase protection assays, cDNA 
arrays and RT-PCR.  However, the exquisite sensitivity of RT-PCR coupled with 
improved reliability in discriminating quantitative differences, suggested that it would 
be reasonable to use RT-PCR in the current study.  
 
bFGF induces cell proliferation, migration and repair-regeneration process in many 
tissues as discussed in section 1.9.2, and for this reason increased expression of 
bFGF by arecoline treated endothelium, coupled with release of this cytokine upon 
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eventual death of the cells, suggests a possible role for arecoline induced endothelial 
bFGF in the pathogenesis of OSF. Increased bFGF protein levels in the absence of 
appreciable increase in mRNA observed in this Chapter, suggests that increased 
levels of the growth factor are achieved by either reduced intracellular degradation or 
alternatively increased translation into protein upon arecoline treatment. In light of the 
electron microscopic evidence for cellular injury in Chapter 2 including reduced 
ribosomal studding, as well as the generally reduced cytokine production observed in 
the current Chapter, disrupted degradation of bFGF may most readily account for 
elevated levels in arecoline treated endothelium.  
 
This is the first in vitro study demonstrating arecoline-induced elevated levels of 
bFGF, an observation of seeming relevance to OSF in light of the role of this cytokine 
in other fibrotic conditions as discussed in section 3.1.2. Arecoline was frankly toxic 
at and above 333 µg/ml, causing death of the HUVEC, although only low toxicity was 
observed at and below 111µg/ml. At sub-lethal arecoline concentrations, most of the 
stimulated bFGF was detected in the cytoplasm, however at toxic concentrations, it 
was released into supernatants as a result of degradation of cells. As previously 
mentioned, bFGF stimulates endothelial growth and proliferation (Lindner, Majack et 
al. 1990), and is produced in response to endothelial injury by various insults 
(Gajdusek and Carbon 1989). Furthermore, expression of bFGF by HUVEC inhibits 
apoptosis (Karsan, Yee et al. 1997) and deprivation of bFGF induces apoptosis in 
endothelium (Araki, Shimada et al. 1990, Fox and Shanley 1996). From these 
disparate observations, it seems reasonable to suggest that elevated bFGF 
represents an adaptive response to general injury and cytotoxicity in endothelium, 
and this is consistent with the absence of a clear similar response to acetylcholine or 
muscarine, since arecoline is considered a muscarinic stimulant, while the modest 
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effect of nicotine in increasing bFGF may be best explained in terms of a non-specific 
toxic effect seen only at extremely high concentrations. This suggestion is also 
consistent with the absence of a signal peptide sequence in bFGF (Abraham, Mergia 
et al. 1986), while it has been generally assumed that bFGF is released following cell 
death or disruption of plasma membrane integrity (McNeil, Muthukrishnan et al. 
1989).  
 
Despite this model, immuno-histochemical detection of bFGF in basement 
membrane (Bashkin, Doctrow et al. 1989), its expression on the extracellular surface 
of some cells (Florkiewicz, Baird et al. 1991), and inhibition of migration of bFGF 
expressing cells by the application of its specific antibodies on cell surfaces (Mignatti 
and Rifkin 1991), suggest that the 18-kD isoform may be exported from cells through 
a unique cellular pathway which is distinct from classical signal peptide-mediated 
secretion (Florkiewicz, Majack et al. 1995). If such a specific export mechanism is 
accepted, it is conceded that bFGF secretion may occur without perturbation and 
breakage of the cell membrane, but no such expression was observed in the current 
study when endothelial cells were subjected to sub-toxic arecoline without damage to 
the cell membrane as observed in Chapter 2. Possible further explanations for this 
include: that the amount of intracellular bFGF might be too low to be transported by 
the unknown distinct transport mechanism; its excretion may need more time for 
activation of the transport mechanism; or HUVEC may lack this transport system, so 
that further characterization of putative transport mechanisms may clarify these 
possibilities.   
 
bFGF acts primarily as a paracrine factor (Nugent and Iozzo 2000), and stimuli which 
cause the release of bFGF from endothelial cells may have essential roles in the 
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pathogenesis of oral submucous fibrosis as well as tumor development and growth. 
The bFGF released from cells is stored in the ECM and basement membrane 
reversibly bound to HSPG (Folkman, Klagsbrun et al. 1988). bFGF alone and in 
assembly with HSPG binds to its cell surface receptor and is subject to internalization 
and nuclear translocation and drives mitogenic activity (Bikfalvi, Klein et al. 1997). 
Increased expression of bFGF occurs in healing wound and various fibrotic 
conditions, including OSF (Broadley, Aquino et al. 1989, Bishen, Radhakrishnan et 
al. 2008). In the view of the presence of bFGF receptors on fibroblasts (Gonzalez, 
Buscaglia et al. 1992) and their modulation and or up-regulation in various fibrotic 
conditions (Kikuchi, Yamakage et al. 1992), it seems reasonable to suggest that 
endothelial release of bFGF in response to arecoline may have substantial effect in 
modulation and proliferation of oral mucosal fibroblasts, and thus contribute to 
excess collagen production and fibrosis. 
 
These separate inflammatory cytokines studied in this Chapter play important roles in 
diverse biological processes and pathological conditions including those 
characterised by fibrosis, and have been discussed in section 1.9. The reduced 
production of IL-1a, IL-1b, IL-6, G-CSF and GM-CSF upon arecoline treatment seen 
in the current study appears in line with earlier studies demonstrating anti-
inflammatory potential of areca nut extracts (Lee and Choi 1999, Chang, Wu et al. 
2004, Huang, Chi et al. 2010). Areca nut possess significant analgesic and anti-
inflammatory activities, which may be due to arecoline (Bhandare, Kshirsagar et al. 
2010). Arecoline has been shown to exert inhibitory effects on several pro-
inflammatory cytokines in other cell lines. For example, arecoline attenuates IL-6 
production coupled with apoptosis and cell cycle arrest in human basal cell 
carcinoma cells (Huang, Hsieh et al. 2012).  Nonetheless, contrary to these inhibitory 
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effects, up-regulation of various pro-inflammatory cytokines has been reported in 
OSF tissues (Haque, Harris et al. 1998, Haque, Meghji et al. 2000, Haque, Meghji et 
al. 2001), while OSF fibroblasts exhibit significantly over expressed IL-6 induced by 
arecoline (Tsai, Yang et al. 2004). The two opposite actions of areca nut and 
arecoline might be explained by the notion that various cells may respond differently 
to the same chemical agent. In addition, areca nut contains many ingredients other 
than arecoline, which may possess inhibitory as well as stimulatory activity for these 
cytokines, and the complex tissue response as evident in OSF may not be fully 
reflected in cell culture conditions employed in this study. 
 
Inflammatory cytokines contribute to inflammation, injury and tissue repair (Dinarello 
2000), and it seems accepted that overexpression and attenuated production may 
exert deleterious effects on immunity and repair processes (Zhang, Caragine et al. 
1997). Immunomodulatory and immune-suppressive potential of sub-toxic arecoline 
has been reported in a few scattered studies, both in vitro and in vivo (Selvan and 
Rao 1993, Demissie, Rogers et al. 1995, Wen, Zhang et al. 2006). The anti-
inflammatory and analgesic potential of areca nut extracts have been linked to its 
inhibitory effects on the cyclooxygenase and lipoxygenase pathways (Khan, 
Mehmood et al. 2011). 
 
The mechanisms responsible for various pharmacological effects of sub-toxic 
arecoline have not been fully investigated, and further studies are required to pinpoint 
the exact pathways involved, and this would also provide insight in the causation of 
OSF. In Chapter 2, work is described showing that toxic arecoline concentrations 
from 333 µg/ml to 1000 µg/ml result in irreversible injury in first 4-8 hours following 
exposure, so that reduction in pro-inflammatory cytokines can be directly related to 
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cell death at these concentrations. However sub-toxic concentrations of arecoline 37 
µg/ml and 111 µg/ml also significantly reduced pro-inflammatory cytokines at the 
protein and mRNA level without causing cell death. It is here speculated, that 
reduced expression of inflammatory cytokines represents an adaptive response to 
toxicity induced sub-lethal injury, with the effect of limiting the effect of potentially 
damaging excessive inflammatory responses.  
 
Human endothelium has a critical role in the regulation of inflammation, which 
involves numerous intracellular signals such as the synthesis of inflammatory 
cytokines, growth factors, neuropeptides, and vasoactive agents (Boyle Jr, Edward et 
al. 1997, Kuldo, Ogawara et al. 2005, Newton and Dixit 2012). However various anti-
inflammatory and counter regulatory mechanisms operate to maintain homeostasis 
and provide cytoprotection to vascular endothelium such as production of cytokines 
and growth factors (IL-10, TGF-β, VEGF and bFGF)(Hu and Wu 2001, Tedgui and 
Mallat 2001), activation of protective genes (heme oxygenase-1, Bcl-2 family) 
(Ackermann, Taylor et al. 1999, Abraham and Kappas 2008), regulator of NF-kB 
signalling pathway (Uwe 2008) and nitric oxide (Harrison, Widder et al. 2006). Vagus 
nerve stimulation and cholinergic agonists such as acetylcholine and nicotine, have 
been shown to exert an inhibitory effect on pro-inflammatory cytokine production 
(Tracey 2003), and have hence been termed as comprising a cholinergic anti-
inflammatory pathway (Pavlov and Tracey 2005, Rosas‐Ballina and Tracey 2009). 
The non-neuronal components of these pathways have been well characterized 
(Wessler, Kilbinger et al. 2003), which has also been reported as active in endothelial 
cells (Kirkpatrick, Bittinger et al. 2003). Arecoline, a cholinergic agonist (Calogero, 
Kamilaris et al. 1989), activates the non neuronal cholinergic pathway (Zhao, Pan et 
al. 2012), which might be responsible for a potent anti-inflammatory profile (Shan, 
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Zhang et al. 2004) and down-regulation of pro-inflammatory cytokines. Although this 
possibility was investigated in the current Chapter with regard to arecoline, 
acetylcholine, muscarine and nicotine, with the exception of arecoline, these agents 
did not attenuate the synthesis of pro-inflammatory cytokines, so that the effects 
seen appear most likely to reflect indirect toxic activity of arecoline, as opposed to 
receptor mediated processes.  
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4. CHAPTER 4: MICROARRAY ANALYSIS OF mRNA EXPRESSION 
IN ARECOLINE STIMULATED HUMAN ENDOTHELIUM 
4.1. Introduction 
4.1.1. Microarray Analysis as a Tool For Investigating Biological Questions 
Observations in Chapter 3 revealed significant changes in expression of 
inflammatory cytokines and bFGF in arecoline stimulated endothelium. The question 
emerges from such observations, however, as to what other responses may have 
occurred in the stimulated cells.  This relates both to expression of other related 
phenotypic changes, in this case other cytokines and growth factors or their 
regulatory mechanisms, as well as to completely unconsidered possible cellular 
responses.  DNA Microarray analysis provides opportunity to address both of these 
issues experimentally, and the current Chapter describes work using DNA microarray 
to study the response of endothelium to arecoline.  
 
In the type of microarray analysis described in this Chapter, cDNA is 'spotted' onto 
slides to create a 'micro-array' representing the breadth of the human genome. 
mRNA is isolated from cells subjected to a given treatment, as is mRNA from control 
cells, while cDNA and cRNA are then produced from the isolated purified mRNA.   
 
Earlier microarray systems labelled test and control nuclear probes with opposing 
'red' and 'green' fluorescent tags.  By hybridizing equivalent amounts of thus labelled 
cRNA with cDNA immobilized in the microarray, it was possible to determine not only 
which mRNA species were present in the cells studied, but also the relative 
abundance of mRNA for each gene based on the relative proportion of 'red' or 'green' 
fluorescent signal detected (Kerr and Churchill 2001).  However, with advances in 
microarray technology including: development of whole genome oligonucleotide 
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sampling sets; localization of oligonucleotide probes to beads; development of a 
range of internal controls for loading, labelling and hybridization efficacy; improved 
sample quantitation and standardization; more sensitive and reproducible 
measurement of fluorescence; lower cost; and powerful software systems for 
analysis; it has become possible to analyze test and control samples separately, and 
for the ratio of test relative to control signal to be determined by the software 
(Kashork, Shaffer et al. 2012). The approach used in this thesis was thus to 
determine mRNA levels for test and control samples separately and for the relevant 
software to then establish the extent to which mRNA levels were modified by cell 
stimulation.  
 
4.1.2. Software Strategies for Analysis of Microarray Data 
Data sets of enormous size are generated by this experimental approach, compelling 
the need to analyze data with the aid of appropriate software tools.  MetaCore is a 
widely accepted software package for analysis of microarray data, and was applied in 
the current study. In MetaCore, genes are clustered into defined ontological 
groupings, so that protein products with related functionality or contributing to defined 
biochemical pathways are grouped together (Henderson-MacLennan, Papp et al. 
2010).  
 
The software evaluates the ratio of test compared with control fluorescence signal for 
each cDNA detected, so that an 'enrichment factor' is calculated and can be set to 
select for consideration increasing ratios of difference depending on the 
experimenter's choice.  It is in some ways arbitrary as to which enrichment factor for 
detection is selected by the investigator within any given study. At the time that 
microarray analysis began, it was common to select only genes where there was a 
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limiting enrichment factor of 'doubling in expression', being over at least a two fold 
increase, or less than a 50% decrease in signal for test compared with control 
samples. This reflected perhaps uncertainty in what was then a new technique, and a 
desire to be conservative in approach.  However, development of software to easily 
accommodate multiple experiments, as well as further development of methods to 
establish background rates of random signal generation and calculation of the 
probability that any given signal is statistically significant, have permitted reliable 
detection of more subtle changes in mRNA level by microarray analysis (Ewis, 
Zhelev et al. 2005, Trevino, Falciani et al. 2007).  
 
Separate to the 'enrichment factor' calculated for each gene detected, MetaCore also 
calculates a specific 'enrichment score' for each ontological group. Inherent in this 
score, is not only the extent to which genes in an ontological group may be up- or 
down- regulated compared with controls, but also the probability that a given number 
of genes in each ontological group is detected relative to random chance.  In this 
way, ontological groups can be reliably ordered from highest to lowest with regard to 
their enrichment scores, providing a reasonable basis for identifying specific 
biological processes as important responses to the experimental stimuli tested 
(Bhasin, Yuan et al. 2010, Hung 2013).  
 
4.1.3. Specific Cellular Responses of Importance for Microarray Data Presented 
in This Chapter 
4.1.3.a. Identification of Unexpected Cellular Responses is Common in Microarray 
Analysis 
From 1.4.1 and 1.4.2, it is clear that inherent in microarray analysis, is opportunity to 
discover unexpected cellular responses to defined stimuli.  In view of the 
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observations made in Chapters 2 and 3, it was expected that the microarray analysis 
described in this Chapter would reveal anti-inflammatory, and possibly stress-related 
cellular responses.  It was not possible, however, to fully anticipate which genes 
related to these processes may or may not be modified by arecoline, as well as 
which if any other possible cellular responses may be affected.  Also inherent in 
microarray analysis, is that changes in almost all possible cellular processes are 
revealed, whether or not they are relevant to the stimulus studied.  
 
It would be impossible and inappropriate to fully review all possible genes or cellular 
processes that potentially could be modified by arecoline in endothelium, as this 
would require a re-statement of much of current known cell biology.  However, it does 
become necessary to provide a brief outline of some important cellular processes, in 
order to facilitate interpretation of data presented in the Results section of this 
Chapter.  
 
4.1.3.b. Chemokines are Chemotactic and Arachidonic Acid Products Contribute to 
Inflammation 
Chemotaxis is the directed movement of cells towards higher concentrations of given 
chemotactic agents, and notably important in the inflammatory response where 
chemotactic agents draw inflammatory cells including polymorphonuclear leukocytes, 
monocyte - macrophages, and lymphocytes, into inflammatory lesions and towards 
their specific targets (Oppenheim and Yang 2005). Chemokines are a group of 
inflammatory cytokines with principally chemotactic activity (Charo and Ransohoff 
2006). 
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Eicosanoids are a large group of lipid inflammatory mediators generated through the 
action of a series of enzymes upon membrane lipid precursors (Funk 2001). Of 
particular importance, is the group of enzymes designated as having phospholipase 
A2 activity, which generate arachidonic acid as the key initial precursor for 
eicosanoid production (Lin, Lin et al. 1992), while in endothelium the major 
arachidonic acid product is prostacyclin with vasodilatory and anti-thrombotic-anti-
platelet aggregatory activity (Goldsmith, Jafvert et al. 1981).  
 
4.1.3.c. Ubiquitinization, The Proteosome and Atrophy as Defensive Mechanisms 
Ubiquitin comprises a group of highly conserved small proteins present in all 
eukaryotic cells (Hershko and Ciechanover 1998).  A series of activating proteins are 
responsible for firstly activating ubiquitin in an ATP dependent manner, and ultimately 
mediating covalent binding to target proteins that become 'marked' for proteolytic 
degradation.   
 
Proteolysis of ubiquitinated proteins is mediated by a complex of separate proteins 
that form a large barrel shaped structure described as 'the proteosome'. The 
proteosome rapidly reduces proteins and peptides to their constituent amino acids, 
but spares ubiquitin which is recycled for further use.  In this way, ubiquitin and the 
proteosome contribute to turn-over and removal of effete or excess protein in the cell.  
 
Atrophy including autophagy is accepted as a protective and reversible cellular 
response to injury, in which cellular components are degraded in order to reduce 
demand of the cell for potentially restrictive nutrients or alternatively to reduce 
potentially damaging metabolic activity (Murrow and Debnath 2013). Because of this, 
mechanisms that increase proteolysis or lipid breakdown, or alternatively reduce 
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biosynthesis of proteins, lipids or nucleic acids, may be considered part of the 
atrophic defensive response in some instances.  
 
4.1.3.d. Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells is an 
Inflammatory Transcription Factor 
Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NFkB) is a key 
transcription factor activated in response to many inflammatory cytokines and driving 
a range of cytokine responses, including the further production of additional cytokines 
(Blackwell and Christman 1997). This transcription factor is present in the cytosol, but 
maintained in an inactivated state by a bound regulatory protein, IkBa.  When cells 
are appropriately stimulated, IkBa is phosphorylated by IkB Kinase with the effect 
that it is released from NFkB for subsequent ubiquitinisation and degradation in the 
proteosome.  NFkB is thus liberated for transport to the nucleus and service as a 
transcription factor for a wide variety of inflammatory genes (Viatour, Merville et al. 
2005). Thus regulation of NF-κB, IkBa and its kinase are important in the 
inflammatory response (Barnes 1997).  
 
4.1.3.e. Heat Shock Proteins 
Heat shock proteins (HSP) are highly conserved and play a key role in chaperoning 
newly formed proteins for correct protein folding, intracellular trafficking and in 
response to denatured proteins.  As such, it is logical that this group of proteins be 
up-regulated by a wide variety of cellular stresses, so that HSP are considered a 
good marker of cellular stress irrespective of the nature of the injury (Hendrick and 
Hartl 1993, Becker and Craig 1994).  
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4.1.3.f. Anti-Oxidant Activity 
While oxygen is required for life, metabolic processes may generate oxygen derived 
free radicals that may damage proteins, nucleic acids and lipids (Floyd and Carney 
1992, Halliwell 2011). Anti-oxidant activity is thus important for protecting cells from 
reactive oxygen species and free radicals (Kobayashi, Li et al. 2009, Dinakar, 
Abhaypratap et al. 2010), and this would seem particularly important where cells are 
further challenged by additional separate cellular stresses.  
 
Amongst the important anti-oxidant activities, is the enzymatic generation of 
glutathione which contains a redox-active sulphur atom which is sacrificed by 
oxidation in terminating free radicals (Sies 1994), while a separate enzymatic 
machinery exists to regenerate glutathione from its oxidized products (Dickinson and 
Forman 2002). Thioredoxin is a protein that contains a readily sacrificed di-sulphide 
bond, and is thus an important scavenger of free radicals, while thioredoxin 
reductase is an enzyme that regenerates active reduced thioredoxin for further 
radical scavenging (Das and Das 2000).  
 
Free ferric iron has significant oxidizing activity via the Fenton reaction with hydrogen 
peroxide to generate hydroxyl radical (Ali and Konishi 1998). In this way, 
haemorrhage into tissues may generate local oxidizing activity by release and 
oxidation of haem and iron from haemoglobin.  Haem oxygenase catalyses the 
degradation of haem into biliverdin, releasing ferrous iron (Gozzelino, Jeney et al. 
2010), that may then be bound by ferritin which is an intracellular storage protein 
sequestering any free iron within the cell (Atkinson, Spanner et al. 2005). In this way, 
despite release of ferric iron through haem oxygenase activity, it is reasonable to 
consider haem oxygenase working in concert with ferritin as part of a coherent anti-
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oxidant activity. Additionally, the entrapment of iron by cells in bound ferritin can be 
thought of as a mechanism depriving any invading bacteria of iron, an important 
micronutrient required by infecting organisms (Wang and Pantopoulos 2011).  
 
4.1.4. The Reported Effect of Arecoline on Cell Expression Profiles  
Regulation of the rate of cell proliferation relative to cell death is important for 
maintenance of organ integrity and tissue homeostasis. Cell death is either normal 
physiological process or the result of cell injury (Maslinska 2003). Patterns of cell 
injury and some of the underlying mechanisms for these have been discussed in 
section 1.8. Cells of different origin have evolved diverse feedback mechanisms to 
combat cell injury resulting from exposure to toxic insults. Arecoline expresses 
cytotoxic potential in different cell lines in cell culture as shown in section 1.5.5, and 
further demonstrated in Chapter 2 of this thesis. Diverse cellular responses to toxic 
and sub-toxic arecoline have been reported in different cell types (Humans 2004).  
 
Arecoline induces epithelial cell death at higher concentration as a result of oxidative 
trauma, whilst sub-lethal exposure to arecoline up-regulates the expression of stress-
response genes such as heme oxygenase-1 (HMOX1), ferritin light chain (FTL), 
glucose-6-phosphate dehydrogenase (G6PD) and glutathione reductase (GRD) 
(Thangjam and Kondaiah 2009). OSCC specimens from areca nut chewers exhibit 
up regulation of heat shock proteins such as HSP47 and HSP27, while oral epithelial 
cells respond to arecoline by over expression of these protein which may involve the 
ERK, P13K, COX2 and tyrosine kinase transduction pathways (Lee, Tseng et al. 
2011, Lee, Tsai et al. 2012). O-6-methylguanine-DNA methyltransferase (MGMT) is a 
specific DNA repair protein, and human oral keratinocytes show significantly 
enhanced expression of this protein following exposure to 80µg/ml arecoline (Lee, 
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Tsai et al. 2012). On the other hand, arecoline exerts inhibitory influence on p53, 
represses DNA repair and triggers a DNA damage response in human epithelial cells 
(Tsai, Lee et al. 2008). 
 
Human gingival fibroblasts exposed to arecoline at 100 µg/ml display a toxic 
response which can be attributed to its wide impact on diverse biological processes 
including: repression of genes involved in xenobiotic metabolism and detoxification; 
chromosomal structure stability; and the DNA repair system (Chiang, Jiang et al. 
2007). In addition, genes related to cellular stress response such as HSPA14 
(HSP70) and DNAJA1 (HSP40) are up-regulated by arecoline in fibroblasts (Chiang, 
Jiang et al. 2007). These proteins play a key role in the in areca nut and tobacco-
related oral tumorigenesis (Kaur and Ralhan 1995), and have also been found to be 
overexpressed in tumors of other tissues (Isomoto, Oka et al. 2003).  
 
Arecoline treated fibroblasts and epithelial cells exhibit elevated expression of COX-2 
mRNA and protein (Jeng, Ho et al. 2000, Chiang, Jiang et al. 2007) which is involved 
in cancer initiation and progression via several pathways such as apoptosis, 
angiogenesis, inflammation and immune response (Williams, Mann et al. 1999, 
SUZUKI 2003).  
 
Stress inducible protein HMOX1 that with potential anti-inflammatory activity has 
been over expressed in hyperplastic tissues of various fibrotic disorders (Maines and 
Abrahamsson 1996, Zhou, Lu et al. 2004). HMOX1 over expression has been 
identified in tissue sections of OSF patients while fibroblasts respond to arecoline by 
regulation of HMOX1 synthesis, which mainly occur at transcriptional level (Tsai, 
Yang et al. 2009). Arecoline at sub-toxic concentrations induces the up-regulation of 
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proto-oncogene c-jun mRNA expression in oral mucosal fibroblasts (Ho, Chiang et al. 
2000), probably via activation of a protein kinase C (PKC) mediated signal 
transduction pathway (Angel and Karin 1991) or its reaction with GSH resulting in 
cysteine β-alkylation adducts (Boyland and Nery 1969), and appears to be one of the 
mechanisms in the carcinogenesis of OSCC.  
 
Arecoline treatment of EAHY endothelial cells have a toxic response to arecoline, 
thought to result from cell cycle deregulation with subsequent genomic instability and 
apoptosis (Tseng, Chang et al. 2012).  In addition, HUVEC produce HMOX1 to 
neutralize reactive oxygen species (ROS) induced by oxidative stress in arecoline 
treated cells (Hung, Huang et al. 2011). The up-regulation of HMOX1 in endothelial 
cells seems to follow activation of c-jun N-terminal kinase (JNK), p38 and tyrosine 
kinase signaling pathways, since blocking these pathways abrogates expression of 
this cytoprotective mechanism.  However, over expression of this gene by gene 
transfer merely attenuates the arecoline mediated cytotoxicity, and does not 
completely abolish this response, which inferred that other cytoprotective 
mechanisms may also operate (Hung, Huang et al. 2011). 
 
In the light of these cytoprotective mechanisms adopted by cells, it seems that 
arecoline at sub-toxic concentrations achieved in saliva of areca nut chewers, may 
regulate diverse signaling pathway and gene expression, this via either direct 
pharmacological actions or indirectly via cytotoxic cellular responses, some of which 
may be protective against this toxic agent. 
 
Endothelial cells mediate key responses to both physiological and pathological 
stimuli by virtue of their strategic, ubiquitous location at the interface between blood 
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and the ECM (Galley and Webster 2004). When disturbed by mechanical or 
biochemical stimuli, a spectrum of responses can be initiated.  Acute responses are 
generated within a few minutes of stimulation, which are independent of de novo 
mRNA or protein synthesis, and include: regulation of local vasoconstrictors and 
vasodilators including prostaglandin, endothelial derived-relaxing factors, endothelin 
and endothelial derived contracting factors, modulators of platelet function, release of 
neurotransmitters and reactivity to vasoconstrictors (Rubanyi and Botelho 1991, 
Vanhoutte 1991, Galley and Webster 2004).  
 
In contrast, endothelial cells manifest chronic complex responses to potentially 
injurious agents via de novo mRNA and protein synthesis. Injury mediated altered 
gene regulation orchestrates endothelial response by amplified production of various 
growth factors and cytokines, augmented proteolysis, increase expression of 
adhesive protein and chemotactic factors for recruiting inflammatory and immune 
cells, and enhances capacity to elaborate vasoactive mediators (Gerritsen and Bloor 
1993).  
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4.2. Materials 
4.2.1. Materials for Cell Culture and RNA Extraction 
Materials for cell culture were the same as those described in Section 2.2.1, while 
those for RNA extraction were the same as those listed in Section 3.2.3. 
 
4.2.2. Materials for Microarray 
4.2.2.a. Materials for RNA Amplification 
Illumina® TotalPrep RNA Amplification Kits which included T7 Oligo(dT) primer, 10X 
First Strand Buffer, dNTP Mix (dATP,dTTP, dCTP, dGTP), RNase inhibitor, Array 
Script, Nuclease free Water, 10X second Stand Buffer, DNA Polymerase, RNase H, 
T7 10X Reaction Buffer, T7 Enzyme Mix, Biotin-NTP Mix, cRNA Binding Buffer, 
cRNA Wash Buffer, and ACS reagent grade 100% Ethanol were purchased from 
Illumina (USA). 
 
4.2.2.b. Materials for Whole-Genome Gene Expression Direct Hybridization 
Illumina Gene Expression System Wash E1BS buffer and components, Illumina 
Gene Expression System High Temp Wash Buffer, Gene Expression System GEX-
HCB and GEX-HYB Buffers and Sentrix® Bead chip Array Human HT-12-V4-
Beadchip for Gene Expression were obtained from Illumina (USA). 
 
4.2.3. Materials for Reverse Transcription and Polymerase Chain Reaction 
Materials for Reverse Transcription (RT) and polymerase chain reaction (RT-PCR) 
were the same as those described in sections 3.2.4 and 3.2.5 respectively. 
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4.3. Methods 
4.3.1. Isolation, Culture and Storage of HUVEC 
Methodology for isolation, culture and storage of HUVEC were as described in 
sections 2.3.1, 2.3.2 and 2.3.5 respectively. 
 
4.3.2. Stimulation of HUVEC with Arecoline for Microarray Analysis 
Confluent HUVEC from three separate donors in passage 5 were incubated with 
arecoline at 111 µg/ml for 4 hr or 10 hr prior to collection of cell lysates for mRNA 
isolation, as previously described in Section 3.3.3.a. 
  
4.3.3. Isolation of mRNA from HUVECs for Microarray 
RNA was extracted at each time point as described in section 3.3.3.b using an 
RNeasy mini kit. The mRNA was quantitated by spectrophotometry as subjected to 
analysis for integrity using an Agilent 2100 Bioanalyzer, while mRNA with an RNA 
Integrity Number (RIN) above 9 was used for amplification.  Quantitative measures of 
isolated mRNA are shown in Table 4.1. 
 
4.3.4. RNA Amplification for Microarray 
400ng RNA from each sample collected was used for amplification. In brief, 400ng 
RNA in 11µl RNase free Water from each of the 12 samples collected was placed 
into nonstick, sterile and RNase-free 0.5ml microcentrifuge tubes followed by addition 
to each sample at room temperature of 9µl of Reverse Transcription Master Mix 
comprising 1µl T7 Oligo(dT) Primer, 2µl 10 X First Strand Buffer, 4µl dNTP Mix, 1µl 
RNase inhibitor, and 1µl ArrayScript.  Following thorough mixing by pipetting 2 to 3 
times, tubes were flicked 3 to 4 times and centrifuged briefly to collect reaction 
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volumes in the bottoms of tubes before incubation at 42ºC for 2 hr. At the end of the 
incubation period, the reaction volumes were centrifuged briefly to collect samples 
and placed on ice prior to addition of Second Strand Master Mix. 
 
For Second Strand cDNA synthesis, a Master Mix comprised of 62µl Nuclease-free 
Water, 10µl 10 X Second Strand Buffer, 4µl dNTP Mix, 2µl DNA Polymerase, and 1µl 
RNase H. 80 µL of Second Strand Master Mix was added to each sample and mixed 
thoroughly by pipetting up and down 2 to 3 times, flicking tubes 3 to 4 times and brief 
centrifugation to collect reaction volumes before incubation in a thermocycler at 16ºC 
for 2 hr followed by placing tubes on ice before cDNA Purification. 
 
Second Strand cDNA was purified by addition of 250µl cDNA binding buffer to each 
100µl sample and mixing thoroughly by pipetting 2 to 3 times, flicking tubes 3 to 4 
times, and briefly centrifuging before transferring to cDNA Filter Cartridges and 
spinning at 10,000 g for 1 minute. Flow-through was discarded before addition of 500 
µl of wash buffer to each cDNA Filter Cartridge prior to centrifugation at 10,000×g for 
1 minute. Flow-through was discarded before an additional spin to remove trace 
amounts of Wash Buffer, and this was followed by changing Filter Cartridges to 
cDNA elution tubes prior to addition of 10µl free heated Nuclease-free Water at 50 to 
55ºC for the elution of cDNA. The Filter Cartridges were centrifuged at 10,000 g for 
1.5 minutes after leaving at room temperature for 2 minutesm followed by application 
of second aliquot of 9µl preheated Nuclease-free Water and a second spin for 2 
minutes. 
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Table 4.1. Quantity and RNA integrity number (RIN) of RNA isolated 
from HUVEC from each of three separate donors at 4 hr or 10 hr 
with or without stimulation with arecoline at (111µg/ml) 
Donor 
Number 
Treatment 
Time Points 
(hours) 
mRNA (ng/ml) RIN 
1 Control 4 76 9.9 
1 Arecoline 4 86 10 
2 Control 4 92 10 
2 Arecoline 4 82 10 
3 Control 4 90 10 
3 Arecoline 4 106 9.9 
1 Control 10 86 9.9 
1 Arecoline 10 76 9.4 
2 Control 10 102 10 
2 Arecoline 10 84 10 
3 Control 10 88 10 
3 Arecoline 10 74 9.9 
Sufficient RNA was available for microarray analysis, and this was of 
High integrity as revealed by RIN. 
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In Vitro Transcription was performed of the purified cDNA to synthesize cRNA by 
preparation and addition to each sample of 7µl IVT Master Mix comprising 2.5µl T7 
10X Reaction Buffer, 2.5µl T7 Enzyme Mix, and 2.5µl Biotin-NTP Mix. Samples were 
incubated in a thermocycler at 37ºC for 14 hr.  The reaction was stopped by addition 
of 75µl Nuclease-free Water to each cRNA sample to bring the final volumes to 
100µl. 
 
Finally, the cRNA was purified by addition of 350µl cRNA Binding Buffer to each 
100µl of cRNA sample prior to application of 250µl of ACS reagent grade 100% 
ethanol per sample and mixed by pipetting up and down 3 to 4 times before adding to 
the centers of filters in cRNA filter Cartridges followed by centrifugation for 1 min at 
10000 rmp and discarding the flow through. In order to wash the samples, 650µl of 
Wash Buffer was added to each cRNA Filter Cartridge and centrifuged for 1 minute 
at 10000 rmp. After discarding the flow through, the spin was repeated for an 
additional 1 minute to remove trace amounts of Wash Buffer before transferring the 
filter cartridges to fresh cRNA collection tubes. cRNA, was eluted with 100µl of 
Nuclease-free Water preheated to 50-60ºC added to the centres of filters, left at room 
temperature for 2 min prior to centrifugation for 1.5 minutes at 10000 rmp. The eluted 
cRNA preparations in 100µl volumes of Nuclease-free Water were concentrated to 
the required concentration by vacuum centrifugation, with final concentrations of 
cRNA determined by spectrophotometry ranging from 52 to 118 ng of cRNA / ml.  
 
4.3.5. Whole Genome Gene Expression Direct Hybridization  
4.3.5.a. Vacuum Centrifugation to achieve the desired cRNA concentrations 
After assessing the cRNA Yield and Quality by Agilent bioanalyzer Analysis, Whole 
Genome Gene Expression Direct Hyberidization was performed on the cRNA 
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samples following the manufacturers instructions. Starting concentration of cRNA for 
each sample of 1500 ng, achieved by concentration by vacuum centrifugation. 
 
4.3.5.b. Set up of BeadChip Hyb Chambers 
Hyb Chamber Gaskets were placed into a Hyb Chamber by matching the wider edge 
of the Hyb Chamber gasket to the barcode ridge side of the Hyb Chamber, and this 
was followed by addition of 200µl HCB into Beadchip Hyb Chamber Reservoirs. 
BeadChip Hyb Chamber lids were closed and locked and left on the bench at room 
termperature until the BeadChips were loaded with samples.  
 
4.3.5.c. Preparation of BeadChips for Hybridization 
The BeadChips were placed in Hyb Chamber inserts, orienting the barcode ends to 
the barcode symbol of the Hyb Chamber inserts. Tubes containing sample were 
preheated to 65ºC for 5 minutes followed by gentle vortexing and pulse centrifugation 
to collect samples. Tubes were allowed to cool to room temperature before adding 
into the centres of each inlet port of BeadChips using a single channel precision 
pipette. Hyb Chamber Inserts containing samples were loaded into a BeadChip Hyb 
Chamber and the lid closed and locked. 
 
4.3.5.d. Hybridization of BeadChips 
BeadChip Hyb Chambers were placed into a preheated Illumina Hybridization Oven 
at 58ºC and incubated for 16 hr. In addition, a Hybex Waterbath insert was placed 
into the Hybex Heating Base, followed by addition of 500µl 1X High-Temp Wash 
buffer, and setting the temperature of the Hybex Heating Base to 55ºC. The High 
Temp Wash buffer was allowed to warm overnight for later use. 
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4.3.5.e. Washing and Staining BeadChips 
Wash E1BC solution was prepared by combining 6ml of E1BC buffer, and 2L RNase-
free water. In preparation for blocking, Block E1 buffer was pre-warmed to room 
temperature for 30 minutes, and then 2ml/BeadChip combined with streptavidin-Cy3 
(2µl of 1mg/ml stock per chip) before storage in a dark place for used in the detection 
step.  The Hyb chamber was removed from the oven before using powder free 
gloves to remove BeadChips from the Hyb Chamber and submerging face up at the 
bottom of a beaker containing diluted Wash E1BC buffer. After removal of coverseals 
from the BeadChips, they were transferred to a slide rack submerged in a staining 
dish containing 250ml Wash E1BC solution.  Using the slide rack handle, the rack 
was transferred into a Hybex Waterbath insert containing High-Temp Wash Buffer 
and incubated for 10 minutes with the lid closed. After 10 minutes incubation, the 
slide rack was immediately transferred into a staining dish containing Wash E1BC by 
plunging the rack in and out of the solution for 5 to 10 minutes prior to transferring to 
an orbital shaker at medium to low setting for 5 minutes followed by shaking at high 
speed whilst ensuring that the solution did splash out of the staining dish. The rack 
was then transferred to a clean staining dish containing 250ml fresh 100% Ethanol by 
plunging the rack in and out of the solution for 5 to 10 minutes, following by shaking 
on the orbital shaker for 10 minutes at room temperature. A further was involved 
transfer of the rack to a clean dish containing 250ml Wash E1BC buffer by plunging 
the rack in and out of the solution for 5 to 10 minutes, followed by placement on the 
orbital shaker at room temperature and shaking for 2 minutes.  Slides were then 
blocked by placing the Beadchip wash tray on a rocker mixer prior to addition of 4ml 
Block E1 buffer.. BeadChips were transferred face up into the wash tray using wells 
at the end of wash trays to grip BeadChips. The wash trays were tilted manually to 
ensure that BeadChips were completely covered with buffer before again placing 
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trays onto the rocker platform and rocking at medium speed for 10 minutes.  2ml of 
the Block E1 buffer was prepared with a 1:1000 dilution of streptavidin-Cy3 and a 
separate 2ml Block E1 buffer with streptavidin-Cy3 into a new BeadChip wash tray 
.BeadChips were then transferred to a wash tray containing streptavidin-Cy3 and 
trays manually tilted to ensure that BeadChips were completely covered with buffer 
followed by placing them on a flat lid provided with the wash tray. The tray was then 
placed onto a rocker mixer and rocked on a setting of 'medium' for 10 minutes  250ml 
of Wash E1BC was then added into a clean staining dish and the BeadChips 
transferred to the slide rack from the washing tray by grasping BeadChips at the 
barcode end using tweezers. The slide rack was then plunged in and out of the 
solution 5 times prior to placing the staining dish on the orbital shaker on medium at 
room temperature for 5 minutes. 
 
4.3.5.f. Drying BeadChips 
Clean paper towels were placed on the centrifuge microtitier plate holders to absorb 
excess solution. The staining dish balance slide rack was filled with an equivalent 
number of standard glass microscope slides followed by pulling the slide holder out 
of the Wash E1BC and transferring the rack of BeadChips from the staining dish to a 
centrifuge and spining the centrifuge at 275rcf for 4 minutes at room temperature. 
 
4.3.5.g. Imaging BeadChips  
The Beadchip was scanned within one hr following drying with Illumina BeadArray 
Reader. During the scan process, the BeadChip barcode was scanned, ensuring 
effective data management. 
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4.3.6. Microarray Data Analysis 
Scanned BeadChip data were uploaded to GenomeStudio (Illumina V2009.2) 
software which was used for preliminary analysis of raw signal intensities for each 
gene. Raw data were subjected to background subtraction and normalized using 
GenomeStudio software by use of the “Average” algorithm and the “Illumina Custom” 
while the error model was chosen for differential gene expression. Following 
uploading and normalization, data was filtered for significant up-regulated and down-
regulated genes at both 4 hr and 10 hr separately, by setting the filter in 
GenomeStudio at a detection p value of <0.05, and diff p value <0.05 for the control 
and treatment. Data with low fluorescence signals were excluded, and only 
differentially expressed genes with an average threshold intensity >100 relative 
fluorescence units (RFU) were considered. Selected gene lists for both time points 
were exported to Microsoft Excel software and fold change calculated for each 
differentially expressed gene.  
 
The minimum threshold for up-regulated and down regulated genes was taken as 
+1.3 and -1.3 respectively. In addition, average values were calculated for those 
differentially expressed genes, which had significantly expressed multiple gene-
specific probes. The excel file with gene symbol/gene ID and fold change value was 
uploaded to MetaCoreTM software (v6.12, GeneGo -Thomson Reuters, San Diego, 
CA, USA) for data mining and pathway analysis.  
 
To facilitate some aspects of analysis of down-regulated genes, in addition to 
representing 'fold change' directly, the 'Relative Enrichment Factor' was also 
calculated by the following formula: -1 x (1/Fold Change in Down-Regulated Gene). 
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In this way, actual mRNA levels were expressed relative to controls, such that a '2 
fold reduction' represented a 50% level of mRNA relative to controls.   
 
4.3.7. Validation of Microarray Data By Real Time Reverse Transcription 
Polymerase Chain Reaction   
Gene specific primers for IL-1α, IL-6, GM-CSF, TXNRD1, OKL38 and HMOX1, and 
House Keeping genes including GAPDH and Beta Actin, were designed using the 
Universal Probe Library (Roche Applied Science) website, and primer 3 Software 
(Tables 3.3 Table 4.2).  Analysis for differential gene expression was performed 
according to the 2ΔΔCT method (Livak and Schmittgen 2001). RT-PCR data were 
expressed as Mean ± SEM. 
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Table 4.2. Sequence of primers for real time reverse transcription polymerase 
chain reaction analysis 
Gene Name Primer from 5' to 3' Sequence of Primer 
TXNRD1 Forward CTAAAAATGAACGGCCCTGA 
TXNRD1 Reverse ACACATGTTCCTCCGAGACC 
OKL38 Forward TGCTGCAGAGGAAGCTCAC 
OKL38 Reverse TCGGACAGGTAGTCCAGGTC 
HMOX1 Forward TCCGATGGGTCCTTACACTC 
HMOX1 Reverse TAAGGAAGCCAGCCAAGAGA 
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4.4. Results 
4.4.1. More Genes Were Regulated at mRNA level at 10 Hours of Arecoline 
Stimulation Than at 4 Hours, with Down-regulation Predominating Over Up-
regulation 
Of the 34,690 genes probed, up-regulation was seen in 248, with only 8 genes up -
regulated after 4 hr arecoline stimulation. While 3 of these were not significantly up-
regulated by 10 hr stimulation, 5 persisted in up-regulation by 10 hr and were joined 
by a further 240 genes up regulated at this later time point (Figures 4.1 and 4.2).  
 
By comparison, more genes were down-regulated as opposed to up-regulated, but 
again of the 455 genes down-regulated, only 14 were down-regulated at the 4 hr time 
point, and of these only 7 persisted in this down-regulation with 448 total genes 
down-regulated at the 10 hr time point (Figures 4.1 and 4.2).  
 
4.4.2. MetaCore Analysis Identified Sets of Genes in Potentially Relevant 
Ontological Groups 
The ontological groups with the 15 highest enrichment scores were identified by 
MetaCore software analysis (Figure 4.3), while many of these appeared relevant to 
arecoline treatment including groups of genes, or 'Map folders' for: the inflammatory 
response, immune response, tissue remodelling and repair, DNA damage response, 
and the oxidative stress response.  Genes within these groups accounted for 90 out 
of the 703 genes regulated upon arecoline treatment, representing 12.8% of 
regulated genes (Table 4.3). 
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4.4.3. Many Regulated Genes Shared Membership in Multiple Ontological 
Groups and Had Seemingly Relevant Biological Roles 
Tables 4.4 and 4.5 provide the specific names of genes, protein descriptions and 
relative enrichment factors for up- and down- regulated genes in ontological groups 
amongst the 15 highest enrichment scores.  It was noteworthy that many of these 
genes shared membership amongst multiple ontogenies as detailed in Tables 4.6 
and 4.7.  
 
4.4.4. Most Up-regulated Genes in Ontological Groups with High Enrichment 
Scores Had Biological Roles Seemingly Relevant to Arecoline Stimulation  
 Amongst the most strongly up-regulated genes, HMOX1, TXNRD1 and GCLM were 
all in ontological groups relevant to oxidative stress, as was HERPUD1 and 
numerous heat shock proteins seemingly relevant to cell stress (Table 4.6).   
 
The predominant biological roles of individual proteins were also considered, and up-
regulated genes were mapped according to whether genes were primarily involved 
with: protein chaperoning, the stress response, anti-oxidant activity, proliferative 
activity, or anti-proliferative activity.  Where the significance of a specific protein 
seemed unclear with regard to a potentially relevant response to arecoline, genes 
were recorded as of 'uncertain significance' (Table 4.6).  Using this approach, 32 out 
of the 43 up-regulated genes belonging to the 15 ontological groups with the highest 
enrichment scores, had predominant biological roles seemingly biologically relevant 
to the response to arecoline.  
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4.4.5. Most Down-regulated Genes in Ontological Groups with High Enrichment 
Scores Had Biological Roles Seemingly Relevant to Arecoline Stimulation and 
Consistent with Data in Chapter 3 
Consistent with the findings in Chapter 3, the most strongly down-regulated genes 
included inflammatory cytokines, while it was noteworthy that chemokines and 
cytokines not studied at the protein level in Chapter 3 were also down-regulated 
(Table 4.7).   
 
The predominant biological roles of individual proteins was also considered, and 
down-regulated genes were mapped according to whether genes were primarily: pro-
inflammatory, proliferative, lipid or protein biosynthetic, pro- or anti- oxidant, anti-
inflammatory, involved with degradative processes, or DNA repair (Table 4.7). 
Although the possible biological relevance of some genes was unclear, many down-
regulated genes were either pro-inflammatory or biosynthetic, consistent with the 
findings in Chapter 3. Of the 48 genes down-regulated in these gene ontological 
groups, 38 had seemingly relevant predominant biological roles (Table 4.7). 
 
4.4.6. Quantitation by Real Time Quantitative Reverse Transcriptase 
Polymerase Chain Reaction of Selected mRNA Species Was Similar to 
Microarray Data 
Figure 4.4 compares levels of mRNA detected by microarray with levels detected by 
RT-PCR in the same samples at both 4 hr and 10 hr. Genes selected for analysis 
included three studied in Chapter 3 (IL-a, IL-6, and GM-CSF), two identified as of 
interest from microarray (TXNRD1, HMOX1), and a separate oxidative stress related 
gene not attributed to the oxidative stress ontology by MetaCore (OKL38).  
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Concordance between RT-PCR and microarray across these differing genes 
increases confidence in the quantitative value of microarray data.  
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Figure 4.1. Scattergrams showing the Relative Fluorescence Units for 
individual genes probed in test compared with control HUVEC treated with 
Arecoline (111 µg/ml) for 4 hr (A) or 10 hr (B).  Where there is no significant 
difference in mRNA fluorescence signal, RFU approach the central axis marked by 
the central red line.  Where there is up-regulation of greater than 1.3 fold, 
fluorescence signals lie above the upper red line indicated, while down-regulation 
below 1.3 fold, equivalent to fluorescence below 76.9% of fluorescence in control 
cells, is marked by the lower red line shown.  
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Figure 4.2. Venn diagram (A) and Table (B) comparing significantly up- and 
down-regulated genes in HUVEC at the mRNA level after 4 hr or 10 hr of 
arecoline stimulation (111 µg/ml).  Relatively few genes were regulated at 4 hr of 
arecoline stimulation, compared with 10 hr stimulation, and amongst these few 
genes, only some persisted in either up- or down-regulation at the 10 hr time point. 
The number of genes that were down-regulated significantly exceeded those which 
were up-regulated.  
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Figure 4.3.  Graph showing relative enrichment scores for the top 15 
ontological groups identified by MetaCore analysis of mRNA expression in 
HUVEC treated with arecoline (111 µg/ml) relative to control cells for 4 hr or 10 
hr. The 15 ontological groups identified had enrichment scores ≥1.7 and p value 
≤2.00E-2. Only 8 of these pathways demonstrated significant enrichment at 4 hr.  
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Figure 4.4. Histograms showing levels of mRNA from HUVEC treated with 
arecoline (111 µg/ml) for 4 hr or 10 hr as compared with untreated cells, for IL-
1α, IL-6, GM-CSF, OKL38, TXNRD1 and HMOX1 in the same samples as 
quantitated by RT-PCR and Microarray. Similar results were obtained by both RT-
PCR and Microarray. 
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4.5. Discussion 
Whilst ontogenies as defined by MetaCore are helpful for defining the broad 
biological processes modulated in stimulated cells, it is important to consider the 
specific function of individual proteins in order to properly interpret the possible 
biological meaning of any changes in mRNA level seen.  The approach taken in the 
current study was to identify genes of interest on the basis of membership to the 
mostly strongly expressed ontological groups, and to then relate the prime biological 
functions of encoded proteins to the possible biological significance in arecoline 
stimulated endothelium.  
 
The integrity of mRNA isolated and used for microarray analysis was suitably high, 
while agreement between RT-PCR and microarray data increased confidence in the 
observations made.  Microarray data on mRNA levels for the down-regulated 
cytokines IL-1a, IL-6, and GM-CSF in arecoline treated HUVEC were in keeping with 
observations in Chapter 3. The absence of detectable increased mRNA for bFGF by 
microarray was also consistent with data in Chapter 3.   However, G-CSF and IL-
1b levels were not detected as reduced by microarray, even though RT-PCR did 
reveal mRNA levels to be reduced for these cytokines in Chapter 3.  This suggests 
that despite good concordance between microarray data and RT-PCR was observed 
for several genes in the current Chapter, that the microarray analysis did fail to detect 
some otherwise significant changes in mRNA level.  
 
A number of additional pro-inflammatory cytokines were detected following arecoline 
treatment of endothelium by microarray. Chemokines were strongly represented 
amongst down-regulated pro-inflammatory cytokines, including: CCL2 chemotactic 
for monocytes and memory T Cells (Daly and Rollins 2003); and both CXCL2 and IL-
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8 which are chemotactic for polymorphonuclear leukocytes (Jeon, Baskaran et al. 
2002, Huising, Stolte et al. 2003). ISG15 is a further pro-inflammatory protein 
released by monocytes and lymphocytes and can modulate the JAK/STAT pathway 
mediating a wide variety of inflammatory responses (Jeon, Yoo et al. 2010).  RIPK2 
is a kinase involved with activation of the NFkB pathway, and was also down-
regulated in arecoline treated HUVEC.  Prostaglandins and leukotriens are potent 
lipid inflammatory mediators derived from arachidonic acid following release by 
phospholipase A2 (Funk 2001), so that down-regulation of PLA2G4C in arecoline 
treated endothelium can be considered anti-inflammatory, and in light of the major 
endothelial arachidonic acid product being anti-thrombotic prostacyclin (Asai, 
Hirabayashi et al. 2003), arecoline could be suggested as having encouraging a pro-
thrombotic state in endothelium. TAP1 is a transporter protein that pumps peptides 
into the endoplasmic reticulum for association with Class I major histocompatibility 
antigen (Gaudet and Wiley 2001), so that down-regulation of this mRNA species 
suggests reduced presentation of self-antigen and hence an anti-inflammatory effect 
of arecoline in endothelium.  
 
Whilst down-regulation of these inflammatory factors is consistent with the broad 
pattern observed in Chapter 3, it is nonetheless also the case that a number of genes 
with primarily anti-inflammatory activity were also down-regulated in arecoline treated 
endothelium, seemingly in contradiction with the anti-inflammatory effect thus far 
inferred. COMMD1 for example promotes ubiquitination of NFkB and thus down 
regulates the response to a range of inflammatory mediators (Geng, Wittwer et al. 
2009). NFkB is also stimulated in TNF-a treated cells by TNFAIP3 (Vereecke, 
Beyaert et al. 2009), and NFKBIA inhibits NFkB, so that down-regulation of both 
TNFAIP3 and NFKBIA in arecoline treated endothelium can be thought of as a pro-
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inflammatory effect. On balance, however, the majority of changes seen appear to be 
anti- as opposed to pro- inflammatory in nature.  IL-10 is thought of as an 'anti-
inflammatory' cytokine (Moore, de Waal Malefyt et al. 2001), so that down-regulation 
of the IL-10 receptor (IL10RB) could be considered both pro-inflammatory by 
reducing the effect on endothelium, and perhaps also anti-inflammatory by increasing 
effective levels of IL-10 through reduction of receptor mediated endocytosis.  
 
The clear cytotoxicity observed in Chapter 2 seems consistent with significant up-
regulation of numerous mRNA species encoding proteins that either activate protein 
chaperones, are chaperones themselves, or in some other way involved with 
ensuring appropriate protein folding.  For example, DNAJB1 mRNA was increased in 
arecoline treated endothelum, and binds to HSPA4 and also to STUB, which in turn 
bind to and inhibits ATPase activity in HSPs, HSC70 and HSP70.  In this way up-
regulation of DNAJB1 increases HSP activity and hence defence against cellular 
injury (Åkerfelt, Morimoto et al. 2010).  DNAJB1 also has ubiquitin ligase activity and 
so promotes ubiquitinization (Ren, Patterson et al. 2011). Similar activities are 
expressed by AHSA1 (Okiyoneda, Barrière et al. 2010), HSPA1A (Gargalovic, Imura 
et al. 2006), HSPA5  (Falahatpisheh, Nanez et al. 2007), HSPA8 (Schröder 2008), 
and HSP14 (Balogh 2011). HSPA9 is also a protein chaperone but has an additional 
role in regulating cell proliferation (Daugaard, Rohde et al. 2007), while CANX may 
act as a chaperone protein for unassembled N-linked glycoproteins in the 
endoplasmic reticulum (Schröder 2008). In context of increased protein chaperone 
mRNA in arecoline treated endothelium, it is also interesting that there was down-
regulation of MATA2, which encodes a methyltranferase that methylates chaperone 
molecules including HSP70, and in this way reduces HSP activity (Markham and 
Pajares 2009), so that reduced MATA2 would be expected to increase HSP activity.  
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Increased mRNA levels for other proteins involved with defence against cellular 
stress also appears an appropriate response of endothelium to arecoline. HERPUD1 
mRNA for example increased 2.38 fold in endothelium upon arecoline treatment, and 
plays a role in the unfolded protein response as well as the endoplasmic reticulum 
protein degradation response, and so contributes to removal of misfolded proteins in 
the endoplasmic reticulum (Kitamura 2013). SQSTM1 also increased in mRNA 
levels, and is involved with the binding of ubiquitinated proteins for degradation 
(Pankiv, Clausen et al. 2007). RAD23B appears to also contribute to ubiquitin 
mediated proteosome activity, but also plays a role in excision repair of DNA 
(Schauber, Chen et al. 1998). Contrasting with potentially increased DNA excision 
repair by SQSTM1, however, was down-regulation of ERCC1 which was down-
regulated and encodes a DNA nucleotide excision repair protein (Li, Peterson et al. 
1995).  With regard to the broadly anti-inflammatory response seen in arecoline 
treated endothelium, it is interesting that CHUK mRNA was increased, as the 
relevant protein product phosphorylates and releases for degradation IkBs, liberating 
NFkB to act as a transcription factor (Senftleben and Karin 2002). 
 
Although apoptosis was not observed in Chapter 2, several stress related genes are 
involved with induction of apoptosis separate to further seemingly relevant roles in 
the endothelial response to arecoline.  Increased mRNA for PRKCE was detected, 
for example, and this encodes for a protein kinase C that increases in cellular stress 
and has a wide variety of effects including apoptosis and the heat shock response 
(Brodie and Blumberg 2003).  SET mRNA was also increased upon arecoline 
stimulation, and is often expressed in serum starved cells to mediate wide variety of 
functions in apoptosis, transcription, and differentiation (Almeida, Goto et al. 2012). 
Increased mRNA for PPP1R15A is also reported for other circumstances of stressful 
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growth conditions or radiation exposure, and is associated with apoptosis (Szegezdi, 
Logue et al. 2006). The biological significance of MLC1 up-regulation in arecoline 
treated endothelium is not readily apparent with regard to apoptosis, because this 
gene product either promotes or inhibits apoptosis dependent upon alternate splicing 
patterns (Lanciotti, Brignone et al. 2012).   
 
Increased mRNA levels for proteins that have anti-oxidant roles seem appropriately 
defensive against cellular stress, and thus consistent with the endothelial response to 
arecoline. In this context, it seems important to appreciate that haemorrhage and 
spillage of haemoglobin into tissues accompanying tissue injury provides opportunity 
for oxidative radical generation via free iron and the Fenton reaction (Valko, Morris et 
al. 2005) .  From this, expression of proteins involved with haem metabolism can be 
thought of as protectively anti-oxidant. Strong up-regulation of HMOX1 in arecoline 
treated endothelium, which converts haem to biliverdin (Thangjam and Kondaiah 
2009), seems consistent with this idea. Similarly, FLT encodes the ferritin light chain, 
and thus entraps otherwise free iron within the cell (Vidal, Miravalle et al. 2008), also 
consistent with the up-regulation seen in this study. GCLM encoding the rate-limiting 
enzyme for glutathione synthesis (Lu 2009), and TXNRD1 which encodes a protein 
with anti-oxidant activity to chemically reduce thioredoxins and other substrates 
(Cebula, Moolla et al. 2013), have clearly anti-oxidant roles and support a defensive 
response in endothelium to arecoline exposure.  Seemingly consistent with an 'anti-
oxidant' response to arecoline, was strong down-regulation of TXNIP at both time-
points studied, because this gene product binds and inactivates thioredoxin, so that 
down-regulation would be expected to increase anti-oxidant activity. One anti-oxidant 
gene was, however, down-regulated, in that GLRX protein product chemically 
reduces disulphide bonds within separate proteins (Kim 2012). Nonetheless, the 
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overall endothelial response to arecoline observed appears to be strongly anti-
oxidant.  
 
There were highly conflicting responses in arecoline treated endothelium, with regard 
to expression of pro- or anti- proliferative proteins.  There was up-regulation for 
example of inhibitors for proliferation including: DUSP inactivating MAP Kinase 
(Theodosiou and Ashworth 2002), BUB1 mediating cell cycle arrest at the spindle 
assembly checkpoint (Jeganathan, Malureanu et al. 2007), and MCD1 that also 
arrests cell cycle upon DNA damage (Guacci, Koshland et al. 1997).  Numerous 
genes mediating cell proliferation were down-regulated, including CDC45, MCM4, 
MCM6 and MCM10, all involved with assembly of the replication fork with DNA 
synthesis and events at the replication fork (Tye 1999, Srinivasan, Dominguez-Sola 
et al. 2013).  Also down-regulated were: PRIM1 generating primers for manufacture 
of Okazaki fragments (Shiratori, Okumura et al. 1995), SPC24 a kinetochore protein 
(Ma, McQueen et al. 2007), RFC4 which is an accessory protein for elongation of 
DNA templates by DNA polymerase (Okumura, Nogami et al. 1995), RAPGEF5 that 
activates RAS (Gloerich and Bos 2011), and TUBB2B encoding tubulin (Uribe 2010). 
This broadly anti-proliferative response appeared in contradiction with up-regulation 
of: FOSL1, AURKA, PLK1, RAF1, RHEB, SRF, and TNFRSF12A all involved with 
signalling driving cell proliferation (Liu, Yan et al. 2004, Chung, Man et al. 2005, 
Senese, Zaragoza et al. 2007, Anjum and Blenis 2008, Jin, Wang et al. 2011), as 
well as CENPA replacing H3 histone in centromeres (Howman, Fowler et al. 2000), 
and H3F3B a key histone (Drane, Ouararhni et al. 2010),  NCAPD involved with 
chromosome condensation (Matsuoka, Ballif et al. 2007). It seems reasonable to 
interpret this in context of loss of contact inhibition related to cellular cytotoxicity 
observed in Chapter 1, combined with a countering protective anti-proliferative 
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response in a toxic and potentially carcinogenic environment.  Irrespective of the 
logic or otherwise for such internally conflicting biological response, data in Chapter 1 
do not support a endothelial proliferation upon arecoline treatment, although 
increased bFGF would seem suggest such a response.   
 
A lack of cell proliferation would seem consistent with a generally anti-biosynthetic 
response, while it has long been accepted that reducing biosynthetic demand is an 
important strategy for cellular survival under stress, as manifested by atrophy and 
autophagy, notably seen in Chapter 2 in arecoline treated endothelium.  In the 
current study, arecoline did increase mRNA for SEC61A1 inserting secretory and 
membrane proteins into the endoplasmic reticulum and associated with ribosomes 
(Lang, Benedix et al. 2012), as well as TNP01 that targets newly synthesized 
proteins to the nucleus (Okada, Ishigami et al. 2008).  Also, PSMB10, encoding a 
proteosome protein (Wu, Yang et al. 2006), was down-regulated, with the presumed 
effect of reducing protein degradation. However, these 'protein synthetic' activities 
appeared much less prevalent or perhaps less important than an anti-biosynthetic 
response.  For example, EIF2B2 required for translation was down-regulated 
(Kubica, Jefferson et al. 2006), as was POLR2A an RNA polymerase subunit 
required for mRNA synthesis (Wagner, Yakovchuk et al. 2013), and LFNG a glucosyl 
transferase involved with glycosylation of newly made proteins (Dunwoodie 2009). 
Notably, reduced protein synthetic capacity seems consistent with the reduced 
production of cytokines observed in Chapter 3.  
 
Reduced lipid biosynthesis also seems consistent with a generally 'atrophic' 
endothelial response to arecoline.  Lipid biosynthetic genes down-regulated in the 
current study included: ACAT2 involved with cholesterol synthesis (Parini, Davis et 
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al. 2004), FADS1 introducing double bonds into fatty acyl chains (Glaser, Heinrich et 
al. 2010), SCD that also introduces double bonds into Stearoyl-CoA (Ntambi 1995), 
HMGCR generating lipid product precursors in the meyalonate pathway (Medina and 
Krauss 2009), HMGCL involved with leucine degradation and ketone body production 
(Puisac, Ramos et al. 2012), and LDLR encoding the receptor for low density 
lipoproteins and hence regulating uptake of lipid biosynthetic precursors (Esterbauer, 
Gebicki et al. 1992).  Contrasting with this anti-lipid biosynthetic profile, seemed to be 
down-regulation upon arecoline treatment of LIPG, an endothelial lipase (Mank-
Seymour, Durham et al. 2004), although it could be argued that may represent a 
coherent mechanism for improving membrane integrity.  
 
A number of genes were modified in endothelium treated with arecoline for which the 
possible relevance to a potentially coherent biological response was not apparent.  
For example, RAB5A and STARD3NL were up-regulated, and encode for proteins 
involved with endosome formation (Barbieri, Roberts et al. 2000) (Alpy and 
Tomasetto 2006), but the possible relevance of this to an response is unclear, as 
was up-regulation of DCTN5 encoding a dynein transporting cargo to minus ends of 
tubulin (Schroer 2004).  Numerous transcription factors of uncertain significance 
were also up-regulated including ELK1, ELF1, MEF2D, MXD1, and TCF3.  Down-
regulated genes of unclear relevance included: CHMP4B, involved with 
multivesicular body formation (Katoh, Shibata et al. 2003); CSRP2, a differentiation 
protein (Herrmann, Borkham-Kamphorst et al. 2006); DDB2, acting as a co-factor for 
some transcription factors to bind (Prost, Lu et al. 2006); DHRS11, a dehydrogenase 
(Persson, Kallberg et al. 2009); DYNLL2, a dyanin light chain; NOTCH1, involved 
with cell differentiation; PDLIM7, localizing proteins to actin filaments; SLC25A4, an 
ADT/ATP translocase enzyme; and SERPIN2, inhibiting some serine proteinases 
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(Buchholz, Biebl et al. 2003, Wagner, Fodor et al. 2006, Camarata, Snyder et al. 
2010, Park, Kim et al. 2011) .  
 
From the above, and despite the difficulties inherent in microarray analysis as well as 
the uncertainty surrounding the possible biological significance of some changes in 
mRNA seen, it does seem reasonable to make some general conclusions from the 
available data.  It is concluded that arecoline has a broadly anti-inflammatory effect 
on endothelium with regard to the synthesis of inflammatory mediators including 
cytokines and possibly eicosanoids, which would be interesting to investigate 
separately.  It is also concluded that there is a coherent cellular response to stress 
induced by arecoline involving increased chaperone and anti-oxidant activity, and 
that this is accompanied by appropriate reduced biosynthesis of proteins and lipids, 
as well as by stalled cellular proliferation.  
 
These observations and conclusions are consistent with those in Chapters 2 and 3 of 
this thesis, and it would be interesting to pursue some of the changes seen by micro-
array at the level of protein expression and activity.  
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5. CHAPTER 5: GENERAL DISCUSSION 
5.1. The Experimental Approach Used Was Appropriate for The 
Current Study 
Based upon maintenance of in-vivo phenotype by cultured cells in-vitro, cell culture 
has become accepted as providing a reasonable experimental tool for investigation 
of cellular responses relevant to disease processes. The current study aimed to 
investigate the endothelial response to arecoline, particularly in light of the 
substantial reduction in vascularity with advanced OSF, and the separate observation 
that endothelial cell injury is an initial event in the pathogenesis of other fibrotic 
diseases such as scleroderma (Sirsat and Pindborg 1967, Wigley 2009). HUVEC are 
a widely accepted source of endothelium used to study pathophysiological processes 
including: immune-endothelial interactions; endothelial dysfunction related to 
vasculopathies and cardiovascular pathologies; tumour growth progression and 
metastasis; and endothelial mesenchymal interactions (Bishop, Bell et al. 1999, Tan, 
Chan et al. 2004). Nonetheless, HUVEC are essentially macrovascular as opposed 
to microvascular in origin, and are also derived from immune-privileged foetal tissue 
(French, Hahne et al. 1996), while unlike adult endothelium, HUVEC are not normally 
subjected to prolonged exposure to cytokines, hormones and other stimuli, potentially 
resulting in an altered phenotype (Tan, Chan et al. 2004). Nonetheless, while 
microvascular human oral epithelium may have been desirable for study, it would 
have been impossible to obtain a sufficient number of such cells from human oral 
specimens in order to perform the experiments described. On balance, HUVEC thus 
seem a reasonable experimental model for use in the current study.  Accepting that 
there is variability amongst donors in cellular responses, HUVEC from multiple 
donors were used, and this provides greater confidence in the observations made.  
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In order to reduce the number of extraneous and potentially confounding stimuli, 
experiments were performed in the absence of serum and ECGS. Cultured 
endothelium rapidly becomes apoptotic in such conditions, but this is greatly reduced 
by inclusion of BSA at physiological levels, via a specific anti-apoptotic activity of this 
protein for endothelial cells (Zoellner, Hofler et al. 1996).  
 
Haemocytometer counts were used to evaluate cell survival, because HUVEC 
become readily detached after death, and haemocytometer counts are both 
reproducible and unambiguous to interpret. MTT and LDH cytotoxicity assays were 
further performed to provide additional information on mitochondrial activity and cell 
leakage, particularly relevant to evaluate possible cell injury at levels of arecoline 
lower than those required to cause frank cell death.  That results were essentially 
similar across multiple experiments with cells from different donors, and using 
different methods for evaluation of cell toxicity, both provides confidence in the 
conclusions drawn and also indicates that sub-toxic levels of arecoline do not cause 
cell leakage or increased mitochondrial permeability. These findings were consistent 
with ultrastructural changes seen by TEM, while the TEM features of reversible cell 
injury are well described (Kumar, Abbas et al. 2012). A very large number of 
transmission electron micrographs were examined for data shown in Chapter 2, so 
that there can be a high level of confidence in the reported changes seen.  
 
In view of the inflammatory role of endothelium, it was interesting to investigate 
endothelial cytokine synthesis in response to arecoline, and while background levels 
of most cytokines were sufficiently high for ready detection, it seemed reasonable to 
use TNF-α as a strong stimulus for inflammatory cytokine synthesis to examine the 
effect of arecoline in stimulated cytokine production (Idriss and Naismith 2000). As 
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outlined in Chapter 3, ELISA and RT-PCR are widely accepted and highly sensitive 
methods for quantitating cytokine production in cultured cells, and once again similar 
responses across multiple experiments with cells from different donors supports 
confidence in the observations made and conclusions drawn.  That the responses 
seen may have biological meaning in context of OSF, is supported by the fact that 
levels of arecoline affecting HUVEC in Chapters 2 and 3, were comparable to those 
reported as achieved in saliva during areca nut chewing (Nair, Ohshima et al. 1985, 
Cox, Vickers et al. 2010). 
 
The power of microarray analysis was applied in Chapter 4 to explore potential 
unexpected cellular responses, as well as to examine more broadly the cytotoxic and 
inflammatory observations made in Chapters 2 and 3. The concentration of arecoline 
of 111 µg//ml, and time points selected for microarray analysis was based on time-
course and dose-response analysis from Chapters 2 and 3, and the seemingly 
intelligible results reported in Chapter 4 suggest that these choices were appropriate.   
 
Throughout, well established methods for statistical analysis were performed, and 
levels of confidence in the observations made are within the range of those accepted 
by the wider scientific literature.  
 
From the above, it is argued that the experimental approach used in this thesis was 
reasonable and appropriate for the biological questions examined, and that because 
of this, reasonable confidence can be had in the conclusions drawn.  
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5.2. The Observed Endothelial Response to Arecoline Relevant to 
Disease  
While work in this thesis defines important endothelial responses to arecoline, it is 
acknowledged that separate significant responses have been described for other cell 
types including fibroblasts and epithelial cells, and that complex interactions between 
all cells present will be important for development of OSF and OSCC secondary to 
arecoline exposure.  
 
The necrosis seen in HUVEC at and above 333 µg/ml of arecoline may not be 
directly relevant to human disease because these very high levels of arecoline have 
not been reported for saliva (Nair, Ohshima et al. 1985, Cox, Vickers et al. 2010).  
However, 333 µg/ml arecoline is an only marginally higher concentration above the 
maximum levels reported of from 97 to 140 µg/ml (Nair, Ohshima et al. 1985, Cox, 
Vickers et al. 2010), so that it does not seem incredible that on some occasions, such 
high levels might be achieved during chewing, despite direct evidence in the two 
studies reported (Nair, Ohshima et al. 1985, Cox, Vickers et al. 2010). Irrespective of 
this, there can be reasonable confidence that responses observed at 37 µg/ml and 
111 µg/ml may be biologically relevant, as such levels have been observed in saliva 
(Nair, Ohshima et al. 1985, Cox, Vickers et al. 2010). TEM changes observed at 
these concentrations support a sub-toxic biological response in the absence of 
apoptosis with seemingly increased autophagy, and are consistent with microarray 
observations of cellular stress and anti-oxidant activities.  The autophagy response of 
endothelial cells can be considered appropriate to recycle cellular components and 
sustain metabolism, while preventing assembly of damaged proteins, lipids and 
cellular organelles due to arecoline oxidative stress as shown in figure 2.8 (Kiffin, 
Bandyopadhyay et al. 2006). It is possible that prolonged exposure to arecoline at 
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these levels may ultimately result in failure in homeostasis with necrosis or perhaps 
apoptosis, but this was not readily supported by the current data.  
 
The arecoline toxicity observed in this thesis was consistent with a recently published 
paper although it is stressed that the published work was with an immortalized 
endothelial cell line (Tseng, Chang et al. 2012),  which it is here argued is of less 
biological relevance compared with the current study using primary cultures of 
human endothelium from multiple donors.  
 
The frequency of areca nut chewing varies among different demographic groups and 
average consumption ranges from 14 to 23 portions per day (Ko, Chiang et al. 1992). 
It seems reasonable to suggest that oral endothelium subjected to a lower baseline 
arecoline with peaks during chewing for a prolong period of time, might be 
responsible for reduced vascularity as seen in OSF. It seems reasonable to infer a 
relationship between the observed arecoline induced cytotoxicity for HUVEC, and 
separate reports of substantially reduced vasculature in advanced OSF (Sirsat and 
Pindborg 1967, Sirsat and Pindborg 1967). Vascular injury is accepted as important 
in other fibrotic conditions such as systemic sclerosis (scleroderma) (Matucci‐Cerinic, 
Kahaleh et al. 2013), pulmonary fibrosis (Farkas and Kolb 2011), hepatic fibrosis 
(Hernandez-Gea and Friedman 2011) and renal fibrosis (Chade 2011). Compelling 
clinical observations and separate biological studies suggest that vascular injury is 
central to initiation and progression of sclerosis in scleroderma (Matucci‐Cerinic, 
Kahaleh et al. 2013). The exact aetiology and mechanism of endothelial injury in 
these settings is unknown, but mechanisms suggested include: apoptosis as a 
consequent of infection; immune-mediated cytotoxicity; antibodies against endothelial 
components; and ischemia-reperfusion injury (Kahaleh 2012).  
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Endothelial apoptosis was first identified in morphological studies of scleroderma 
biopsies in association with inflammation (Fleischmajer and Perlish 1980), while the 
apoptotic cells are possibly cleared by the immune cells leading to immune 
recognition of vascular antigens (Albert, Pearce et al. 1998). Endothelial involvement 
in fibrotic conditions supports the idea that arecoline mediated toxic injury to 
endothelial cells may play a key role in the pathogenesis of OSF, and possibly its 
progression to OSCC. As outlined in Section 1.7, injured endothelial cells may affect 
the neighboring tissue milieu via biological actions.  
 
Connective tissue fibrosis is the hallmark of OSF and many fibrotic conditions, and 
results from activation of fibroblasts to produce an abnormally large amount of ECM 
(Zeisberg, Strutz et al. 2000, Wynn 2007). Multiple mechanisms may contribute to 
interplay between vascular injury and tissue fibrosis (Wynn 2007, Guiducci, Distler et 
al. 2008, Müller-Ladner, Distler et al. 2009). Accumulating evidence suggests that the 
production and secretion of cytokines by injured endothelial cells, which may 
stimulate fibroblast proliferation and activation to result in enhanced synthesis and 
secretion of collagen and other ECM components (Villanueva, Farber et al. 1991). 
There is considerable evidence supporting the notion that endothelial products may 
modulate fibroblast properties, and such cross-talk may have important implications 
in the initiation and progression of fibrosis (Denton, Shi-wen et al. 1997, Le, Zhang et 
al. 2004).  
 
Phenotypically altered fibroblasts have been identified in fibrotic tissues with 
enhanced capacity for proliferation and collagen production, and or down-regulation 
of collagen breakdown, constitutive secretion of cytokines and chemokines and over 
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expression of cell surface receptors (Rajkumar, Howell et al. 2005, Zhu, Gao et al. 
2012). Chronic exposure to pro-fibrotic cytokines and growth factors has been 
postulated as a possible mechanism by which fibroblasts acquire altered phenotype. 
Occurrences of endothelial injury co-existing, or in some cases preceding fibrosis, 
implicate the role of endothelial derived mediators (Shi-wen, Denton et al. 2001). 
Endothelial mediators not only directly stimulate fibroblasts via factors such as TGF-β 
and CTGF (Laplante, Sirois et al. 2009), but also via recruitment of immune cells, 
which release cytokines and growth factors and may thus further exacerbate the 
process of fibrosis (Pober and Sessa 2007). 
 
In this context, it is interesting that the current study demonstrated reduced levels of 
most cytokines at both protein and mRNA levels upon arecoline stimulation, while the 
single clear exception was in bFGF which although increasing at the level of protein, 
was not modulated at mRNA level. Endothelial bFGF may combat the injury caused 
by arecoline, so that this growth factor may act by paracrine activity to stimulate 
fibroblast proliferation. The reduced pro-inflammatory cytokine profile of arecoline 
stimulated cells could be thought of as a coherent and cogent mechanism reducing 
the inflammatory response and hence limiting disease progression.  
 
Oxidative stress encompasses the molecular, cellular and tissue abnormalities 
following excess ROS production and or depleted antioxidant defence mechanisms 
(Janssen, Van Houten et al. 1993). Oxidative stress results from increased 
production of reactive oxygen species (ROS) overriding the antioxidant ability of 
target cells. Oxidants are produced as a consequence of normal cellular metabolism 
in mitochondria and peroxisomes, as well as from diverse cytosolic enzymatic 
systems (Kiffin, Bandyopadhyay et al. 2006). In addition, numerous external agents 
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such as drugs, hormones and other xenobiotic chemicals can induce the production 
of ROS (Halliwell 1996). Cells have evolved a number of sophisticated intracellular 
enzymatic and non-enzymatic mechanisms to counteract the effect of ROS and 
regulate physiological homeostasis (Kobayashi, Li et al. 2009). Reducing ROS levels 
below the homeostatic set-point, disturbs the physiological role of oxidants in cellular 
defense and proliferation. Similarly, over production of ROS results in oxidative 
stress, and may have detrimental effects on cell survival (Finkel and Holbrook 2000). 
Excessive ROS production is detrimental via the effects of oxidative stress, and while 
small perturbations can be overcame to maintain homeostasis, intense oxidative 
stress may result in cell death with apoptosis or necrosis following moderate or 
severe stress respectively (Moslen 1994). The impairment caused by increased ROS 
synthesis is thought to follow its interaction with critical cellular macromolecules such 
as cellular proteins, lipids and DNA, and results in random cellular damage (Ding, 
Hudson et al. 2005). Furthermore, raised ROS level may induce stress signals that 
activate redox-sensitive signalling pathways, which may have either damaging or 
potentially protective functions (von Harsdorf, Li et al. 1999). 
 
Oxidative stress plays a key role in many pathological conditions including tissue 
fibrosis and carcinogenesis (Klaunig and Kamendulis 2004, Kryston, Georgiev et al. 
2011, Piera-Velazquez and Jimenez 2013). Expression and synthesis of pro-
fibrogenic cytokines and growth factors are mainly mediated via redox sensitive 
reactions in hepatic fibrosis. ROS and lipid peroxidation have been clearly 
demonstrated as fundamental event for hepatic fibrogenesis via activation of stellate 
cells, as well as expression of metalloproteinases and their inhibitors. Oxidative 
stress appears to contribute to onset as well as progression of fibrosis as induced by 
alcohol, viruses, iron and copper overload, cholestasis and hepatic blood congestion 
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(Poli 2000). An imbalance in ROS production and anti-oxidant defences likely 
accounts for some important regulatory pathways involving various cells and 
organelles in pulmonary fibrosis such as: ER stress; mitochondria and p53-regulated 
death pathways; and important interactive effects among stress induced genes and 
p53 in DNA repair, and oxidant induced intrinsic apoptosis (Cheresh, Kim et al. 
2012). The generation of ROS has been linked to the pathogenesis of systemic 
sclerosis (Murrell 1993), while there is overwhelming evidence documenting the 
presence of an abnormal redox state in scleroderma (Simonini, Cerinic et al. 1999, 
Dooley, Bruckdorfer et al. 2011, Piera-Velazquez and Jimenez 2013), and anti-
oxidant therapeutic strategies have been suggested (Gabriele, Alberto et al. 2000, 
Mirshafiey and Mohsenzadegan 2009). Oxidative stress and the generation of ROS 
have also been investigated in the pathogenesis of OSF and oral carcinogenesis 
(Chang, Lee et al. 2004, Gupta and Reddy 2004, Tsai, Yang et al. 2009). Arecoline 
has been shown to induce the generation of ROS, resulting in diverse cellular 
responses and toxicity in different cell lines (Chang, Hu et al. 2001, Thangjam and 
Kondaiah 2009, Shih, Chen et al. 2010, Hung, Huang et al. 2011).  
 
The results of microarray studies demonstrated a similar oxidative stress response 
by human endothelium to arecoline, influencing and regulating a number of signalling 
pathways and cellular responses as shown in chapter 4. Previously, very limited 
oxidative stress responses have been reported but the current study demonstrates 
these mechanisms at a wider scale, and might pinpoint some important mechanisms 
implicated in the pathogenesis of OSF and its progression to OSCC. 
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5.3. The Direction of Future Work 
A number of biologically relevant responses of endothelial cells have been reported 
for the first time in relation to OSF, which provide further understanding of the role of 
endothelium in the pathogenesis of the disease and also form a basis for further 
investigation.   
 
The current work was performed using HUVEC, and although a convenient and 
effective model for endothelial responses to arecoline, it would be interesting to 
confirm similarity or otherwise of the microvascular endothelial response to arecoline. 
With particular regard to OSF, this would of necessity require the isolation and 
culture of human buccal mucosal endothelial cells, which could only be obtained from 
biopsies or resection specimens in small number.  However, by selecting 
concentrations of arecoline shown to be effective in HUVEC for specific biosynthetic 
and cytotoxic effects, and then further focusing on specific experimental read-outs 
also identified in HUVEC, a combination of light microscopy, RT-PCR and TEM could 
be used to establish the extent to which the HUVEC response to arecoline is 
paralleled by that of buccal mucosal endothelium.  
 
While cultured endothelium and co-cultures with fibroblasts are informative, work with 
explant cultures of human buccal mucosa could help establish the biological 
relevance or otherwise of observations made with isolated cell cultures. Explant 
culture systems could be interrogated by light microscopy, TEM or 
immunohistochemical studies to examine arecoline induced effects in endothelium 
integrated into tissues. Furthermore, gingival or buccal tissue explants would provide 
a reasonable preliminary experimental basis for extending studies into animals.  
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Animal experimentation could then be performed using both isolated cultured 
endothelium from animals, as well as oral mucosal tissues.  
 
Loss of calcium homeostasis plays a critical role in cell injury through activation of a 
range of degradative intracellular enzymes (Trump, Berezesky et al. 1980, Trump 
and Berezesky 1995, Kawai, Nakao et al. 2006). It is possible that a gradual increase 
in calcium level might be associated with increasing levels of arecoline, and that this 
contributes to toxic and sub-toxic cellular responses. Furthermore, while the 
ultrastructural changes characterized in Chapter 2 in arecoline treated HUVEC were 
seemingly very clear, it would be interesting to return to this work and perform 
quantitative analysis for the presence of relevant intracellular structures including 
altered mitochondrial morphology, lysosomes and autophagic required to clear 
damaged cellular organelles (Castro-Obregón 2010, Yu, McPhee et al. 2010). 
 
Arecoline caused endothelial necrosis at high levels, while a reversible cell injury 
response was seen at lower levels over 24 hr, but it would be interesting to determine 
if still further time periods of arecoline stimulation had other effects, or if prolonged 
exposure results in similar effects at lower arecoline levels. This may have particular 
relevance to OSF, because of the frequent long exposure to the drug. . 
 
Endothelium plays a significant role in orchestrating the responses of adjacent cells 
such as fibroblasts (Guarda, Myers et al. 1993), epithelial cells (Blume, Taylor et al. 
1998), stellate cells (Tsukamoto 1999), smooth muscle cells (Yoshida, Nakamura et 
al. 1996), and other ECM components by paracrine activity, and this has implications 
for wound healing, keloid formation and tissue fibrosis (Mutsaers, Bishop et al. 1997, 
Lingen 2001, Le, Zhang et al. 2004). A similar paracrine role would be interesting to 
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investigate with regard to OSF, since release of endothelial products in response to 
arecoline may act in a paracrine manner to contribute to sub-epithelial fibrosis.  For 
example, there may be release of fibrogenic growth factors similar to bFGF by 
fibroblasts in response to conditioned media from arecoline treated endothelial cells, 
while transwell and direct contact co-cultures of endothelium with fibroblasts could be 
performed to investigate the role of short-lived mediators and cell contact.  
 
In view of arecoline inhibitory influence on the production of pro-inflammatory 
cytokines by endothelial cells at both protein and mRNA level, it would be interesting 
to determine if anticholinergic agents antagonize such effects, this despite the fact 
that cholinergic agents did not appear to have a clear role in the current study.  
 
The oxidative stress response is important in arecoline-induced cytotoxicity to human 
endothelium, and a number of associated genes have been reported in our study. 
However additional studies are required to further characterize this response at the 
protein level, as well as with regard to the accumulation or otherwise of reactive 
oxygen species and relevant biochemical lesions, as well as the effect of exogenous 
anti- and pro-oxidant agents.  
 
Oxidative stress has been demonstrated to influence various pathways responsible 
for tissue fibrosis as discussed in section 5.2 and also influences numerous biological 
responses as a cumulative effect of diverse biological pathways as shown in chapter 
4. It would be interesting to study the most significant and relevant pathways 
individually, that might also be potentially therapeutic targets in fibrosis related 
disorders. 
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